{"SLR NAME":"Effect of sofosbuvir-based treatment on clinical outcomes of patients with COVID-19: a systematic review and meta-analysis of randomised controlled trials","References":[{"title1":"Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial","References":[{"title2":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","References":[{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: adescriptivestudy"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"First case of 2019 novel coronavirus in the United States"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Lung CT image of a confirmed case of the 2019 novel coronavirus (2019-nCoV) infected pneumonia (With differential diagnosis of the SARS)"},{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"Role of neutrophil to lymphocyte and monocyte to lymphocyte ratios in the diagnosis of bacterial infection in patients with fever"},{"title3":"Coronavirus infections-more than just the common cold"},{"title3":"The association between the neutrophil-to-lymphocyte ratio and mortality in critical illness: an observational cohort study"},{"title3":"A new coronavirus associated with human respiratory disease in China"},{"title3":"Monocyte/lymphocyte ratio as a better predictor of cardiovascular and all-cause mortality in hemodialysis patients: a prospective cohort study"},{"title3":"Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill"},{"title3":"Neutrophil-lymphocyte ratio as an early new marker in AIV-H7N9-infected patients: a retrospective study"}]},{"title2":"A systematic review of COVID-19 epidemiology based on current evidence","References":[{"title3":"BNO Tracking Coronavirus: Map, Data and Timeline"},{"title3":"Clinical Characteristics of Coronavirus Disease 2019 in China"},{"title3":"Presumed Asymptomatic Carrier Transmission of COVID-19"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study"},{"title3":"Epidemiological research priorities for public health control of the ongoing global novel coronavirus (2019-nCoV) outbreak"},{"title3":"Measurement and Modeling: Infectious Disease Modeling"},{"title3":"Risk for Transportation of 2019 Novel Coronavirus Disease from Wuhan to Other Cities in China"},{"title3":"Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: A modelling study"},{"title3":"The Rate of Underascertainment of Novel Coronavirus (2019-nCoV) Infection: Estimation Using Japanese Passengers Data on Evacuation Flights"},{"title3":"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia"},{"title3":"Incorporating Human Movement Data to Improve Epidemiological Estimates for 2019-nCoV"},{"title3":"The effect of travel restrictions on the spread of the 2019 novel coronavirus (2019-nCoV) outbreak"},{"title3":"Simulating the infected population and spread trend of 2019-nCov under different policy by EIR model"},{"title3":"Analysis of the epidemic growth of the early 2019-nCoV outbreak using internationally confirmed cases"},{"title3":"Estimating the Unreported Number of Novel Coronavirus (2019-nCoV) Cases in China in the First Half of January 2020: A Data-Driven Modelling Analysis of the Early Outbreak"},{"title3":"Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: A data-driven analysis in the early phase of the outbreak"},{"title3":"Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020"},{"title3":"Estimation of the Transmission Risk of the 2019-nCoV and Its Implication for Public Health Interventions"},{"title3":"Real-Time Estimation of the Risk of Death from Novel Coronavirus (COVID-19) Infection: Inference Using Exported Cases"},{"title3":"Modelling the epidemic trend of the 2019 novel coronavirus outbreak in China"},{"title3":"Novel coronavirus 2019-nCoV: Early estimation of epidemiological parameters and epidemic predictions"},{"title3":"Transmission dynamics of 2019 novel coronavirus (2019-nCoV)"},{"title3":"Early Transmissibility Assessment of a Novel Coronavirus in Wuhan, China (January 26, 2020)"},{"title3":"Transmission dynamics of the etiological agent of SARS in Hong Kong: Impact of public health interventions"},{"title3":"Transmission dynamics and control of severe acute respiratory syndrome"},{"title3":"Middle East respiratory syndrome coronavirus: Quantification of the extent of the epidemic, surveillance biases, and transmissibility"},{"title3":"Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020"},{"title3":"Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data"},{"title3":"Epidemiologic characteristics of early cases with 2019 novel coronavirus (2019-nCoV) disease in Republic of Korea"},{"title3":"Does SARS-CoV-2 has a longer incubation period than SARS and MERS?"},{"title3":"The incubation period of 2019-nCoV from publicly reported confirmed cases: Estimation and application"},{"title3":"Evolving epidemiology of novel coronavirus diseases 2019 and possible interruption of local transmission outside Hubei Province in China: A descriptive and modeling study"},{"title3":"A comparative epidemiologic analysis of SARS in Hong Kong, Beijing and Taiwan"},{"title3":"Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015"},{"title3":"The serial interval of COVID-19 from publicly reported confirmed cases"},{"title3":"Serial interval of novel coronavirus (2019-nCoV) infections"},{"title3":"Estimating the serial interval of the novel coronavirus disease (COVID-19): A statistical analysis using the public data in Hong Kong from January 16 to February 15, 2020"},{"title3":"Hospital outbreak of Middle East respiratory syndrome coronavirus"},{"title3":"Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases from the Chinese Center for Disease Control and Prevention"},{"title3":"Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: A retrospective review of medical records"},{"title3":"Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Summary of Probable SARS Cases with Onset of Illness from 1 November 2002 to 31 July 2003"},{"title3":"Middle East Respiratory Syndrome Coronavirus (MERS-CoV)"},{"title3":"Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus"},{"title3":"Estimating the case fatality ratio of the COVID-19 epidemic in China"},{"title3":"Early epidemiological assessment of the transmission potential and virulence of 2019 Novel Coronavirus in Wuhan City: China, 2019-2020"},{"title3":"Estimating the Case Fatality Risk of COVID-19 using Cases from Outside China"},{"title3":"Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020"},{"title3":"Early evaluation of transmission control measures in response to the 2019 novel coronavirus outbreak in China"},{"title3":"Interventions to mitigate early spread of SARS-CoV-2 in Singapore: A modelling study"},{"title3":"Effectiveness of airport screening at detecting travellers infected with novel coronavirus (2019-nCoV)"},{"title3":"Estimated effectiveness of traveller screening to prevent international spread of 2019 novel coronavirus (2019-nCoV)"}]},{"title2":"Coronavirus disease 2019 (COVID-19) outbreak in Iran: actions and problems","References":[{"title3":" . World Health Organization website. . Published 2020. Accessed March 24, 2020."},{"title3":" . . Updated 2020. Accessed March 24, 2020."},{"title3":"Identification of 743 cases of definitive new infections with Covid in the country Iranian Ministry of Health and Medical Education website. . Published 2020. Accessed March 24, 2020."},{"title3":"An interactive web-based dashboard to track COVID-19 in real time"}]},{"title2":"WHO. WHO COVID-19 Data Explorer. https://covid19.who.int/explorer.","References":[]},{"title2":"Observational study of hydroxychloroquine in hospitalized patients with Covid-19","References":[{"title3":"Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities."},{"title3":"Mechanism of action of hydroxychloroquine as an antirheumatic drug."},{"title3":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?"},{"title3":"Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection."},{"title3":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial."},{"title3":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)."},{"title3":"Nonlinear imputation of PaO2/FIO2 from SpO2/FIO2 among mechanically ventilated patients in the ICU: a prospective, observational study."},{"title3":"Nonlinear imputation of Pao2/Fio2 from Spo2/Fio2 among patients with acute respiratory distress syndrome."},{"title3":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial."},{"title3":"Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial."},{"title3":"A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)"}]},{"title2":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","References":[{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China."},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study."},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China."},{"title3":"Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province."},{"title3":"Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings."},{"title3":"In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds."},{"title3":"Small molecules targeting severe acute respiratory syndrome human coronavirus."},{"title3":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture."},{"title3":"Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset."},{"title3":"Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome."},{"title3":"Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen."},{"title3":"Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity."},{"title3":"Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus."},{"title3":"Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays."},{"title3":"Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial."},{"title3":"International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) home page ()."},{"title3":"Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection."},{"title3":"Coronavirus disease (COVID-2019) R&amp;D. Geneva: World Health Organization ()."},{"title3":"National Early Warning Score (NEWS) 2: standardising the assessment of acute-illness severity in the NHS. London: Royal College of Physicians, 2017 ()."},{"title3":"Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study."},{"title3":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data."},{"title3":"Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09."},{"title3":"Early oseltamivir after hospital admission is associated with shortened hospitalization: a 5-year analysis of oseltamivir timing and clinical outcomes."},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study."},{"title3":"SARS-CoV-2 viral load in upper respiratory specimens of infected patients."},{"title3":"HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus."}]},{"title2":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial","References":[{"title3":"Coronavirus covid-19 global cases by Johns Hopkins CSSE. https://www.arcgis.com/apps/opsdashboard/index.html#/85320e2ea5424dfaaa75ae62e5c06e61."},{"title3":"Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies"},{"title3":"A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19"},{"title3":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"},{"title3":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)"},{"title3":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of covid-19 associated pneumonia in clinical studies"},{"title3":"National Health Commission of the People's Republic of China. Chinese guideline for the management COVID-19 (version 7.0, in Chinese). 2020. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989/files/ce3e6945832a438eaae415350a8ce964.pdf."},{"title3":"US Food and Drug Administration. Emergency Use Authorization. Hydroxychloroquine sulfate health care provider fact sheet. https://www.fda.gov/media/136534/download."},{"title3":"Piller C. &quot;This is insane!&quot; Many scientists lament Trump's embrace of risky malaria drugs for coronavirus. 2020. https://www.sciencemag.org/news/2020/03/insane-many-scientists-lament-trump-s-embrace-risky-malaria-drugs-coronavirus#."},{"title3":"Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases"},{"title3":"Covid-19 - the search for effective therapy"},{"title3":"National Health Commission of the People's Republic of China. Chinese guideline for the management covid-19 (version 5.0, in Chinese). 2020. http://www.nhc.gov.cn/yzygj/s7653p/202002/d4b895337e19445f8d728fcaf1e3e13a/files/ab6bec7f93e64e7f998d802991203cd6.pdf."},{"title3":"Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study [correction in: BMJ 2020;368:m1295]"},{"title3":"Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study"},{"title3":"Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America"},{"title3":"Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis"},{"title3":"Rapid onset of retinal toxicity from high-dose hydroxychloroquine given for cancer therapy"},{"title3":"An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists"},{"title3":"Oral erythromycin and the risk of sudden death from cardiac causes"},{"title3":"Antimicrobial-associated QT interval prolongation: pointes of interest"},{"title3":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology"},{"title3":"Detection of SARS-CoV-2 in different types of clinical specimens"}]},{"title2":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","References":[{"title3":"COVID-19 map. Johns Hopkins Coronavirus Resource Centre"},{"title3":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"},{"title3":"Covid-19 in critically ill patients in the Seattle region-case series"},{"title3":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"},{"title3":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro"},{"title3":"Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial"},{"title3":"Favipiravir versus arbidol for COVID-19: a randomized clinical trial"},{"title3":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma"},{"title3":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19"},{"title3":"GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses"},{"title3":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses"},{"title3":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys"},{"title3":"Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase"},{"title3":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV"},{"title3":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection"},{"title3":"Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia"},{"title3":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2"},{"title3":"A randomized, controlled trial of Ebola virus disease therapeutics"},{"title3":"Compassionate use of remdesivir for patients with severe Covid-19"},{"title3":"First case of 2019 novel coronavirus in the United States"},{"title3":"Group sequential clinical trials with triangular continuation regions"},{"title3":"Gilead Sciences. Investigator's brochure of remdesivir, 5th edition. Feb 21, 2020."},{"title3":"Late Ebola virus relapse causing meningoencephalitis: a case report"},{"title3":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease"},{"title3":"Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients"},{"title3":"Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome"}]},{"title2":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","References":[]},{"title2":"Remdesivir for the treatment of COVID-19:preliminary report","References":[]},{"title2":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","References":[]},{"title2":"SD1000: high sustained viral response rate in 1361 patients with hepatitis C genotypes 1, 2, 3, and 4 using a low-cost, fixed-dose combination tablet of generic sofosbuvir and daclatasvir: a multicenter, Phase III clinical trial","References":[]},{"title2":"Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo","References":[{"title3":"Yellow fever virus: genetic and phenotypic diversity and implications for detection, prevention and therapy"},{"title3":"Fears rise over yellow fever's next move"},{"title3":"@NewsfromScience. When will yellow fever strike Brazil again? Monkeys and mosquitoes hold clues | Science | AAAS. 2017. Available from: https:// https://www.sciencemag.org/news/2017/08/when-will-yellow-fever-strike-brazil-again-monkeys-and-mosquitoes-hold-clues"},{"title3":"Villegoureix I. PAHO/WHO | 20 March 2018: Yellow Fever:Epidemiological Update 2018 [updated 2018-03-20 19:57:54. Available from: https://www.paho.org/hq/index.php?option=com_content&amp;view=article&amp;id=14207:20-march-2018-yellow-fever-epidemiological-update&amp;Itemid=42346(=en."},{"title3":"Phylodynamics of Yellow Fever Virus in the Americas: new insights into the origin of the 2017 Brazilian outbreak"},{"title3":"Amarela CF. MONITORAMENTO DOS CASOS E OBITOS DE FEBRE AMARELA NO BRASIL, INFORME-No 43/2017 2017 [Available from: http://portalarquivos2.saude.gov.br/images/pdf/2017/junho/02/COES-FEBRE-AMARELA:INFORME-43:Atualiza:-o-em-31maio2017.pdf."},{"title3":"(CDC) CfDCaP. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)"},{"title3":"Adverse event reports following yellow fever vaccination"},{"title3":"The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication"},{"title3":"Sofosbuvir protects Zika virus-infected mice from mortality, preventing short- and long-term sequelae"},{"title3":"The FDA-approved drug sofosbuvir inhibits Zika virus infection"},{"title3":"Evaluation of Sofosbuvir (beta-D-2'-deoxy-2'-alpha-fluoro-2'-beta-C-methyluridine) as an inhibitor of Dengue virus replication"},{"title3":"Sofosbuvir: A novel treatment option for chronic hepatitis C infection"},{"title3":"Gilead. Product Monograph Pr SOVALDI (sofosbuvir) Tablets 400 mg sofosbuvir Antiviral Agent 2015 [Available from: http://www.gilead.ca/pdf/ca/sovaldi_pm_english.pdf."},{"title3":"European Medicines Agency, EMA. Sovaldi 2013 [Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Public_assessment_report/human/002798/WC500160600.pdf."},{"title3":"Gilead Sciences Canada I. Product Monograph SOVALDI (sofosbuvir) Tablets 400 mg sofosbuvir Antiviral Agent 2015 [Available from: http://www.gilead.ca/application/files/3915/2589/0723/Sovaldi_English_PM_e162880-GS-007.pdf."},{"title3":"FDA FaDA. Copegus (ribavirin) tablets 2015 [Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm218877.htm."},{"title3":"Inhibition of HSV-1 replication and HSV DNA polymerase by the chloroxoquinolinic ribonucleoside 6-chloro-1,4-dihydro-4-oxo-1-(beta-D-ribofuranosyl) quinoline-3-carboxylic acid and its aglycone"},{"title3":"Platelets mediate increased endothelium permeability in dengue through NLRP3-inflammasome activation"},{"title3":"A simple method of estimating fifty percent endpoints"},{"title3":"Genomic and epidemiological monitoring of yellow fever virus transmission potential"},{"title3":"The IFITM proteins inhibit HIV-1 infection"},{"title3":"ExPASy: The proteomics server for in-depth protein knowledge and analysis"},{"title3":"Data deposition and annotation at the worldwide protein data bank"},{"title3":"Comparative protein modelling by satisfaction of spatial restraints"},{"title3":"TI. PROCHECK: a program to check the stereochemical quality of protein structures"},{"title3":"VERIFY3D: assessment of protein models with three-dimensional profiles"},{"title3":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research"},{"title3":"A Model of DENV-3 Infection That Recapitulates Severe Disease and Highlights the Importance of IFN-gamma in Host Resistance to Infection"},{"title3":"Molecular basis for specific viral RNA recognition and 2'-O-ribose methylation by the dengue virus nonstructural protein 5 (NS5)"},{"title3":"Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase"},{"title3":"Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides"},{"title3":"Synergistic in vitro interactions between alpha interferon and ribavirin against bovine viral diarrhea virus and yellow fever virus as surrogate models of hepatitis C virus replication"},{"title3":"Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model"},{"title3":"The anti-yellow fever virus activity of ribavirin is independent of error-prone replication"},{"title3":"Zika virus evolution and spread in the Americas"},{"title3":"First report of autochthonous transmission of Zika virus in Brazil"},{"title3":"Secretaria Municipal de Saude. Boletim da Febre do Chikungunya"},{"title3":"Dengue: twenty-five years since reemergence in Brazil"},{"title3":"The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication"},{"title3":"Yellow fever"},{"title3":"Clinical and epidemiological characteristics of yellow fever in Brazil: analysis of reported cases 1998-2002"},{"title3":"Hepatocyte lesions and cellular immune response in yellow fever infection"},{"title3":"Pathogenesis of the viral hemorrhagic fevers"},{"title3":"Liver transplantation for fulminant hepatitis due to yellow fever"},{"title3":"Paulo F-FdMdUdS. The first liver transplant due to Yellow Fever patient will be discharged from the hospital his week 2018 [Available from: http://www.fm.usp.br/en/news/the-first-liver-transplant-due-to-yellow-fever-patient-will-be-discharged-from-the-hospital-his-week."},{"title3":"Maxwell Finland Laboratory for Infectious Diseases BMC, Boston, Massachusetts. Yellow Fever: Epidemiology and Prevention"},{"title3":"A mouse model for studying viscerotropic disease caused by yellow fever virus infection"},{"title3":"Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment"},{"title3":"Randomized, controlled trial of oral ribavirin for Japanese encephalitis in children in Uttar Pradesh, India"},{"title3":"Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication"},{"title3":"Discovery of a beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus"},{"title3":"Sofosbuvir and Ribavirin Liver Pharmacokinetics in Patients Infected with Hepatitis C Virus"}]},{"title2":"The FDA-approved drug sofosbuvir inhibits Zika virus infection","References":[{"title3":"Characterization of Lethal Zika Virus Infection in AG129 Mice"},{"title3":"The Emergence of Zika Virus: A Narrative Review"},{"title3":"Guillain-Barre syndrome associated with the Zika virus outbreak in Brazil"},{"title3":"Infection dynamics in a traveller with persistent shedding of Zika virus RNA in semen for six months after returning from Haiti to Italy, January 2016"},{"title3":"Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era"},{"title3":"Recognition of RNA cap in the Wesselsbron virus NS5 methyltransferase domain: implications for RNA-capping mechanisms in Flavivirus"},{"title3":"Zika Virus Infection in Pregnant Women in Rio de Janeiro - Preliminary Report"},{"title3":"Guillain-Barre syndrome associated with Zika virus infection"},{"title3":"Sofosbuvir"},{"title3":"Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study"},{"title3":"Zika Virus Associated with Meningoencephalitis"},{"title3":"The structure of the RNA-dependent RNA polymerase from bovine viral diarrhea virus establishes the role of GTP in de novo initiation"},{"title3":"Sofosbuvir: a novel oral agent for chronic hepatitis C"},{"title3":"Adenosine Analog NITD008 Is a Potent Inhibitor of Zika Virus"},{"title3":"Zika virus. II. Pathogenicity and physical properties"},{"title3":"Zika virus. I. Isolations and serological specificity"},{"title3":"General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2'-modified nucleotide analogues"},{"title3":"Structural and functional analysis of methylation and 5'-RNA sequence requirements of short capped RNAs by the methyltransferase domain of dengue virus NS5"},{"title3":"Analysis of flavivirus NS5 methyltransferase cap binding"},{"title3":"Zika virus infection damages the testes in mice"},{"title3":"Characterization of West Nile virus RNA-dependent RNA polymerase and cellular terminal adenylyl and uridylyl transferases in cell-free extracts"},{"title3":"The flavivirus NS5 protein is a true RNA guanylyltransferase that catalyzes a two-step reaction to form the RNA cap structure"},{"title3":"Sofosbuvir: first global approval"},{"title3":"Evolution and taxonomy of positive-strand RNA viruses: implications of comparative analysis of amino acid sequences"},{"title3":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus"},{"title3":"Zika Virus: New Clinical Syndromes and Its Emergence in the Western Hemisphere"},{"title3":"A Mouse Model of Zika Virus Pathogenesis"},{"title3":"Assessing the global threat from Zika virus"},{"title3":"The dengue virus NS5 protein as a target for drug discovery"},{"title3":"Zika virus: high infectious viral load in semen, a new sexually transmitted pathogen?"},{"title3":"Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro"},{"title3":"Zika Virus Infection during Pregnancy in Mice Causes Placental Damage and Fetal Demise"},{"title3":"Zika Virus Infection in Mice Causes Panuveitis with Shedding of Virus in Tears"},{"title3":"Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977"},{"title3":"Zika virus infection complicated by Guillain-Barre syndrome--case report, French Polynesia, December 2013"},{"title3":"Zika Virus Disrupts Phospho-TBK1 Localization and Mitosis in Human Neuroepithelial Stem Cells and Radial Glia"},{"title3":"Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial"},{"title3":"Time Lags between Exanthematous Illness Attributed to Zika Virus, Guillain-Barre Syndrome, and Microcephaly, Salvador, Brazil"},{"title3":"Interim Guidelines for Pregnant Women During a Zika Virus Outbreak--United States, 2016"},{"title3":"Zika Virus"},{"title3":"Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors"},{"title3":"Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir"},{"title3":"Zika Virus and Birth Defects--Reviewing the Evidence for Causality"},{"title3":"Assessment of the clinical cardiac drug-drug interaction associated with the combination of hepatitis C virus nucleotide inhibitors and amiodarone in guinea pigs and rhesus monkeys"},{"title3":"Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial"},{"title3":"Rapid emergence of protease inhibitor resistance in hepatitis C virus"},{"title3":"Resistance to direct antiviral agents in patients with hepatitis C virus infection"},{"title3":"Discovery of a beta-d-2'-Deoxy-2'-alpha-fluoro-2'-beta-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus"},{"title3":"Identification of a novel antiviral inhibitor of the flavivirus guanylyltransferase enzyme"},{"title3":"Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity"},{"title3":"Late sexual transmission of Zika virus related to persistence in the semen"},{"title3":"Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen"},{"title3":"Genomic characterization and phylogenetic analysis of Zika virus circulating in the Americas"},{"title3":"Structural Basis of Zika Virus-Specific Antibody Protection"},{"title3":"The Viral Polymerase Inhibitor 7-Deaza-2'-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model"},{"title3":"Three atypical lethal cases associated with acute Zika virus infection in Suriname"},{"title3":"Functional analysis of two cavities in flavivirus NS5 polymerase"}]},{"title2":"Sofosbuvir as treatment against dengue?","References":[]},{"title2":"Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication","References":[]},{"title2":"Emerging coronaviruses: genome structure, replication, and pathogenesis","References":[{"title3":"Emerging coronaviruses: Genome structure, replication, and pathogenesis"}]},{"title2":"Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase","References":[{"title3":"for the China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019"},{"title3":"Coronaviruses - drug discovery and therapeutic options"},{"title3":"Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy"},{"title3":"Common and unique features of viral RNA-dependent polymerases"},{"title3":"Structural and functional basis of the fidelity of nucleotide selection by Flavivirus RNA-dependent RNA polymerases"},{"title3":"Inhibitors of viral nucleic acid polymerases. Pyrophosphate analogues"},{"title3":"Rational design of polymerase inhibitors as antiviral drugs"},{"title3":"Inhibitors of the hepatitis C virus polymerase; mode of action and resistance"},{"title3":"Approved antiviral drugs over the past 50 years"},{"title3":"Nucleotide analogues as inhibitors of viral polymerases"},{"title3":"Nucleotide analogues as inhibitors of SARS-CoV polymerase"},{"title3":"Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study"},{"title3":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus"},{"title3":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency"},{"title3":"Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19"},{"title3":"SARS-CoV-2 RNA polymerase as target for antiviral therapy"},{"title3":"Sofosbuvir as repurposed antiviral drug against COVID-19: why were we convinced to evaluate the drug in a registered/approved clinical trial?"},{"title3":"A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19"},{"title3":"One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities"},{"title3":"Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors"},{"title3":"Advances in nucleotide antiviral development from scientific discovery to clinical applications: Tenofovir disproxil fumarate for hepatitis B"},{"title3":"Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)"},{"title3":"Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors"},{"title3":"Rare emergence of drug resistance in HIV-1 treatment-naive patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks"},{"title3":"Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics"},{"title3":"Twenty-five years of lamivudine: current and future use for the treatment of HIV-1 infection"},{"title3":"Elucidating molecular interactions of L-nucleotides with HIV-1 reverse transcriptase and mechanism of M184V-caused drug resistance"},{"title3":"A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B"},{"title3":"Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89"},{"title3":"Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir"},{"title3":"Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase"},{"title3":"The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2"},{"title3":"Sofosbuvir protects human brain organoids against SARS-CoV-2"},{"title3":"Development of a simple in vitro assay to identify and evaluate nucleotide analogs against SARS-CoV-2 RNA-dependent RNA polymerase"},{"title3":"The Spanish HIV/COVID-19 Collaboration. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy. A cohort study"},{"title3":"The ProTide prodrug technology: where next?"}]},{"title2":"Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses","References":[{"title3":"Isolation of a novel Coronavirus from a man with pneumonia in Saudi Arabia"},{"title3":"Coronaviruses:drug discovery and therapeutic options"},{"title3":"Pathogenesis of Middle East respiratory syndrome coronavirus"},{"title3":"Emergence of MERS-CoV in the Middle East: origins, transmission, treatment, and perspectives"},{"title3":"Isolation and characterization of viruses related to the SARS Coronavirus from animals in southern China"},{"title3":"WHO, 2016. Middle East respiratory syndrome coronavirus (MERS-CoV) WHO. "},{"title3":"Evidence supporting a zoonotic origin of human coronavirus strain NL63"},{"title3":"Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event"},{"title3":"Evidence for an ancestral association of human coronavirus 229E with bats"},{"title3":"Evidence for zoonotic origins of Middle East respiratory syndrome coronavirus"},{"title3":"Mechanisms of zoonotic severe acute respiratory syndrome Coronavirus host range expansion in human airway epithelium"},{"title3":"Mechanisms of coronavirus cell entry mediated by the viral spike protein"},{"title3":"A previously undescribed coronavirus associated with respiratory disease in humans"},{"title3":"Coronaviruses: important emerging human pathogens"},{"title3":"Evidence for camel-to-human transmission of MERS coronavirus"},{"title3":"Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels a comparative serological study"},{"title3":"From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses"},{"title3":"SARS-beginning to understand a new virus"},{"title3":"Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease"},{"title3":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus"},{"title3":"Human aminopeptidase N is a receptor for human coronavirus 229E"},{"title3":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC"},{"title3":"Human Coronavirus HKU1 spike protein uses O-Acetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-Esterase protein as a receptor-Destroying enzyme"},{"title3":"Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry"},{"title3":"Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans"},{"title3":"Anti-HCV drugs in the pipeline"},{"title3":"Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes"},{"title3":"Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy"},{"title3":"IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study"},{"title3":"The QSAR and docking calculations of fullerene derivatives as HIV-1 protease inhibitors"},{"title3":"Integrative computational modeling of protein interactions"},{"title3":"2'-Methylguanosine prodrug (IDX-184), phosphoramidate prodrug (Sofosbuvir), diisobutyryl prodrug (R7128) are better than their parent nucleotides and ribavirin in hepatitis C virus inhibition: a molecular modeling study"},{"title3":"Structural properties of metal-free apometallothioneins"},{"title3":"The EBI Search engine: providing search and retrieval functionality for biological data from EMBL-EBI"},{"title3":"Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega"},{"title3":"Deciphering key features in protein structures with the new ENDscript server"},{"title3":"The I-TASSER Suite: protein structure and function prediction"},{"title3":"Verification of protein structures: patterns of nonbonded atomic interactions"},{"title3":"Deviations from standard atomic volumes as a quality measure for protein crystal structures"},{"title3":"Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): structural evidence for nucleotide import and de-novo initiation"},{"title3":"A comparative QSAR analysis and molecular docking studies of quinazoline derivatives as tyrosine kinase (EGFR) inhibitors: a rational approach to anticancer drug design"},{"title3":"Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design"},{"title3":"1.7.6, V., The PyMOL Molecular Graphics System, Version 1.7.6 Schrodinger, LLC. "},{"title3":"Water determines the structure and dynamics of proteins"},{"title3":"Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects"},{"title3":"Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials"}]},{"title2":"Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19)","References":[{"title3":"Origin and evolution of pathogenic coronaviruses"},{"title3":"Effects of a 'new' human respiratory virus in volunteers"},{"title3":"The severe acute respiratory syndrome"},{"title3":"Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans"},{"title3":"Clinical characteristics of coronavirus disease 2019 in China"},{"title3":"Lai, M. M. C. &amp; Cavanagh, D. The Molecular Biology of Coronaviruses. In: Advances in Virus Research (eds. Maramorosch, K., Murphy, F. A. &amp; Shatkin, A. J.) vol. 48, pp 1-100 (Academic Press, 1997)."},{"title3":"Antagonism of the interferon-induced OAS-RNase L pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology"},{"title3":"Evidence for coronavirus discontinuous transcription"},{"title3":"Structure, function, and evolution of coronavirus spike proteins"},{"title3":"Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry"},{"title3":"Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites"},{"title3":"Severe acute respiratory syndrome coronavirus nsp1 protein suppresses host gene expression by promoting host mRNA degradation"},{"title3":"Incorporation of spike and membrane glycoproteins into coronavirus virions"},{"title3":"Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response"},{"title3":"Sommerstein, R. Re: Preventing a covid-19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid-19. 2020."},{"title3":"Outcomes in patients with COVID-19 infection taking ACEI/ARB"},{"title3":"Potential effects of coronaviruses on the cardiovascular system: a review"},{"title3":"Impact of COVID-19 on the cardiovascular system: a review"},{"title3":"Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic"},{"title3":"Toll-Like Receptor 3 Signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection"},{"title3":"COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression"},{"title3":"Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies"},{"title3":"ACE for all:a molecular perspective"},{"title3":"ACE and ACE2: a tale of two enzymes"},{"title3":"Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis"},{"title3":"Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model"},{"title3":"The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K + channels and insulin secretion: comparison with the sulfonylureas and nateglinide"},{"title3":"Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside"},{"title3":"Circulating biomarkers of antioxidant status and oxidative stress in people with cystic fibrosis: a systematic review and meta-analysis"},{"title3":"Antioxidant supplementation for lung disease in cystic fibrosis"},{"title3":"R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation"},{"title3":"Syk inhibitors in clinical development for hematological malignancies"},{"title3":"Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C"},{"title3":"Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen"},{"title3":"New aspects in the management of obesity: operation and the impact of lipase inhibitors"},{"title3":"A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina"},{"title3":"Platelet Glycoprotein IIb/IIIa Receptor Inhibitor Tirofiban in Acute Ischemic Stroke"},{"title3":"Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome"},{"title3":"Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination"},{"title3":"Evidence for antiviral activity of glutathione: in vitro inhibition of herpes simplex virus type 1 replication"},{"title3":"limma powers differential expression analyses for RNA-sequencing and microarray studies"},{"title3":"Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse"},{"title3":"Ung M, et al. Metastasis: Leveraging transcriptomics to identify potential therapeutics. In: Session PO.TB04.03 - Molecular Profiles, Circulating Cancer Cells, and Metastasis, 2018."},{"title3":"Ung M, et al. Cachexia: Leveraging transcriptomics to identify potential therapeutics. In: Session PO.MCB04.06 - Novel Biomarkers and Drivers of the Cancer Transcriptome, 2018."},{"title3":"The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease"}]},{"title2":"Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study","References":[{"title3":"Pneumonia of unknown etiology in Wuhan, China: potential for international spread via commercial air travel"},{"title3":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health:the latest 2019 novel coronavirus outbreak in Wuhan, China"},{"title3":"The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak"},{"title3":"Pneumonia in China: lack of information raises concerns among Hong Kong health workers"},{"title3":"Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease"},{"title3":"Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses"},{"title3":"COVID-19 spike-host cell receptor GRP78 binding site prediction"},{"title3":"Catalytic function and substrate specificity of the papain-like protease domain of nsp3 from the Middle East respiratory syndrome coronavirus"},{"title3":"Some one health based control strategies for the Middle East respiratory syndrome coronavirus"},{"title3":"Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials"},{"title3":"Zika virus: novel guanosine derivatives revealed strong binding and possible inhibition of the polymerase"},{"title3":"Novel guanosine derivatives as anti-HCV NS5b polymerase: a QSAR and molecular docking study"},{"title3":"IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study"},{"title3":"Molecular dynamics simulation revealed binding of nucleotide inhibitors to ZIKV polymerase over 444 nanoseconds"},{"title3":"Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes"},{"title3":"Molecular dynamics and docking reveal the potency of novel GTP derivatives against RNA dependent RNA polymerase of genotype 4a HCV"},{"title3":"Molecular modeling and docking revealed superiority of IDX-184 as HCV polymerase inhibitor"},{"title3":"Applications of computer-aided approaches in the development of hepatitis C antiviral agents"},{"title3":"The mechanism of action of T7 DNA polymerase"},{"title3":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19"},{"title3":"Molecular docking revealed the binding of nucleotide/side inhibitors to Zika viral polymerase solved structures"},{"title3":"Announcing the worldwide Protein Data Bank"},{"title3":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods"},{"title3":"National center of biotechnology informatics (NCBI) database website"},{"title3":"SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information"},{"title3":"Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors"},{"title3":"MolProbity: more and better reference data for improved all-atom structure validation"},{"title3":"AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR"},{"title3":"Deviations from standard atomic volumes as a quality measure for protein crystal structures"},{"title3":"Errors in protein structures"},{"title3":"The antiviral Sofosbuvir against mucormycosis: an in silico perspective"},{"title3":"Structural properties of metal-free apometallothioneins"},{"title3":"Molecular mechanics. The MM3 force field for hydrocarbons. 3. The van der Waals' potentials and crystal data for aliphatic and aromatic hydrocarbons"},{"title3":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading"},{"title3":"PLIP: fully automated protein-ligand interaction profiler"},{"title3":"Density-functional thermochemistry. III. The role of exact exchange"},{"title3":"Optimization of parameters for semiempirical methods V: modification of NDDO approximations and application to 70 elements"},{"title3":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility"}]},{"title2":"In silico study of various antiviral drugs, vitamins, and natural substances as potential binding compounds with SARS-CoV-2 main protease","References":[]},{"title2":"Simeprevir suppresses SARS-CoV-2 replication and synergizes with remdesivir","References":[{"title3":"Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China"},{"title3":"Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study"},{"title3":"Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study"},{"title3":"Clinical Characteristics of Coronavirus Disease 2019 in China"},{"title3":"Substantial Undocumented Infection Facilitates the Rapid Dissemination of Novel Coronavirus (SARS-CoV-2)"},{"title3":"Covid-19: New Coronavirus Variant Is Identified in UK"},{"title3":"Spike Mutation D614G Alters SARS-CoV-2 Fitness"},{"title3":"Emerging SARS-CoV-2 Mutation Hot Spots Include a Novel RNA-Dependent-RNA Polymerase Variant"},{"title3":"Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review"},{"title3":"Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)"},{"title3":"Coronaviruses - Drug Discovery and Therapeutic Options"},{"title3":"An Orally Bioavailable Broad-Spectrum Antiviral Inhibits SARS-CoV-2 in Human Airway Epithelial Cell Cultures and Multiple Coronaviruses in Mice"},{"title3":"Remdesivir Is a Direct-Acting Antiviral That Inhibits RNA-Dependent RNA Polymerase from Severe Acute Respiratory Syndrome Coronavirus 2 with High Potency"},{"title3":"Structural Basis for Inhibition of the RNA-Dependent RNA Polymerase from SARS-CoV-2 by Remdesivir"},{"title3":"Coronavirus RNA Proofreading: Molecular Basis and Therapeutic Targeting"},{"title3":"Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State"},{"title3":"Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19"},{"title3":"A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19"},{"title3":"Should Chloroquine and Hydroxychloroquine Be Used to Treat COVID-19? A Rapid Review"},{"title3":"QT Interval Prolongation and Torsade de Pointes in Patients with COVID-19 Treated with Hydroxychloroquine/Azithromycin"},{"title3":"Remdesivir in Adults with Severe COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial"},{"title3":"Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-NCoV) in Vitro"},{"title3":"Remdesivir, Lopinavir, Emetine, and Homoharringtonine Inhibit SARS-CoV-2 Replication in Vitro"},{"title3":"Discovery of SARS-CoV-2 Antiviral Drugs through Large-Scale Compound Repurposing"},{"title3":"Identification of Existing Pharmaceuticals and Herbal Medicines as Inhibitors of SARS-CoV-2 Infection"},{"title3":"Comparative Analysis of Antiviral Efficacy of FDA-approved Drugs against SARS-CoV-2 in Human Lung Cells"},{"title3":"Broad Anti-Coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In Vivo"},{"title3":"Crystal Structure of SARS-CoV-2 Main Protease Provides a Basis for Design of Improved alpha-Ketoamide Inhibitors"},{"title3":"Structure of Mpro from SARS-CoV-2 and Discovery of Its Inhibitors"},{"title3":"Papain-like Protease Regulates SARS-CoV-2 Viral Spread and Innate Immunity"},{"title3":"Structure of the RNA-Dependent RNA Polymerase from COVID-19 Virus"},{"title3":"Structural Basis for the Inhibition of SARS-CoV-2 Main Protease by Antineoplastic Drug Carmofur"},{"title3":"Discovery and Development of Simeprevir (TMC435), a HCV NS3/4A Protease Inhibitor"},{"title3":"Anti-HCV and Anti-Malaria Agent, Potential Candidates to Repurpose for Coronavirus Infection: Virtual Screening, Molecular Docking, and Molecular Dynamics Simulation Study"},{"title3":"Repurposing Simeprevir, Calpain Inhibitor IV and a Cathepsin F Inhibitor against SARS-CoV-2 and Insights into Their Interactions with Mpro"},{"title3":"An Integrated Drug Repurposing Strategy for the Rapid Identification of Potential SARS-CoV-2 Viral Inhibitors"},{"title3":"Exogenous ACE2 Expression Allows Refractory Cell Lines to Support Severe Acute Respiratory Syndrome Coronavirus Replication"},{"title3":"In Vitro Activity and Preclinical Profile of TMC435350, a Potent Hepatitis C Virus Protease Inhibitor"},{"title3":"Hepatitis C Virus Drugs Simeprevir and Grazoprevir Synergize with Remdesivir to Suppress SARS-CoV-2 Replication in Cell Culture"},{"title3":"Profiling of Substrate Specificity of SARS-CoV 3CL"},{"title3":"Boceprevir, GC-376, and Calpain Inhibitors II, XII Inhibit SARS-CoV-2 Viral Replication by Targeting the Viral Main Protease"},{"title3":"Molecular Investigation of SARS-CoV-2 Proteins and Their Interactions with Antiviral Drugs"},{"title3":"One Severe Acute Respiratory Syndrome Coronavirus Protein Complex Integrates Processive RNA Polymerase and Exonuclease Activities"},{"title3":"A Fluorescence-Based High Throughput-Screening Assay for the SARS-CoV RNA Synthesis Complex"},{"title3":"Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19"},{"title3":"Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19"},{"title3":"H5N1 Influenza Virus-Induced Mediators Upregulate RIG-I in Uninfected Cells by Paracrine Effects Contributing to Amplified Cytokine Cascades"},{"title3":". Clinical Pharmacology and Biopharmaceutics Reivew(s) (Application Number 205123Orig1s000), ."},{"title3":"Mechanistic Understanding of the Nonlinear Pharmacokinetics and Intersubject Variability of Simeprevir: A PBPK-Guided Drug Development Approach"},{"title3":"Dose-Response Curve Slope Sets Class-Specific Limits on Inhibitory Potential of Anti-HIV Drugs"},{"title3":"A Critical Subset Model Provides a Conceptual Basis for the High Antiviral Activity of Major HIV Drugs"},{"title3":"Genome-Wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection"},{"title3":"Epigenetic Control of Influenza Virus: Role of H3K79 Methylation in Interferon-Induced Antiviral Response"},{"title3":"MERS-CoV and H5N1 Influenza Virus Antagonize Antigen Presentation by Altering the Epigenetic Landscape"},{"title3":"Tropism, Replication Competence, and Innate Immune Responses of the Coronavirus SARS-CoV-2 in Human Respiratory Tract and Conjunctiva: An Analysis in Ex-Vivo and in-Vitro Cultures"},{"title3":"ZINC 15--Ligand Discovery for Everyone"},{"title3":"AutoDock Vina: Improving the Speed and Accuracy of Docking with a New Scoring Function, Efficient Optimization, and Multithreading"},{"title3":"Design, Synthesis and Crystallographic Analysis of Nitrile-Based Broad-Spectrum Peptidomimetic Inhibitors for Coronavirus 3C-like Proteases"},{"title3":"Rapid Incorporation of Favipiravir by the Fast and Permissive Viral RNA Polymerase Complex Results in SARS-CoV-2 Lethal Mutagenesis"},{"title3":"System-Wide Modulation of HECT E3 Ligases with Selective Ubiquitin Variant Probes"},{"title3":"Gene Set Enrichment Analysis: A Knowledge-Based Approach for Interpreting Genome-Wide Expression Profiles"},{"title3":"STAR: ultrafast universal RNA-seq aligner"},{"title3":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features"},{"title3":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2"},{"title3":"BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis"}]},{"title2":"The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2","References":[]},{"title2":"Evaluation of 19 antiviral drugs against SARS-CoV-2 infection","References":[]},{"title2":"Minimum costs to manufacture new treatments for COVID-19","References":[{"title3":"Responding to Covid-19 - a once-in-a-century pandemic?"},{"title3":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)"},{"title3":"Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model"},{"title3":"Drug repurposing: progress, challenges and recommendations"},{"title3":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses"},{"title3":"Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazine-4-amino] adenine C-nucleoside (GS-5374) for the treatment of Ebola and emerging viruses"},{"title3":"Influenza virus polymerase inhibitors in clinical development"},{"title3":"Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS, or COVID-19: initial assessment"},{"title3":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19"},{"title3":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)"},{"title3":"Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries"},{"title3":"Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C"},{"title3":"Estimation of cost-based prices for injectable medicines in the WHO Essential Medicines List"},{"title3":"Estimated costs of production and potential prices for the WHO Essential Medicines List"},{"title3":"Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial"},{"title3":"A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)"},{"title3":"Hydroxychloroquine and azithromycin as a treatment for COVID-19: results of an open-label, non-randomized clinical trial"},{"title3":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection"},{"title3":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies"},{"title3":"Favipiravir versus arbidol for COVID-19: a randomized clinical trial"},{"title3":"A practical and step-economic route to Favipiravir"},{"title3":"The complete synthesis of favipiravir from 2-aminopyrazine"},{"title3":"Impact of fluid choice in systemic inflammatory response syndrome patients on hospital cost savings"},{"title3":"Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind"},{"title3":"Era of biosimilars in rheumatology: reshaping the healthcare environment"},{"title3":"Commissioning Framework for Biological Medicines (Including Biosimilar Medicines)"},{"title3":"Indian pharma threatened by COVID-19 shutdowns in China"}]},{"title2":"Radiologic management of COVID-19: preliminary experience of the Iranian Society of Radiology COVID-19 Consultant Group (ISRCC)","References":[]},{"title2":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","References":[{"title3":"Coronavirus disease 2019 (COVID-19) situation report-107"},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"A pathological report of three COVID-19 cases by minimally invasive autopsies"},{"title3":"Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in golden syrian hamster model: implications for disease pathogenesis and tansmissibility"},{"title3":"In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds"},{"title3":"Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus"},{"title3":"Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings"},{"title3":"Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset"},{"title3":"Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study"},{"title3":"Medical treatment of viral pneumonia including SARS in immunocompetent adult"},{"title3":"Antiviral combinations for severe influenza"},{"title3":"Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: an open-label randomized, controlled, phase IIb/III trial"},{"title3":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonulcease"},{"title3":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)"},{"title3":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"},{"title3":"Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus"},{"title3":"Advances in respiratory virus therapeutics - a meeting report from the 6th isirv Antiviral Group conference"},{"title3":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV"},{"title3":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis"},{"title3":"Treatment of COVID-19: old tricks for new challenges"},{"title3":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)"},{"title3":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19"},{"title3":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial"},{"title3":"Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: a retrospective cohort study"},{"title3":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents"},{"title3":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture"},{"title3":"Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs"},{"title3":"Ribavirin and interferon therapy for critically ill patients with Middle East Respiratory Syndrome: a multicentre observational study"},{"title3":"Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19"},{"title3":"TLR9-induced interferon beta is associated with protection from gammaherpesvirus-induced exacerbation of lung fibrosis"}]}]},{"title1":"The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19","References":[{"title2":"Treating COVID-19:off-label drug use, compassionate use, and randomized clinical trials during pandemics","References":[]},{"title2":"Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19","References":[{"title3":"The proximal origin of SARS-CoV-2"},{"title3":"Coronavirus"},{"title3":"Human coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategies"},{"title3":"From SARS to MERS, Thrusting Coronaviruses into the Spotlight"},{"title3":"Jumping species-a mechanism for coronavirus persistence and survival"},{"title3":"Middle East respiratory syndrome coronavirus (MERS-CoV): animal to human interaction"},{"title3":"A pneumonia outbreak associated with a new coronavirus of probable bat origin"},{"title3":"Director-General's opening remarks at the media briefing on COVID-19"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia"},{"title3":"Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention"},{"title3":"Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis"},{"title3":"Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy"},{"title3":"An interactive web-based dashboard to track COVID-19 in real time"},{"title3":"Endocrine and metabolic link to coronavirus infection"},{"title3":"Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China"},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"},{"title3":"Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission"},{"title3":"Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms"},{"title3":"The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients"},{"title3":"Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study"},{"title3":"Nervous system involvement after infection with COVID-19 and other coronaviruses"},{"title3":"Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases"},{"title3":"Tissue and cellular tropism of the coronavirus associated with severe acute respiratory syndrome: an in-situ hybridization study of fatal cases"},{"title3":"Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19"},{"title3":"SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes"},{"title3":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses"},{"title3":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor"},{"title3":"The coronavirus E protein: assembly and beyond"},{"title3":"Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV"},{"title3":"Coronavirus puts drug repurposing on the fast track"},{"title3":"First up for COVID-19: nearly 30 clinical readouts before end of April"},{"title3":"The epidemiology, diagnosis and treatment of COVID-19"},{"title3":"A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals"},{"title3":"In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication"},{"title3":"Identification of inhibitors of SARS-CoV-2 in-vitro cellular toxicity in human (Caco-2) cells using a large scale drug repurposing collection"},{"title3":"Autophagy therapeutics: preclinical basis and initial clinical studies"},{"title3":"Nucleotide Prodrug GS-5734 Is a Broad-Spectrum Filovirus Inhibitor That Provides Complete Therapeutic Protection Against the Development of Ebola Virus Disease (EVD) in Infected Non-human Primates"},{"title3":"Strategies in the design of antiviral drugs"},{"title3":"Aryloxy phosphoramidate triesters: a technology for delivering monophosphorylated nucleosides and sugars into cells"},{"title3":"The evolution of nucleoside analogue antivirals: A review for chemists and non-chemists. Part 1: Early structural modifications to the nucleoside scaffold"},{"title3":"Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses"},{"title3":"Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides"},{"title3":"Cell-based Assays to Identify Inhibitors of Viral Disease"},{"title3":"Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease"},{"title3":"Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies"},{"title3":"Broad-spectrum Investigational Agent GS-5734 for the Treatment of Ebola, MERS Coronavirus and Other Pathogenic Viral Infections with High Outbreak Potential"},{"title3":"Intracellular Metabolism of Nucleoside/Nucleotide Analogues: a Bottleneck to Reach Active Drugs on HIV Reverse Transcriptase"},{"title3":"Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase"},{"title3":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection"},{"title3":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"},{"title3":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV"},{"title3":"A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics"},{"title3":"Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides"},{"title3":"Ribavirin--current status of a broad spectrum antiviral agent"},{"title3":"Design, synthesis, and broad spectrum antiviral activity of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides"},{"title3":"RNA virus error catastrophe: direct molecular test by using ribavirin"},{"title3":"Molecular targets for AIDS therapy"},{"title3":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency"},{"title3":"Structure of RNA-dependent RNA polymerase from 2019-nCoV, a major antiviral drug target"},{"title3":"The ProTide Prodrug Technology: From the Concept to the Clinic"},{"title3":"Phosphoramidates and phosphonamidates (ProTides) with antiviral activity"},{"title3":"Synthesis and anti-HIV evaluation of some phosphoramidate derivatives of AZT: studies on the effect of chain elongation on biological activity"},{"title3":"Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT"},{"title3":"Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977"},{"title3":"Characterization of the activation pathway of phosphoramidate triester prodrugs of stavudine and zidovudine"},{"title3":"Synthesis and biological studies of novel nucleoside phosphoramidate prodrugs"},{"title3":"Protease-mediated enzymatic hydrolysis and activation of aryl phosphoramidate derivatives of stavudine"},{"title3":"Pre-steady state of reaction of nucleoside diphosphate kinase with anti-HIV nucleotides"},{"title3":"Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides"},{"title3":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses"},{"title3":"Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase"},{"title3":"Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir"},{"title3":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys"},{"title3":"Role of Mitochondrial RNA Polymerase in the Toxicity of Nucleotide Inhibitors of Hepatitis C Virus"},{"title3":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus"},{"title3":". Mild/Moderate 2019-nCoV Remdesivir RCT. . Accessed April 10, 2020."},{"title3":". Severe 2019-nCoV Remdesivir RCT. . Accessed April 10, 2020."},{"title3":"First Case of 2019 Novel Coronavirus in the United States"},{"title3":"First 12 patients with coronavirus disease 2019 (COVID-19) in the United States"},{"title3":". Adaptive COVID-19 Treatment Trial (ACTT). . Accessed April 10, 2020."},{"title3":". Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment (NCT04292730). . Accessed April 10, 2020."},{"title3":". &quot;Solidarity&quot; clinical trial for COVID-19 treatments. . Accessed April 7, 2020."},{"title3":". The Efficacy of Different Anti-viral Drugs in (Severe Acute Respiratory Syndrome-Corona Virus-2) SARS-CoV-2. . Accessed April 6, 2020."},{"title3":". Adverse Events Related to Treatments Used Against Coronavirus Disease 2019 (CovidTox). . Accessed April 6, 2020."},{"title3":". Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy), . Accessed April 6, 2020."},{"title3":". Launch of a European clinical trial against COVID-19. . Accessed April 9, 2020."},{"title3":"Simple Features for R: Standardized Support for Spatial Vector Data"},{"title3":". Expanded Access Remdesivir (RDV; GS-5734). . Accessed April 6, 2020."},{"title3":". Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection. . Accessed April 11, 2020."},{"title3":"An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice"},{"title3":"Nucleotide analogues as inhibitors of SARS-CoV polymerase"},{"title3":"Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases"},{"title3":"The SARS-CoV-2 Vaccine Pipeline: an Overview"},{"title3":"The pandemic pipeline"},{"title3":"Catching Up to Coronavirus: Top 60 Treatments in Development. Genetic Engineering &amp; Biotechnology News"},{"title3":"NCATS launches drug repurposing program"},{"title3":"Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs"},{"title3":"Compassionate Use of Remdesivir for Patients with Severe Covid-19"},{"title3":"NIAID News Release, April 29, 2020. NIH Clinical Trial Shows Remdesivir Accelerates Recovery from Advanced COVID-19. ()."},{"title3":"FDA News Release, May 1, 2020. Remdesivir EUA Letter of Authorization. ()."}]},{"title2":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","References":[{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study"},{"title3":"A new coronavirus associated with human respiratory disease in China"},{"title3":"A pneumonia outbreak associated with a new coronavirus of probable bat origin"},{"title3":"The coronavirus replicase"},{"title3":"One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities"},{"title3":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"},{"title3":"First Case of 2019 Novel Coronavirus in the United States"},{"title3":"Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors"},{"title3":"Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerase-containing protein of all nidoviruses"},{"title3":"Insights into SARS-CoV transcription and replication from the structure of the nsp7-nsp8 hexadecamer"},{"title3":"RNA synthetic mechanisms employed by diverse families of RNA viruses"},{"title3":"Structural basis for RNA replication by the hepatitis C virus polymerase"},{"title3":"Structural basis for active site closure by the poliovirus RNA-dependent RNA polymerase"},{"title3":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys"},{"title3":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C"},{"title3":"Automated electron microscope tomography using robust prediction of specimen movements"},{"title3":"MotionCor2: Anisotropic correction of beam-induced motion for improved cryo-electron microscopy"},{"title3":"cryoSPARC: Algorithms for rapid unsupervised cryo-EM structure determination"},{"title3":"New nsp8 isoform suggests mechanism for tuning viral RNA synthesis"},{"title3":"UCSF Chimera:A visualization system for exploratory research and analysis"},{"title3":"Features and development of Coot"},{"title3":"Towards automated crystallographic structure refinement with phenix.refine"}]},{"title2":"Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors","References":[{"title3":",  (accessed 13rd March, 2021)."},{"title3":"A novel coronavirus outbreak of global health concern"},{"title3":"Databases for the targeted COVID-19 therapeutics"},{"title3":"Computational Design and Modeling of Nanobodies toward SARS-CoV-2 Receptor Binding Domain"},{"title3":"Discovering small-molecule therapeutics against SARS-CoV-2"},{"title3":"A pneumonia outbreak associated with a new coronavirus of probable bat origin"},{"title3":"A new coronavirus associated with human respiratory disease in China"},{"title3":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease"},{"title3":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors"},{"title3":"From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design"},{"title3":"Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors"},{"title3":"Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV-2 Main Protease"},{"title3":"Computational Determination of Potential Inhibitors of SARS-CoV-2 Main Protease"},{"title3":"In Silico Exploration of the Molecular Mechanism of Clinically Oriented Drugs for Possibly Inhibiting SARS-CoV-2's Main Protease"},{"title3":"Lead Discovery of SARS-CoV-2 Main Protease Inhibitors through Covalent Docking-Based Virtual Screening"},{"title3":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease"},{"title3":"Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur"},{"title3":"Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel In Silico Method"},{"title3":"Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors"},{"title3":"MCCS: a novel recognition pattern-based method for fast track discovery of anti-SARS-CoV-2 drugs"},{"title3":"Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs"},{"title3":"Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design"},{"title3":"SARS-CoV-2 Main Protease: A Molecular Dynamics Study"},{"title3":"Molecular Dynamics Simulations Related to SARS-COV-2,  (accessed 13rd March, 2021)."},{"title3":"Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation"},{"title3":"Large-scale systematic analysis of 2D fingerprint methods and parameters to improve virtual screening enrichments"},{"title3":"End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design"},{"title3":"Revealing the molecular mechanisms of proteolysis of SARS-CoV-2 Mpro by QM/MM computational methods"},{"title3":"Mechanism of inhibition of SARS-CoV-2 Mpro by N3 peptidyl Michael acceptor explained by QM/MM simulations and design of new derivatives with tunable chemical reactivity"},{"title3":"Hyperproduction of 3-hydroxypropionate by Halomonas bluephagenesis"},{"title3":"Discovery of human macrophage migration inhibitory factor (MIF)-CD74 antagonists via virtual screening"},{"title3":"The role of dipyridamole in the therapy of vascular disease"},{"title3":"Structure-based design, synthesis, and evaluation of peptide-mimetic SARS 3CL protease inhibitors"},{"title3":"Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments"},{"title3":"OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins"},{"title3":"Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening"},{"title3":"Accelerated structure-based design of chemically diverse allosteric modulators of a muscarinic G protein-coupled receptor"},{"title3":"Epik: a software program for pK(a) prediction and protonation state generation for drug-like molecules"},{"title3":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy"},{"title3":"Elucidating the tight-binding mechanism of two oral anticoagulants to factor Xa by using induced-fit docking and molecular dynamics simulation"},{"title3":"ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB"},{"title3":"Automatic atom type and bond type perception in molecular mechanical calculations"},{"title3":"Development and testing of a general amber force field"},{"title3":"Comparison of multiple Amber force fields and development of improved protein backbone parameters"}]},{"title2":"Sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study","References":[{"title3":"Pneumonia of unknown etiology in Wuhan, China: potential for international spread via commercial air travel"},{"title3":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health:the latest 2019 novel coronavirus outbreak in Wuhan, China"},{"title3":"The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak"},{"title3":"Pneumonia in China: lack of information raises concerns among Hong Kong health workers"},{"title3":"Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease"},{"title3":"Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses"},{"title3":"COVID-19 spike-host cell receptor GRP78 binding site prediction"},{"title3":"Catalytic function and substrate specificity of the papain-like protease domain of nsp3 from the Middle East respiratory syndrome coronavirus"},{"title3":"Some one health based control strategies for the Middle East respiratory syndrome coronavirus"},{"title3":"Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials"},{"title3":"Zika virus: novel guanosine derivatives revealed strong binding and possible inhibition of the polymerase"},{"title3":"Novel guanosine derivatives as anti-HCV NS5b polymerase: a QSAR and molecular docking study"},{"title3":"IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study"},{"title3":"Molecular dynamics simulation revealed binding of nucleotide inhibitors to ZIKV polymerase over 444 nanoseconds"},{"title3":"Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes"},{"title3":"Molecular dynamics and docking reveal the potency of novel GTP derivatives against RNA dependent RNA polymerase of genotype 4a HCV"},{"title3":"Molecular modeling and docking revealed superiority of IDX-184 as HCV polymerase inhibitor"},{"title3":"Applications of computer-aided approaches in the development of hepatitis C antiviral agents"},{"title3":"The mechanism of action of T7 DNA polymerase"},{"title3":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19"},{"title3":"Molecular docking revealed the binding of nucleotide/side inhibitors to Zika viral polymerase solved structures"},{"title3":"Announcing the worldwide Protein Data Bank"},{"title3":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods"},{"title3":"National center of biotechnology informatics (NCBI) database website"},{"title3":"SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information"},{"title3":"Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors"},{"title3":"MolProbity: more and better reference data for improved all-atom structure validation"},{"title3":"AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR"},{"title3":"Deviations from standard atomic volumes as a quality measure for protein crystal structures"},{"title3":"Errors in protein structures"},{"title3":"The antiviral Sofosbuvir against mucormycosis: an in silico perspective"},{"title3":"Structural properties of metal-free apometallothioneins"},{"title3":"Molecular mechanics. The MM3 force field for hydrocarbons. 3. The van der Waals' potentials and crystal data for aliphatic and aromatic hydrocarbons"},{"title3":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading"},{"title3":"PLIP: fully automated protein-ligand interaction profiler"},{"title3":"Density-functional thermochemistry. III. The role of exact exchange"},{"title3":"Optimization of parameters for semiempirical methods V: modification of NDDO approximations and application to 70 elements"},{"title3":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility"}]},{"title2":"Nucleotide analogues as inhibitors of SARS-CoV polymerase","References":[{"title3":"A novel coronavirus from patients with pneumonia in China, 2019"},{"title3":"Coronaviruses - drug discovery and therapeutic options"},{"title3":"Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy"},{"title3":"Common and unique features of viral RNA-dependent polymerases"},{"title3":"Structural and functional basis of the fidelity of nucleotide selection by Flavivirus RNA-dependent RNA polymerases"},{"title3":"Inhibitors of viral nucleic acid polymerases"},{"title3":"Rational design of polymerase inhibitors as antiviral drugs"},{"title3":"Inhibitors of the hepatitis C virus polymerase; mode of action and resistance"},{"title3":"Approved antiviral drugs over the past 50 years"},{"title3":"Nucleotide analogues as inhibitors of viral polymerases"},{"title3":"Finally sofosbuvir: an oral anti-HCV drug with wide performance capability"},{"title3":"Discovery of a beta-D-2'-Deoxy-2'-alpha-fluoro-2'-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus"},{"title3":"NS5A inhibitors for the treatment of hepatitis C infection"},{"title3":"The hepatitis C virus NS5A stimulates NS5B during in vitro RNA synthesis in a template specific manner"},{"title3":"First case of 2019 novel coronavirus in the United States"},{"title3":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"},{"title3":"The ProTide prodrug technology: where next?"},{"title3":"Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy"},{"title3":"Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo-controlled study in patients with chronic hepatitis C"},{"title3":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus"},{"title3":"Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by Remdesivir"},{"title3":"Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase"},{"title3":"Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides"},{"title3":"General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2'-modified nucleotide analogues"},{"title3":"Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses"},{"title3":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19"},{"title3":"Inhibition of viral RNA polymerases by nucleoside and nucleotide analogs: therapeutic applications against positive-strand RNA viruses beyond hepatitis C virus"},{"title3":"New antiviral approaches for respiratory syncytial virus and other mononegaviruses: Inhibiting the RNA polymerase"},{"title3":"Four-color DNA sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators"},{"title3":"Four-color DNA sequencing with 3'-O-modified nucleotide reversible terminators and chemically cleavable fluorescent dideoxynucleotides"},{"title3":"Design and synthesis of a 3'-O-allyl photocleavable fluorescent nucleotide as a reversible terminator for DNA sequencing by synthesis"},{"title3":"A single residue in DNA polymerases of Escherichia coli DNA polymerase I family is critical for distinguishing between deoxy- and dideoxynucleotides"},{"title3":"Structure of the anti-human immunodeficiency virus agent 3'-fluoro-3'-deoxythymidine and electronic charge calculations for 3'-deoxythymidines"},{"title3":"Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants"},{"title3":"Antiviral activity of low-dose alovudine in antiretroviral-experienced patients: results from a 4-week randomized, double-blind, placebo-controlled dose-ranging trial"},{"title3":"3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro"},{"title3":"Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex"},{"title3":"Molecular targets for AIDS therapy"},{"title3":"Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase"},{"title3":"AZT: An old drug with new perspectives"},{"title3":"One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities"},{"title3":"Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors"},{"title3":"Discovery of an RNA virus 3'-5' exoribonuclease that is critically involved in coronavirus RNA synthesis"},{"title3":"Coronavirus susceptibility to the antiviral Remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exonuclease"},{"title3":"Nucleotide analogues as inhibitors of SARS-CoV polymerase"},{"title3":"Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a Key Drug Target for COVID-19"},{"title3":"A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19"},{"title3":"Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic"},{"title3":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus"},{"title3":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir"},{"title3":"Structure of replicating SARS-CoV-2 polymerase"},{"title3":"Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study"},{"title3":"SARS-CoV-2 RNA polymerase as target for antiviral therapy"},{"title3":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency"},{"title3":"The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2"},{"title3":"Sofosbuvir protects human brain organoids against SARS-CoV-2"},{"title3":"Sofosbuvir as repurposed antiviral drug against COVID-19: Why were we convinced to evaluate the drug in a registered/approved clinical trial?"},{"title3":"  . https://www.worldhepatitisalliance.org/latest-news/infohep/3548907/hepatitis-c-drugs-may-offer-inexpensive-treatment-option-covid-19."},{"title3":"Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial"},{"title3":"The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19"},{"title3":"Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial"},{"title3":"Daclatasvir: A NS5A replication complex inhibitor for hepatitis C infection"},{"title3":"Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19"},{"title3":"Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir"},{"title3":"The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY"},{"title3":"The Concise Guide to PHARMACOLOGY 2019/20: Enzymes"}]},{"title2":"Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase","References":[{"title3":"for the China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019"},{"title3":"Coronaviruses - drug discovery and therapeutic options"},{"title3":"Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy"},{"title3":"Common and unique features of viral RNA-dependent polymerases"},{"title3":"Structural and functional basis of the fidelity of nucleotide selection by Flavivirus RNA-dependent RNA polymerases"},{"title3":"Inhibitors of viral nucleic acid polymerases. Pyrophosphate analogues"},{"title3":"Rational design of polymerase inhibitors as antiviral drugs"},{"title3":"Inhibitors of the hepatitis C virus polymerase; mode of action and resistance"},{"title3":"Approved antiviral drugs over the past 50 years"},{"title3":"Nucleotide analogues as inhibitors of viral polymerases"},{"title3":"Nucleotide analogues as inhibitors of SARS-CoV polymerase"},{"title3":"Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study"},{"title3":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus"},{"title3":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency"},{"title3":"Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19"},{"title3":"SARS-CoV-2 RNA polymerase as target for antiviral therapy"},{"title3":"Sofosbuvir as repurposed antiviral drug against COVID-19: why were we convinced to evaluate the drug in a registered/approved clinical trial?"},{"title3":"A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19"},{"title3":"One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities"},{"title3":"Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors"},{"title3":"Advances in nucleotide antiviral development from scientific discovery to clinical applications: Tenofovir disproxil fumarate for hepatitis B"},{"title3":"Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)"},{"title3":"Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors"},{"title3":"Rare emergence of drug resistance in HIV-1 treatment-naive patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks"},{"title3":"Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics"},{"title3":"Twenty-five years of lamivudine: current and future use for the treatment of HIV-1 infection"},{"title3":"Elucidating molecular interactions of L-nucleotides with HIV-1 reverse transcriptase and mechanism of M184V-caused drug resistance"},{"title3":"A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B"},{"title3":"Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89"},{"title3":"Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir"},{"title3":"Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase"},{"title3":"The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2"},{"title3":"Sofosbuvir protects human brain organoids against SARS-CoV-2"},{"title3":"Development of a simple in vitro assay to identify and evaluate nucleotide analogs against SARS-CoV-2 RNA-dependent RNA polymerase"},{"title3":"The Spanish HIV/COVID-19 Collaboration. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy. A cohort study"},{"title3":"The ProTide prodrug technology: where next?"}]},{"title2":"Prediction of small molecule inhibitors targeting the novel coronavirus (SARS-CoV-2) RNA-dependent RNA polymerase","References":[]},{"title2":"Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model","References":[{"title3":"Coronavirus avian infectious bronchitis virus"},{"title3":"Human coronaviruses: a review of virus-host interactions"},{"title3":"Coronavirus pathogenesis"},{"title3":"Coronavirus genomics and bioinformatics analysis"},{"title3":"Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome"},{"title3":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia"},{"title3":"WHO. Summary of probable SARS cases with oneset of illness from 1 November 2002 to 31 July 2003. Dec 31, 2003. (https://wwwwhoint/csr/sars/country/table2004_04_21/en/). 2020."},{"title3":"WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). November, 2019. (http://wwwwhoint/emergencies/mers-cov/en/). 2020."},{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV"},{"title3":"Human coronavirus: host-pathogen interaction"},{"title3":"Self-attention based molecule representation for predicting drug-target interaction"},{"title3":"Drug Target Commons 2.0: a community platform for systematic analysis of drug-target interaction profiles"},{"title3":"BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities"},{"title3":"Global mapping of pharmacological space"},{"title3":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"},{"title3":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading"},{"title3":"Open Babel: an open chemical toolbox"},{"title3":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility"},{"title3":"Software for molecular docking: a review"},{"title3":"DeepDTA: deep drug-target binding affinity prediction"},{"title3":"SimBoost: a read-across approach for predicting drug-target binding affinities using gradient boosting machines"},{"title3":"Toward more realistic drug-target interaction predictions"},{"title3":"Making sense of large-scale kinase inhibitor bioactivity data sets: a comparative and integrative analysis"},{"title3":"Comprehensive analysis of kinase inhibitor selectivity"},{"title3":"Z. Jin, X. Du, Y. Xu, Y. Deng, M. Liu, Z. Zhao, et al. Structure of Mpro from COVID-19 virus and discovery of its inhibitors. bioRxiv. 2020."},{"title3":"Lopinavir; a potent drug against coronavirus infection: insight from molecular docking study"},{"title3":"SARS and MERS: recent insights into emerging coronaviruses"},{"title3":"drugmakers ship therapies to China, seeking to treat coronavirus"},{"title3":"Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings"},{"title3":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"},{"title3":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)"},{"title3":"First case of 2019 novel coronavirus in the United States"},{"title3":"Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment"},{"title3":"More than 80 clinical trials launch to test coronavirus treatments"}]},{"title2":"In silico study of various antiviral drugs, vitamins, and natural substances as potential binding compounds with SARS-CoV-2 main protease","References":[]},{"title2":"The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2","References":[]},{"title2":"Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome","References":[{"title3":"Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide"},{"title3":"Diagnosis, management, and treatment of hepatitis C"},{"title3":"Use of ribavirin in the treatment of respiratory syncytial virus infection"},{"title3":"Lassa fever: effective therapy with ribavirin"},{"title3":"Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome"},{"title3":"Treatment of Bolivian hemorrhagic fever with intravenous ribavirin"},{"title3":"Antiviral treatment of Argentine hemorrhagic fever"},{"title3":"Hemorrhagic fever viruses as biological weapons: medical and public health management"},{"title3":"Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug"},{"title3":"The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase"},{"title3":"A major outbreak of severe acute respiratory syndrome in Hong Kong"},{"title3":"Identification of severe acute respiratory syndrome in Canada"},{"title3":"In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds"},{"title3":"Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus"},{"title3":"Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-alpha"},{"title3":"Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings"},{"title3":"Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area"},{"title3":"Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China"},{"title3":"Severe acute respiratory syndrome: clinical outcome and prognostic correlates"},{"title3":"Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003"},{"title3":"Clinical course and management of SARS in health care workers in Toronto: a case series"},{"title3":"Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada"},{"title3":"Ribavirin in the treatment of SARS: a new trick for an old drug?"},{"title3":"Public health measures to control the spread of the severe acute respiratory syndrome during the outbreak in Toronto"},{"title3":"Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience"},{"title3":"Early diagnosis of SARS: lessons from the Toronto SARS outbreak"},{"title3":"Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C"},{"title3":"Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane hepato-biliary group systematic review and meta-analysis of randomized trials"},{"title3":"The safety and tolerability of daily infergen plus ribavirin in the treatment of naive chronic hepatitis C patients"},{"title3":"Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin"},{"title3":"Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience"},{"title3":"SARS: pharmacotherapy"},{"title3":"Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong"},{"title3":"Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients"},{"title3":"SARS: prognosis, outcome and sequelae"},{"title3":"Prognostic factors for severe acute respiratory syndrome: a clinical analysis of 165 cases"},{"title3":"Severe acute respiratory syndrome: prognostic implications of chest radiographic findings in 52 patients"},{"title3":"Value of initial chest radiographs for predicting clinical outcomes in patients with severe acute respiratory syndrome"},{"title3":"Multiple imputation: a primer"},{"title3":"Selection bias in observational and experimental studies"},{"title3":"Multiple significance tests: the Bonferroni method [statistics notes]"},{"title3":"Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers"},{"title3":"Development of a standard treatment protocol for severe acute respiratory syndrome"},{"title3":"Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study"},{"title3":"Clinical characteristics, management and prognostic factors in patients with probable severe acute respiratory syndrome (SARS) in a SARS center in Taiwan"},{"title3":"The multifactorial basis for hypocalcemia during sepsis: studies of the parathyroid hormonevitamin D axis"},{"title3":"Hypocalcemia: a pervasive metabolic abnormality in the critically ill"},{"title3":"SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases"}]},{"title2":"SD1000: high sustained viral response rate in 1361 patients with hepatitis C genotypes 1, 2, 3, and 4 using a low-cost, fixed-dose combination tablet of generic sofosbuvir and daclatasvir: a multicenter, phase III clinical trial","References":[]},{"title2":"The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment","References":[]},{"title2":"A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19","References":[{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China."},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study."},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China."},{"title3":"Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province."},{"title3":"Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings."},{"title3":"In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds."},{"title3":"Small molecules targeting severe acute respiratory syndrome human coronavirus."},{"title3":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture."},{"title3":"Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset."},{"title3":"Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome."},{"title3":"Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen."},{"title3":"Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity."},{"title3":"Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus."},{"title3":"Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays."},{"title3":"Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial."},{"title3":"International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) home page ()."},{"title3":"Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection."},{"title3":"Coronavirus disease (COVID-2019) R&amp;D. Geneva: World Health Organization ()."},{"title3":"National Early Warning Score (NEWS) 2: standardising the assessment of acute-illness severity in the NHS. London: Royal College of Physicians, 2017 ()."},{"title3":"Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study."},{"title3":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data."},{"title3":"Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09."},{"title3":"Early oseltamivir after hospital admission is associated with shortened hospitalization: a 5-year analysis of oseltamivir timing and clinical outcomes."},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study."},{"title3":"SARS-CoV-2 viral load in upper respiratory specimens of infected patients."},{"title3":"HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus."}]},{"title2":"Remdesivir for the treatment of COVID-19:preliminary report","References":[]},{"title2":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","References":[{"title3":"COVID-19 map. Johns Hopkins Coronavirus Resource Centre"},{"title3":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"},{"title3":"Covid-19 in critically ill patients in the Seattle region-case series"},{"title3":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"},{"title3":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro"},{"title3":"Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial"},{"title3":"Favipiravir versus arbidol for COVID-19: a randomized clinical trial"},{"title3":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma"},{"title3":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19"},{"title3":"GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses"},{"title3":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses"},{"title3":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys"},{"title3":"Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase"},{"title3":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV"},{"title3":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection"},{"title3":"Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia"},{"title3":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2"},{"title3":"A randomized, controlled trial of Ebola virus disease therapeutics"},{"title3":"Compassionate use of remdesivir for patients with severe Covid-19"},{"title3":"First case of 2019 novel coronavirus in the United States"},{"title3":"Group sequential clinical trials with triangular continuation regions"},{"title3":"Gilead Sciences. Investigator's brochure of remdesivir, 5th edition. Feb 21, 2020."},{"title3":"Late Ebola virus relapse causing meningoencephalitis: a case report"},{"title3":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease"},{"title3":"Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients"},{"title3":"Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome"}]},{"title2":"Favipiravir versus arbidol for COVID-19: a randomized clinical trial","References":[{"title3":"Discovering Drugs to Treat Coronavirus Disease 2019 (COVID-19)"},{"title3":"Favipiravir: Pharmacokinetics and Concerns about Clinical Trials for 2019-nCoV Infection"},{"title3":"In Vitro and In Vivo Activities of Anti-influenza Virus Compound T-705"},{"title3":"The Mechanism of Resistance to Favipiravir in Influenza"},{"title3":"Clinical Characteristics of Coronavirus Disease 2019 in China"},{"title3":"Arbidol and Other Low-Molecular-Weight Drugs that Inhibit Lassa and Ebola Viruses"},{"title3":"Virus Susceptibility and Clinical Effectiveness of Anti-influenza Drugs during the 2010-2011 Influenza Season in Russia"},{"title3":"Umifenovir Susceptibility Monitoring and Characterization of Influenza Viruses Isolated during ARBITR Clinical Study"},{"title3":"Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia"},{"title3":"Dose Regimen of Favipiravir for Ebola Virus Disease"},{"title3":"Effect of Arbidol (Umifenovir) on COVID-19: a Randomized Controlled Trial"},{"title3":"Clinical Efficacy of Umifenovir in Influenza and ARVI (Study ARBITR)"},{"title3":"Coronavirus Disease (COVID-19)-Statistics and Research"},{"title3":"Antiviral Activity of Arbidol against Influenza A Virus, Respiratory Syncytial Virus, Rhinovirus, coxsackie Virus and Adenovirus In Vitro and In Vivo "},{"title3":"Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China"},{"title3":"Coronavirus Disease 2019 (COVID-19) Situation Report"},{"title3":"Clinical Efficacy of Arbidol in Patients with 2019 Novel Coronavirus-Infected Pneumonia: A Retrospective Cohort Study"},{"title3":"Potential of Arbidol for post-exposure Prophylaxis of COVID-19 Transmission: a Preliminary Report of a Retrospective Cohort Study"}]}]},{"title1":"Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial","References":[{"title2":"SD1000: high sustained viral response rate in 1361 patients with hepatitis C genotypes 1, 2, 3, and 4 using a low-cost, fixed-dose combination tablet of generic sofosbuvir and daclatasvir: a multicenter, phase III clinical trial","References":[]},{"title2":"Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic","References":[{"title3":"Severe acute respiratory syndrome: historical, epidemiological and clinical features"},{"title3":"The Middle East respiratory syndrome (MERS)"},{"title3":"WHO. Coronavirus disease (COVID-19) Situation dashboard - April 18th, 2020, https://covid19.who.int/ (2020)."},{"title3":"A yellow flag on the horizon: the looming threat of yellow fever to North America"},{"title3":"The curious case of the Nidovirus exoribonuclease: its role in RNA synthesis and replication fidelity"},{"title3":"WHO. Solidarity clinical trial for the COVID-19 treatments, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments (2020)"},{"title3":"Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 cofactors"},{"title3":"Structural analysis of monomeric RNA-dependent polymerases: evolutionary and therapeutic implications"},{"title3":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase"},{"title3":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in Rhesus monkeys"},{"title3":"Coronavirus susceptibility to the antiviral Remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exonuclease"},{"title3":"Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res., 10.1038/s41422-020-0282-0 (2020)"},{"title3":"Structural basis for RNA replication by the Hepatitis C virus polymerase"},{"title3":"Sofosbuvir as treatment against Dengue?"},{"title3":"Blocking Zika virus vertical transmission"},{"title3":"Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro"},{"title3":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19"},{"title3":"More than 80 clinical trials launch to test coronavirus treatment"},{"title3":"Sofosbuvir, a significant paradigm change in HCV treatment"},{"title3":"Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir"},{"title3":"Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics"},{"title3":"Shu, Y., McCauley, J. GISAID: Global initiative on sharing all influenza data - from vision to reality. EuroSurveillance, 22, 10.2807/1560-7917.ES.2017.22.13.30494 (2017)."},{"title3":"MEGA X: molecular evolutionary genetics analysis across computing platforms"},{"title3":"BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT"},{"title3":"UCSF Chimera - a visualization system for exploratory research and analysis"},{"title3":"Tools for integrated sequence-structure analysis with UCSF Chimera"}]},{"title2":"Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model","References":[{"title3":"Coronavirus avian infectious bronchitis virus"},{"title3":"Human coronaviruses: a review of virus-host interactions"},{"title3":"Coronavirus pathogenesis"},{"title3":"Coronavirus genomics and bioinformatics analysis"},{"title3":"Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome"},{"title3":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia"},{"title3":"WHO. Summary of probable SARS cases with oneset of illness from 1 November 2002 to 31 July 2003. Dec 31, 2003. (https://wwwwhoint/csr/sars/country/table2004_04_21/en/). 2020."},{"title3":"WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). November, 2019. (http://wwwwhoint/emergencies/mers-cov/en/). 2020."},{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV"},{"title3":"Human coronavirus: host-pathogen interaction"},{"title3":"Self-attention based molecule representation for predicting drug-target interaction"},{"title3":"Drug Target Commons 2.0: a community platform for systematic analysis of drug-target interaction profiles"},{"title3":"BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities"},{"title3":"Global mapping of pharmacological space"},{"title3":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"},{"title3":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading"},{"title3":"Open Babel: an open chemical toolbox"},{"title3":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility"},{"title3":"Software for molecular docking: a review"},{"title3":"DeepDTA: deep drug-target binding affinity prediction"},{"title3":"SimBoost: a read-across approach for predicting drug-target binding affinities using gradient boosting machines"},{"title3":"Toward more realistic drug-target interaction predictions"},{"title3":"Making sense of large-scale kinase inhibitor bioactivity data sets: a comparative and integrative analysis"},{"title3":"Comprehensive analysis of kinase inhibitor selectivity"},{"title3":"Z. Jin, X. Du, Y. Xu, Y. Deng, M. Liu, Z. Zhao, et al. Structure of Mpro from COVID-19 virus and discovery of its inhibitors. bioRxiv. 2020."},{"title3":"Lopinavir; a potent drug against coronavirus infection: insight from molecular docking study"},{"title3":"SARS and MERS: recent insights into emerging coronaviruses"},{"title3":"drugmakers ship therapies to China, seeking to treat coronavirus"},{"title3":"Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings"},{"title3":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"},{"title3":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)"},{"title3":"First case of 2019 novel coronavirus in the United States"},{"title3":"Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment"},{"title3":"More than 80 clinical trials launch to test coronavirus treatments"}]},{"title2":"The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2","References":[]},{"title2":"Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China","References":[]},{"title2":"Rapid Review Neurological associations of COVID-19","References":[]},{"title2":"Sofosbuvir protects human brain organoids against SARS-CoV-2","References":[]},{"title2":"The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19","References":[]},{"title2":"Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial","References":[{"title3":"World Health Organization (WHO). Coronavirus Disease (COVID-19) Situation Report 116 https://www.who.int/emergencies/diseases/novel-coronavirus-2019."},{"title3":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention"},{"title3":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial"},{"title3":"A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19"},{"title3":"Emerging coronaviruses: genome structure, replication, and pathogenesis"},{"title3":"PolyPill for prevention of cardiovascular disease in an urban Iranian population with special focus on nonalcoholic steatohepatitis: a pragmatic randomized controlled trial within a cohort (PolyIran:Liver):study protocol"},{"title3":"Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses"},{"title3":"Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase"},{"title3":"Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model"},{"title3":"In silico study of various antiviral drugs, vitamins, and natural substances as potential binding compounds with SARS-CoV-2 main protease"},{"title3":"Evaluation of 19 antiviral drugs against SARS-CoV-2 infection"},{"title3":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir"},{"title3":"Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo"},{"title3":"The FDA-approved drug sofosbuvir inhibits Zika virus infection"},{"title3":"Beyond members of the flaviviridae family, sofosbuvir also inhibits chikungunya virus replication"},{"title3":"Sofosbuvir as treatment against dengue?"},{"title3":"Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial"},{"title3":"Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial"},{"title3":"Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1"},{"title3":"Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial"},{"title3":"Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study"},{"title3":"Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study"},{"title3":"Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1"},{"title3":"Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation:implications for maternal dosing, foetal exposure, and safety for mother and child"},{"title3":"The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment"},{"title3":"Minimum costs to manufacture new treatments for COVID-19"},{"title3":"Radiologic management of COVID-19: preliminary experience of the Iranian Society of Radiology COVID-19 Consultant Group (ISRCC)"},{"title3":"Observational study of hydroxychloroquine in hospitalized patients with COVID-19"},{"title3":"Understanding COVID-19: what does viral RNA load really mean?"},{"title3":"Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study"},{"title3":"Viral dynamics in mild and severe cases of COVID-19"},{"title3":"Virological assessment of hospitalized patients with COVID-2019"},{"title3":"The trinity of COVID-19: immunity, inflammation and intervention"}]},{"title2":"Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single centre, randomized controlled trial","References":[{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"A systematic review of COVID-19 epidemiology based on current evidence"},{"title3":"Coronavirus disease 2019 (COVID-19) outbreak in Iran: actions and problems"},{"title3":"WHO. WHO COVID-19 Data Explorer. https://covid19.who.int/explorer."},{"title3":"Observational study of hydroxychloroquine in hospitalized patients with Covid-19"},{"title3":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19"},{"title3":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial"},{"title3":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial"},{"title3":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review"},{"title3":"Remdesivir for the treatment of COVID-19:preliminary report"},{"title3":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus"},{"title3":"SD1000: high sustained viral response rate in 1361 patients with hepatitis C genotypes 1, 2, 3, and 4 using a low-cost, fixed-dose combination tablet of generic sofosbuvir and daclatasvir: a multicenter, Phase III clinical trial"},{"title3":"Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo"},{"title3":"The FDA-approved drug sofosbuvir inhibits Zika virus infection"},{"title3":"Sofosbuvir as treatment against dengue?"},{"title3":"Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication"},{"title3":"Emerging coronaviruses: genome structure, replication, and pathogenesis"},{"title3":"Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase"},{"title3":"Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses"},{"title3":"Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19)"},{"title3":"Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study"},{"title3":"In silico study of various antiviral drugs, vitamins, and natural substances as potential binding compounds with SARS-CoV-2 main protease"},{"title3":"Simeprevir suppresses SARS-CoV-2 replication and synergizes with remdesivir"},{"title3":"The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2"},{"title3":"Evaluation of 19 antiviral drugs against SARS-CoV-2 infection"},{"title3":"Minimum costs to manufacture new treatments for COVID-19"},{"title3":"Radiologic management of COVID-19: preliminary experience of the Iranian Society of Radiology COVID-19 Consultant Group (ISRCC)"},{"title3":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial"}]},{"title2":"Minimum costs to manufacture new treatments for COVID-19","References":[{"title3":"Responding to Covid-19 - a once-in-a-century pandemic?"},{"title3":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)"},{"title3":"Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model"},{"title3":"Drug repurposing: progress, challenges and recommendations"},{"title3":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses"},{"title3":"Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazine-4-amino] adenine C-nucleoside (GS-5374) for the treatment of Ebola and emerging viruses"},{"title3":"Influenza virus polymerase inhibitors in clinical development"},{"title3":"Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS, or COVID-19: initial assessment"},{"title3":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19"},{"title3":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)"},{"title3":"Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries"},{"title3":"Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C"},{"title3":"Estimation of cost-based prices for injectable medicines in the WHO Essential Medicines List"},{"title3":"Estimated costs of production and potential prices for the WHO Essential Medicines List"},{"title3":"Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial"},{"title3":"A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)"},{"title3":"Hydroxychloroquine and azithromycin as a treatment for COVID-19: results of an open-label, non-randomized clinical trial"},{"title3":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection"},{"title3":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies"},{"title3":"Favipiravir versus arbidol for COVID-19: a randomized clinical trial"},{"title3":"A practical and step-economic route to Favipiravir"},{"title3":"The complete synthesis of favipiravir from 2-aminopyrazine"},{"title3":"Impact of fluid choice in systemic inflammatory response syndrome patients on hospital cost savings"},{"title3":"Treatment advocate tactics to expand access to antiviral therapy for HIV and viral hepatitis C in low- to high-income settings: making sure no one is left behind"},{"title3":"Era of biosimilars in rheumatology: reshaping the healthcare environment"},{"title3":"Commissioning Framework for Biological Medicines (Including Biosimilar Medicines)"},{"title3":"Indian pharma threatened by COVID-19 shutdowns in China"}]},{"title2":"Radiologic management of COVID-19: preliminary experience of the Iranian Society of Radiology COVID-19 Consultant Group (ISRCC)","References":[]},{"title2":"Favipiravir, an antiviral for COVID-19?","References":[{"title3":"Investigation and comparison of pristine/doped BN, AlN, and CN nanotubes as drug delivery systems for Tegafur drug: a theoretical study"},{"title3":"Investigation of the pristine and functionalized carbon nanotubes as a delivery system for the anticancer drug dacarbazine: drug encapsulation"},{"title3":"Theoretical investigation of favipiravir antiviral drug based on fullerene and boron nitride nanocages"},{"title3":"Theoretical study of gallium nitride nanocage as a carrier for 5-fluorouracil anticancer drug"},{"title3":"AlN and AlP doped graphene quantum dots as novel drug delivery systems for 5-fluorouracil drug: theoretical studies"},{"title3":"Study to molecular insight into the role of aluminum nitride nanotubes on to deliver of 5-fluorouracil (5FU) drug in smart drug delivery"},{"title3":"Application of aluminum nitride nanotubes as a promising nanocarriers for anticancer drug 5-aminosalicylic acid in drug delivery system"},{"title3":"Boron nitride nanotubes for curcumin delivery as an anticancer drug: a DFT investigation"},{"title3":"Theory of graphitic boron nitride nanotubes"},{"title3":"Chopra NG et al (1995) Boron nitride nanotubes. science 269(5226):966-967"},{"title3":"Hexagonal boron nitride nanosheet as novel drug delivery system for anticancer drugs: insights from DFT calculations and molecular dynamics simulations"},{"title3":"Pristine and alkali and alkaline Earth metals encapsulated B36N36 nanoclusters as prospective delivery agents and detectors for 5-fluorouracil anticancer drug"},{"title3":"Surface adsorption of crizotinib on carbon and boron nitride nanotubes as anti-cancer drug carriers: COSMO-RS and DFT molecular insights"},{"title3":"Gholami A, Shakerzadeh E, Anota EC (2023) Exploring the potential use of pristine and metal-encapsulated B36N36 fullerenes in delivery of beta-lapachone anticancer drug: DFT approach. Polyhedron 116295"},{"title3":"Stability and electronic structure of AlN nanotubes"},{"title3":"Dopamine drug adsorption on the aluminum nitride single-wall nanotube: ab initio study"},{"title3":"Synthesis and crystal structure of 6-fluoro-3-hydroxypyrazine-2-carboxamide"},{"title3":"Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study"},{"title3":"Experimental treatment with favipiravir for COVID-19: an open-label control study"},{"title3":"Role of favipiravir in the treatment of COVID-19"},{"title3":"A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19"},{"title3":"Kamali A et al (2023) Evaluation of the effect of favipiravir on patients with COVID-19. J Family Med Prim Care 12(2):242-245"},{"title3":"Candidate drugs against SARS-CoV-2 and COVID-19"},{"title3":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor"},{"title3":"Favipiravir (T-705) inhibits in vitro norovirus replication"},{"title3":"Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106"},{"title3":"Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents"},{"title3":"Recent progress on the treatment of Ebola virus disease with Favipiravir and other related strategies"},{"title3":"The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset"},{"title3":"Synergistic effect of Si-doping and Fe2O3-encapsulation on drug delivery and sensor applications of gamma-graphyne nanotube toward favipiravir as an antiviral for COVID-19: A DFT study"},{"title3":"Interactions between favipiravir and a BNC cage towards drug delivery applications"},{"title3":"Metal doped fullerene complexes as promising drug delivery materials against COVID-19"},{"title3":"Frisch MJ (2009) gaussian09.https://www.gaussian.com"},{"title3":"Density functional theory of electronic structure"},{"title3":"Synthesis and investigation of anti-COVID19 ability of ferrocene Schiff base derivatives by quantum chemical and molecular docking"},{"title3":"Becke AD (1993) Density-functional thermochemistry. III. The role of exact exchange. J Chem Phys 98(7):5648-5652"},{"title3":"Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density"},{"title3":"B24N24 fullerene as a carrier for 5-fluorouracil anti-cancer drug delivery: DFT studies"},{"title3":"A new hybrid exchange-correlation functional using the Coulomb-attenuating method (CAM-B3LYP)"},{"title3":"Effect of methyl substituents on the electronic transitions in simple meso-aniline-BODIPY based dyes: RI-CC2 and TD-CAM-B3LYP computational investigation"},{"title3":"A new hybrid exchange-correlation functional using the Coulomb-attenuating method (CAM-B3LYP)"},{"title3":"Energies, structures, and electronic properties of molecules in solution with the C-PCM solvation model"},{"title3":"Quantum calculation of molecular energies and energy gradients in solution by a conductor solvent model"},{"title3":"Boys SF, Bernardi F (1970) The calculation of small molecular interactions by the differences of separate total energies. Some procedures with reduced errors. Mol Phys 19(4):553-566"},{"title3":"O'boyle NM, Tenderholt AL, Langner KM (2008) Cclib: a library for package-independent computational chemistry algorithms. J Comput Chem 29(5):839-845"},{"title3":"Multiwfn: a multifunctional wavefunction analyzer"},{"title3":"VMD: visual molecular dynamics"},{"title3":"Matta CF, Boyd RJ (2007) An introduction to the quantum theory of atoms in molecules. The quantum theory of atoms in molecules: from solid state to DNA and drug design"},{"title3":"Atoms in molecules"},{"title3":"A quantum theory of molecular structure and its applications"},{"title3":"Favipiravir tautomerism: a theoretical insight"},{"title3":"Favipiravir: structural analysis and activity against COVID-19"},{"title3":"Theoretical insights into the effect of halogenated substituent on the electronic structure and spectroscopic properties of the favipiravir tautomeric forms and its implications for the treatment of COVID-19"},{"title3":"Mind the gap!"},{"title3":"Hydrogen storage by BeO nano-cage: a DFT study"},{"title3":"Electronic and magnetic properties and structural stability of BeO sheet and nanoribbons"},{"title3":"Theoretical study of gallium nitride nanocage as a carrier for 5-fluorouracil anticancer drug"},{"title3":"Stability of GaN nanocages"},{"title3":"DFT studies of electro-conductivity of carbon-doped boron nitride nanotube"},{"title3":"A DFT/B3LYP computational study of boron-nitride nanotubes"},{"title3":"Epitaxially grown AlN and its optical band gap"},{"title3":"The computational quantum mechanical investigation of the functionalized boron nitride nanocage as the smart carriers for favipiravir drug delivery: a DFT and QTAIM analysis"},{"title3":"Ibrahim MA et al (2023) Investigation of aluminum nitride nanocarrier for drug delivery process of favipiravir: a DFT study. J Mol Liq 21209"},{"title3":"PAMAM and polyester dendrimers as favipiravir nanocarriers: a comparative study using DFT method"},{"title3":"A density functional theory study on favipiravir drug interaction with BN-doped C60 heterofullerene"},{"title3":"DFT/QTAIM analysis of favipiravir adsorption on pristine and silicon doped C20 fullerenes"},{"title3":"Favipiravir attachment to a conical nanocarbon: DFT assessments of the drug delivery approach"},{"title3":"Revealing noncovalent interactions"},{"title3":"NCIPLOT: a program for plotting noncovalent interaction regions"},{"title3":"Carbon nanotube sensors for gas and organic vapor detection"},{"title3":"Si-doped phagraphene as a drug carrier for adrucil anti-cancer drug: DFT studies"},{"title3":"Adsorption behavior of nucleobases on doped MoS2 monolayer: a DFT study"},{"title3":"PAMAM and polyester dendrimers as favipiravir nanocarriers: a comparative study using DFT method"},{"title3":"Gholami A, Shakerzadeh E, Anota EC (2023) Exploring the potential use of pristine and metal-encapsulated B36N36 fullerenes in delivery of beta-lapachone anticancer drug: DFT approach. Polyhedron 232 116295"},{"title3":"Absolute hardness: companion parameter to absolute electronegativity"},{"title3":"The electronic chemical potential and chemical hardness"},{"title3":"Parr RG, Szentpaly LV, Liu S (1999) Electrophilicity index. J Am Chem Soc 121(9):1922-1924"},{"title3":"Stability and electronic properties of armchair boron nitride/carbon nanotubes"},{"title3":"Muz I, Kurban H, Kurban M (2021) A DFT study on stability and electronic structure of AlN nanotubes. Mater Today Commun 26:102118"},{"title3":"Investigation of the adsorption properties of gemcitabine anticancer drug with metal-doped boron nitride fullerenes as a drug-delivery carrier: a DFT study"},{"title3":"A DFT study on the transition metal doped BN and AlN nanocages as a drug delivery vehicle for the cladribine drug"},{"title3":"Sensing functions of an iron-doped boron nitride nanocone towards acetaminophen and its thio/thiol analogs: A DFT outlook"},{"title3":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading"},{"title3":"Kang S et al (2020) Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. Acta Pharm Sin B  10(7):1228-1238"},{"title3":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors"},{"title3":"Ligand docking and binding site analysis with PyMOL and Autodock/Vina"},{"title3":"Automatic identification of mobile and rigid substructures in molecular dynamics simulations and fractional structural fluctuation analysis"}]},{"title2":"Experimental treatment with favipiravir for COVID-19: an open-label control study","References":[{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"National Health Commission of the People's Republic of China. Daily briefing on novel coronavirus cases in China [Internet]. Beijing: National Health Commission of the People's Republic of China; c2020 [updated 2020 Mar 12; cited 2020; c2020 Feb 25]. Available form: http://en.nhc.gov.cn/DailyBriefing.html."},{"title3":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding"},{"title3":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"},{"title3":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model"},{"title3":"Computed tomography findings from patients with ARDS due to Influenza A (H1N1) virus-associated pneumonia"},{"title3":"Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: evaluation with thin-section CT"},{"title3":"Ebola virus dynamics in mice treated with favipiravir"},{"title3":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea"},{"title3":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor"},{"title3":"Favipiravir for children with Ebola"},{"title3":"MDVI, LLC. Phase 3 efficacy and safety study of favipiravir for treatment of uncomplicated influenza in adults [Internet]. Bethesda: National Library of Medicine; [update 2015 Nov 11; cited 2020 Mar 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT02008344."},{"title3":"MERS-CoV: understanding the latest human coronavirus threat"}]},{"title2":"A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19","References":[{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China."},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study."},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China."},{"title3":"Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province."},{"title3":"Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings."},{"title3":"In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds."},{"title3":"Small molecules targeting severe acute respiratory syndrome human coronavirus."},{"title3":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture."},{"title3":"Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset."},{"title3":"Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome."},{"title3":"Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen."},{"title3":"Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity."},{"title3":"Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus."},{"title3":"Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays."},{"title3":"Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial."},{"title3":"International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) home page ()."},{"title3":"Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection."},{"title3":"Coronavirus disease (COVID-2019) R&amp;D. Geneva: World Health Organization ()."},{"title3":"National Early Warning Score (NEWS) 2: standardising the assessment of acute-illness severity in the NHS. London: Royal College of Physicians, 2017 ()."},{"title3":"Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study."},{"title3":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data."},{"title3":"Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09."},{"title3":"Early oseltamivir after hospital admission is associated with shortened hospitalization: a 5-year analysis of oseltamivir timing and clinical outcomes."},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study."},{"title3":"SARS-CoV-2 viral load in upper respiratory specimens of infected patients."},{"title3":"HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus."}]},{"title2":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","References":[{"title3":"COVID-19 map. Johns Hopkins Coronavirus Resource Centre"},{"title3":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"},{"title3":"Covid-19 in critically ill patients in the Seattle region-case series"},{"title3":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"},{"title3":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro"},{"title3":"Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial"},{"title3":"Favipiravir versus arbidol for COVID-19: a randomized clinical trial"},{"title3":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma"},{"title3":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19"},{"title3":"GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses"},{"title3":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses"},{"title3":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys"},{"title3":"Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase"},{"title3":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV"},{"title3":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection"},{"title3":"Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia"},{"title3":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2"},{"title3":"A randomized, controlled trial of Ebola virus disease therapeutics"},{"title3":"Compassionate use of remdesivir for patients with severe Covid-19"},{"title3":"First case of 2019 novel coronavirus in the United States"},{"title3":"Group sequential clinical trials with triangular continuation regions"},{"title3":"Gilead Sciences. Investigator's brochure of remdesivir, 5th edition. Feb 21, 2020."},{"title3":"Late Ebola virus relapse causing meningoencephalitis: a case report"},{"title3":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease"},{"title3":"Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients"},{"title3":"Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome"}]},{"title2":"Remdesivir for 5 or 10 Days in Patients with Severe Covid-19","References":[]},{"title2":"Remdesivir for the treatment of Covid-19:preliminary report","References":[]},{"title2":"Effect of Dexamethasone in Hospitalized Patients with COVID-19: preliminary Report","References":[]},{"title2":"The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment","References":[]},{"title2":"The efficacy of 12 weeks of sofosbuvir, daclatasvir, and ribavirin in treating hepatitis C patients with cirrhosis, genotypes 1 and 3","References":[]}]},{"title1":"Efficacy and safety of sofosbuvir/ledipasvir in treatment of patients with COVID-19; A randomized clinical trial","References":[{"title2":"A Novel Coronavirus from Patients with Pneumonia in China","References":[{"title3":"An update on the epidemiological characteristics of novel coronavirus pneumonia (COVID-19)"},{"title3":"World Health Organization [Internet]. Rolling updates on coronavirus disease (COVID-19). 2020 [cited 2020 11 March]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen."},{"title3":"Coronavirus Disease 2019 (COVID-19): A Perspective from China"},{"title3":"An analysis of global research on SARS-CoV-2"},{"title3":"A Novel Coronavirus from Patients with Pneumonia in China, 2019"},{"title3":"Clinical Characteristics of Coronavirus Disease 2019 in China"},{"title3":"Clinical Characteristics of Imported Cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: A Multicenter Descriptive Study"},{"title3":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China"},{"title3":"COVID-19 length of hospital stay: a systematic review and data synthesis"},{"title3":"Risk factors associated with disease severity and length of hospital stay in COVID-19 patients"},{"title3":"COVID-19 Case Report: An 84-Year-Old Man with Exacerbation of Multiple Comorbidities Due to COVID-19 Managed by a Multidisciplinary Team Using Patient-Reported Outcomes"},{"title3":"Obesity prolongs the hospital stay in patients affected by COVID-19, and may impact on SARS-COV-2 shedding"},{"title3":"World Health Organization [Internet]. Novel Coronavirus (COVID-19) Situation. 2020 [cited 2020 9 March]. https://experience.arcgis.com/experience/685d0ace521648f8a5beeeee1b9125cd."},{"title3":"Study on progress of Infectious disease Prevention and Control in China"},{"title3":"Health Commission of Sichuan Province [Internet]. Health Resources. 2020 [cited 2020 Mar 1]. http://wsjkw.sc.gov.cn/scwsjkw/wszy/tygl.shtml."},{"title3":"General Office of National Health Commission, General Office of National Administration of Traditional Chinese Medicine [Internet]. Diagnostic and treatment protocol for Novel Coronavirus Pneumonia (Trial version 7). 2020 [cited 2020 Mar 3]. http://www.nhc.gov.cn/xcs/zhengcwj/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml."},{"title3":"Survival analysis and regression models"},{"title3":"Wikipedia [Internet]. Sichuan. 2020 [cited 2020 Mar 9]. https://en.wikipedia.org/wiki/Sichuan."},{"title3":"The People's Government of Sichuan Province [Internet]. The 41st executive meeting of sichuan provincial people's government. 2020 [cited 2020 Jan 21]. http://www.sc.gov.cn/10462/10464/10856/10857/2020/1/21/b8d453617c434fa4b9197f477fe94d7f.shtml."},{"title3":"The People's Government of Sichuan Province [Internet]. Ten questions about &quot;first level emergency response&quot;. 2020 [cited 2020 Jan 26]. http://www.sc.gov.cn/10462/c102250/2020/1/26/a869dd8500f54d8e8259fc0c95fdab54.shtml."},{"title3":"The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China"},{"title3":"Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention"},{"title3":"Coronavirus covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate"},{"title3":"The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?"},{"title3":"COVID-19: Lessons from SARS and MERS"},{"title3":"COVID-19: Forecasting short term hospital needs in France"},{"title3":"Impact of sex and age on respiratory support and length of hospital stay among 1792 patients with COVID-19 in Wuhan, China"},{"title3":"Factors associated with the duration of hospitalisation among COVID-19 patients in Vietnam: A survival analysis"},{"title3":"What is the role of Primary Health Care in the COVID-19 pandemic?"},{"title3":"Retooling Primary Care in the COVID-19 Era"},{"title3":"The role and response of primary healthcare services in the delivery of palliative care in epidemics and pandemics: A rapid review to inform practice and service delivery during the COVID-19 pandemic"},{"title3":"Redesigning Primary Care to Address the COVID-19 Pandemic in the Midst of the Pandemic"},{"title3":"The Central People's Government of the People's Republic of China [Internet]. Notice on completing the basic public health service project in 2019. 2019 [cited 2019 Sep 5]. http://www.gov.cn/xinwen/2019-09/05/content_5427467.htm."},{"title3":"ChinaDaily [Internet]. COVID-19 more severe than influenza, says WHO chief. 2020 [cited 2020 Mar 4]. http://www.chinadaily.com.cn/a/202003/04/WS5e5ea17aa31012821727c087.html."},{"title3":"Milenkovic M, Russo CA, Elixhauser A (2006) Hospital Stays for Influenza, 2004: Statistical Brief #16. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD): Agency for Healthcare Research and Quality (US)."},{"title3":"National Health Commission of the People's Republic of China [Internet]. Guidance for Corona Virus Disease 2019: Prevention, Control, Diagnosis and Management. 2020 [cited 2020 Mar 3]. https://mp.weixin.qq.com/s?__biz=MzAwNDE4Njk5MQ==&amp;mid=2736129023&amp;idx=1&amp;sn=d2719645230da1d6582d50d06726b9bb&amp;chksm=bdc%E2%80%A6."},{"title3":"World Health Organization [Internet]. Home care for patients with suspected novel coronavirus (COVID-19) infection presenting with mild symptoms, and management of their contacts. 2020 [cited 2020 4 February]. https://www.who.int/publications-detail/home-care-for-patients-with-suspected-novel-coronavirus-(ncov)-infection-presenting-with-mild-symptoms-and-management-of-contacts."},{"title3":"World Health Organization [Internet]. Coronavirus disease (COVID-19) technical guidance: Patient management. 2020 [cited 2020 4 February]. https://www.who.int/publications-detail/home-care-for-patients-with-suspected-novel-coronavirus-(ncov)-infection-presenting-with-mild-symptoms-and-management-of-contacts."},{"title3":"MEDBOX [Internet]. COVID-19 TOOLBOX. 2020 [cited 2020 Dec 30]. https://www.medbox.org/toolbox/5E6EA419CA7A4."},{"title3":"PAHO [Internet]. Hospital Readiness Checklist for COVID-19. 2020 [cited 2020 Feb 10]. https://iris.paho.org/handle/10665.2/52402?show=full."},{"title3":"World Health Organization [Internet]. Rapid Hospital Readiness Checklist 2020 [cited 2020 25 June]. https://apps.who.int/iris/rest/bitstreams/1284123/retrieve."},{"title3":"Defining the Epidemiology of Covid-19:Studies Needed"},{"title3":"Sichuan Provincial Bureau of Statistics [Internet]. Statistical yearbook of Sichuan Province. 2018 [cited 2019 Dec 30]. http://web.sctjj.cn/tjcbw/tjnj/2018/zk/indexch.htm."}]},{"title2":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster","References":[{"title3":"CHP closely monitors cluster of pneumonia cases on Mainland"},{"title3":"CHP provides further information on cluster of pneumonia cases in Wuhan"},{"title3":"Wuhan wet market closes amid pneumonia outbreak"},{"title3":"Viral load in patients infected with pandemic H1N1 2009 influenza A virus"},{"title3":"Saliva as a diagnostic specimen for testing respiratory virus by a point-of-care molecular assay: a diagnostic validity study"},{"title3":"Evaluation of NxTAG Respiratory pathogen panel and comparison with xTAG respiratory viral panel fast v2 and film array respiratory panel for detecting respiratory pathogens in nasopharyngeal aspirates and swine/avian-origin influenza A subtypes in culture isolates"},{"title3":"Coronavirus as a possible cause of severe acute respiratory syndrome"},{"title3":"Zika virus infection in dexamethasone-immunosuppressed mice demonstrating disseminated infection with multi-organ involvement including orchitis effectively treated by recombinant type I interferons"},{"title3":"High prevalence of four novel astrovirus genotype species identified from rodents in China"},{"title3":"Metagenomic analysis of viromes of dromedary camel fecal samples reveals large number and high diversity of circoviruses and picobirnaviruses"},{"title3":"Identification of a novel bat papillomavirus by metagenomics"},{"title3":"Metagenomic nanopore sequencing of influenza virus direct from clinical respiratory samples"},{"title3":"Severe acute respiratory syndrome (SARS) coronavirus ORF8 protein is acquired from SARS-related coronavirus from greater horseshoe bats through recombination"},{"title3":"Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study"},{"title3":"Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection"},{"title3":"A patient with asymptomatic severe acute respiratory syndrome (SARS) and antigenemia from the 2003-2004 community outbreak of SARS in Guangzhou, China"},{"title3":"Viral replication in the nasopharynx is associated with diarrhea in patients with severe acute respiratory syndrome"},{"title3":"Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease"},{"title3":"Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus"},{"title3":"Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection"},{"title3":"Viral loads in clinical specimens and SARS manifestations"},{"title3":"Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndrome"},{"title3":"Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia"},{"title3":"Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus"},{"title3":"Discovery of a novel coronavirus, China Rattus coronavirus HKU24, from Norway rats supports the murine origin of Betacoronavirus 1 and has implications for the ancestor of Betacoronavirus lineage A"},{"title3":"Genomic characterization and infectivity of a novel SARS-like coronavirus in Chinese bats"},{"title3":"Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats"},{"title3":"Bats are natural reservoirs of SARS-like coronaviruses"},{"title3":"Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43"}]},{"title2":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","References":[{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: adescriptivestudy"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"First case of 2019 novel coronavirus in the United States"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Lung CT image of a confirmed case of the 2019 novel coronavirus (2019-nCoV) infected pneumonia (With differential diagnosis of the SARS)"},{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"Role of neutrophil to lymphocyte and monocyte to lymphocyte ratios in the diagnosis of bacterial infection in patients with fever"},{"title3":"Coronavirus infections-more than just the common cold"},{"title3":"The association between the neutrophil-to-lymphocyte ratio and mortality in critical illness: an observational cohort study"},{"title3":"A new coronavirus associated with human respiratory disease in China"},{"title3":"Monocyte/lymphocyte ratio as a better predictor of cardiovascular and all-cause mortality in hemodialysis patients: a prospective cohort study"},{"title3":"Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill"},{"title3":"Neutrophil-lymphocyte ratio as an early new marker in AIV-H7N9-infected patients: a retrospective study"}]},{"title2":"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)","References":[{"title3":"Distinguishing opinion from evidence in guidelines"},{"title3":"GRADE handbook, GRADE working group. 2013. https://gdt.gradepro.org/app/handbook/handbook.html. Accessed 22 Jan 2020."},{"title3":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations"},{"title3":"McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome"},{"title3":"Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (Full version). Yixue Xinzhi. 2020;30(1):35-64. 10.12173/j.issn.1004-5511.2020.01.09 [Article in China]."},{"title3":"Chan JFW, Yuan S, Kok KH, To KKT, Chu HC, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020. 10.1016/S0140-6736(20)30154-9."},{"title3":"Health Emergency Office of National Health Commission of the PRC. Update on the epidemic of novel coronavirus (2019-nCoV) infected pneumonia as at 24:00 on 26 January. http://www.nhc.gov.cn/xcs/yqfkdt/202001/3882fdcdbfdc4b4fa4e3a829b62d518e.shtml. Accessed 26 Jan 2020."},{"title3":"Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020. https://doi.org/10.1038/s41586-020-2012-7."},{"title3":"Perlman S. Another decade, another coronavirus. N Engl J Med. 2020. 10.1056/NEJMe2001126."},{"title3":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020. 10.1056/NEJMoa2001017."},{"title3":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020. 10.1016/S0140-6736(20)30183-5."},{"title3":"Lung CT image of a confirmed case of the 2019 novel coronavirus (2019-nCoV) infected pneumonia (With differential diagnosis of the SARS)"},{"title3":"Middle East respiratory syndrome infection control and prevention guideline for healthcare facilities"},{"title3":"Image of pulmonary and diagnosis of atypicalnovel coronavirus (2019-nCoV) infected pneumonia: case series of 14 patients"},{"title3":"Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study"},{"title3":"Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings"},{"title3":"Treatment of severe acute respiratory syndrome"},{"title3":"MERS-COV disease associated ARDS -a case report"},{"title3":"The possibility of using Lopinave/Litonawe (LPV/r) as treatment for novel coronavirus 2019-nCov pneumonia: a quick systematic review based on earlier coronavirus clinical studies"},{"title3":"Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques"},{"title3":"Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset"},{"title3":"Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study"},{"title3":"Middle east respiratory syndrome (MERS): a systematic review"},{"title3":"Clinical analysis of 190 cases of outbreak with atypical pneumonia in Guangzhou in spring, 2003"},{"title3":"Use of glucocorticoid in treatment of severe acute respiratory syndrome cases"},{"title3":"Glucocorticoid-induced diabetes in severe acute respiratory syndrome: the impact of high dosage and duration of methylprednisolone therapy"},{"title3":"Acute respiratory distress syndrome: the Berlin Definition"}]},{"title2":"COVID-19 infection: the perspectives on immune responses","References":[{"title3":"Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. The New England journal of medicine. 2020. 10.1056/NEJMoa2002032."},{"title3":"Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama. 2020. 10.1001/jama.2020.1585."},{"title3":"Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany"},{"title3":"Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory medicine. 2020. 10.1016/S2213-2600(20)30076-X."},{"title3":"Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications"},{"title3":"Kynurenic acid, an IDO metabolite, controls TSG-6-mediated immunosuppression of human mesenchymal stem cells"},{"title3":"Effects of nicotinamide and niacin on bleomycin-induced acute injury and subsequent fibrosis in hamster lungs"},{"title3":"HLA and infectious diseases"},{"title3":"The MHC locus and genetic susceptibility to autoimmune and infectious diseases"},{"title3":"Polymorphism of HLA class I and class II alleles in influenza A(H1N1)pdm09 virus infected population of Assam, Northeast India"},{"title3":"MacLaren G, Fisher D, Brodie D. Preparing for the most critically Ill patients with COVID-19: the potential role of extracorporeal membrane oxygenation. JAMA. 2020. 10.1001/jama.2020.2342."},{"title3":"Accumulation of hyaluronan (hyaluronic acid) in the lung in adult respiratory distress syndrome"},{"title3":"Defective lung function following influenza virus is due to prolonged, reversible hyaluronan synthesis"},{"title3":"Inhibition of hyaluronan synthesis attenuates pulmonary hypertension associated with lung fibrosis"}]},{"title2":"Epidemiology, genetic recombination, and pathogenesis of coronaviruses","References":[{"title3":"Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus"},{"title3":"The molecular biology of coronaviruses"},{"title3":"Attachment of mouse hepatitis virus to O-acetylated sialic acid is mediated by hemagglutinin-esterase and not by the spike protein"},{"title3":"Rotavirus and coronavirus associated diarrhoea in domestic animals"},{"title3":"Coronavirus avian infectious bronchitis virus"},{"title3":"Detection of a group 2 coronavirus in dogs with canine infectious respiratory disease"},{"title3":"Pathogenesis of demyelination induced by a mouse hepatitis"},{"title3":"Transmissible gastroenteritis of swine: virus-intestinal cell interactions. II. Electron microscopy of the epithelium in isolated jejunal loops"},{"title3":"Transmissible gastroenteritis of swine: virus-intestinal cell interactions. I. Immunofluorescence, histopathology and virus production in the small intestine through the course of infection"},{"title3":"Replication of an enteric bovine coronavirus in intestinal organ cultures"},{"title3":"Pathogenicity studies of feline coronavirus isolates 79-1146 and 79-1683"},{"title3":"Recovery and Characterization of a Coronavirus from Military Dogs with Diarrhea"},{"title3":"Pathogenicity of turkey coronavirus in turkeys and chickens"},{"title3":"Recently discovered human coronaviruses"},{"title3":"Cultivation of a novel type of common-cold virus in organ cultures"},{"title3":"Genomic analysis of 15 human coronaviruses OC43 (HCoV-OC43s) circulating in France from 2001 to 2013 reveals a high intra-specific diversity with new recombinant genotypes"},{"title3":"Medical reviews. Coronaviruses"},{"title3":"Coronavirus as a possible cause of severe acute respiratory syndrome"},{"title3":"MERS: emergence of a novel human coronavirus"},{"title3":"Coronavirus infections in working adults. Eight-year study with 229 E and OC 43"},{"title3":"Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong"},{"title3":"A new virus isolated from the human respiratory tract"},{"title3":"Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease"},{"title3":"Signs and symptoms in common colds"},{"title3":"Human coronavirus NL63, a new respiratory virus"},{"title3":"A previously undescribed coronavirus associated with respiratory disease in humans"},{"title3":"Evidence of a novel human coronavirus that is associated with respiratory tract disease in infants and young children"},{"title3":"Understanding human coronavirus HCoV-NL63"},{"title3":"Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia"},{"title3":"More and more coronaviruses: human coronavirus HKU1"},{"title3":"Clinical and molecular epidemiological features of coronavirus HKU1-associated community-acquired pneumonia"},{"title3":"Coronavirus HKU1 and other coronavirus infections in Hong Kong"},{"title3":"Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method"},{"title3":"Coronavirus HKU1 infection in the United States"},{"title3":"Evidence of human coronavirus HKU1 and human bocavirus in Australian children"},{"title3":"Detection of the new human coronavirus HKU1: a report of 6 cases"},{"title3":"Coronavirus HKU1 in children, Brazil, 1995"},{"title3":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia"},{"title3":"Middle East respiratory syndrome"},{"title3":"Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients"},{"title3":"Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study"},{"title3":"Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection"},{"title3":"Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection"},{"title3":"MERS in South Korea and China: a potential outbreak threat?"},{"title3":"Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China"},{"title3":"Identification of a novel coronavirus in bats"},{"title3":"Coronaviruses post-SARS: update on replication and pathogenesis"},{"title3":"Antibodies to SARS coronavirus in civets"},{"title3":"Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms"},{"title3":"Ecoepidemiology and complete genome comparison of different strains of severe acute respiratory syndrome-related Rhinolophus bat coronavirus in China reveal bats as a reservoir for acute, self-limiting infection that allows recombination events"},{"title3":"Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor"},{"title3":"ORF8-related genetic evidence for Chinese horseshoe bats as the source of human severe acute respiratory syndrome coronavirus"},{"title3":"Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study"},{"title3":"Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease"},{"title3":"MERS coronavirus in dromedary camel herd, Saudi Arabia"},{"title3":"Isolation of MERS coronavirus from a dromedary camel, Qatar, 2014"},{"title3":"MERS coronaviruses in dromedary camels, Egypt"},{"title3":"Concerns about misinterpretation of recent scientific data implicating dromedary camels in epidemiology of Middle East respiratory syndrome (MERS)"},{"title3":"Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26"},{"title3":"Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26"},{"title3":"Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia"},{"title3":"Mosaic structure of human coronavirus NL63, one thousand years of evolution"},{"title3":"Does IBV change slowly despite the capacity of the spike protein to vary greatly?"},{"title3":"Genetic drift of human coronavirus OC43 spike gene during adaptive evolution"},{"title3":"Moderate mutation rate in the SARS coronavirus genome and its implications"},{"title3":"Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus"},{"title3":"Coronavirus diversity, phylogeny and interspecies jumping"},{"title3":"Infectious diseases emerging from Chinese wet-markets: zoonotic origins of severe respiratory viral infections"},{"title3":"Comparative analysis of 22 coronavirus HKU1 genomes reveals a novel genotype and evidence of natural recombination in coronavirus HKU1"},{"title3":"Recombination between nonsegmented RNA genomes of murine coronaviruses"},{"title3":"Evidence of recombinant strains of porcine epidemic diarrhea virus, United States, 2013"},{"title3":"Emergence of pathogenic coronaviruses in cats by homologous recombination between feline and canine coronaviruses"},{"title3":"Recombinant canine coronaviruses related to transmissible gastroenteritis virus of Swine are circulating in dogs"},{"title3":"Molecular epidemiology of human coronavirus OC43 reveals evolution of different genotypes over time and recent emergence of a novel genotype due to natural recombination"},{"title3":"Genotype shift in human coronavirus OC43 and emergence of a novel genotype by natural recombination"},{"title3":"Phylogenetic and recombination analysis of coronavirus HKU1, a novel coronavirus from patients with pneumonia"},{"title3":"Evidence from the evolutionary analysis of nucleotide sequences for a recombinant history of SARS-CoV"},{"title3":"Testing the hypothesis of a recombinant origin of the SARS-associated coronavirus"},{"title3":"Origin and possible genetic recombination of the Middle East respiratory syndrome coronavirus from the first imported case in China: phylogenetics and coalescence analysis"},{"title3":"Coronavirus 229E-related pneumonia in immunocompromised patients"},{"title3":"Coronaviruses in children, Greece"},{"title3":"Epidemiological and clinical features of human coronavirus infections among different subsets of patients"},{"title3":"Isolation and characterization of current human coronavirus strains in primary human epithelial cell cultures reveal differences in target cell tropism"},{"title3":"Severe Acute Respiratory Syndrome (SARS)"},{"title3":"Multiple organ infection and the pathogenesis of SARS"},{"title3":"A cluster of cases of severe acute respiratory syndrome in Hong Kong"},{"title3":"Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study"},{"title3":"A novel pancoronavirus RT-PCR assay: frequent detection of human coronavirus NL63 in children hospitalized with respiratory tract infections in Belgium"},{"title3":"Human coronavirus NL63 infection in Canada"},{"title3":"Croup is associated with the novel coronavirus NL63"},{"title3":"Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China"},{"title3":"The common cold: a review of the literature"},{"title3":"Detection of viruses identified recently in children with acute wheezing"},{"title3":"State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans"},{"title3":"Viral Shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection"}]},{"title2":"A novel coronavirus associated with severe acute respiratory syndrome","References":[{"title3":"Ahmadi KS, Vahabizad F, Banihashemi G, Sahraian MA,  Gheini MR, Eslami M, Marhamati H, Mirhadi MS (2020) Ischemic stroke in patients with COVID-19 disease: a report of 10 cases from Iran Cerebrovasc Dis 1-6 10.1159/000513279"},{"title3":"Emerging coronaviruses: first SARS, second MERS and third SARS-CoV-2: epidemiological updates of COVID-19"},{"title3":"COVID-19 infection recurrence presenting with meningoencephalitis"},{"title3":"Matos AR, Quintas-Neves M, Oliveira AI, Dias L, Marques S, Carvalho R, Alves JN (2020) COVID-19 associated central nervous system vasculopathy Can J Neurol Sci 1-6 10.1017/cjn.2020.1092020.1092020.1092020.109"},{"title3":"Focal cerebral arteriopathy in a COVID-19 pediatric patient"},{"title3":"An updated review of the association of host genetic factors with susceptibility and resistance to COVID-19"},{"title3":"A first case of meningitis/encephalitis associated with SARS-Coronavirus-2"},{"title3":"COVID-19, SARS and MERS: a neurological perspective"},{"title3":"Frontier therapeutics and vaccine strategies for sars-cov-2 (COVID-19): a review"},{"title3":"A review of Coronavirus Disease-2019 (COVID-19)"},{"title3":"Neurological manifestations in severe acute respiratory syndrome"},{"title3":"Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, Liu C, Yang C (2020) Nervous system involvement after infection with COVID-19 and other coronaviruses Brain Behav Immun 18-22 10.1016/j.bbi.2020.03.0312020.03.0312020.03.0312020.03.031"},{"title3":"Encephalitis as a clinical manifestation of COVID-19"},{"title3":"Mild encephalitis/encephalopathy with reversible splenial lesion (MERS) in adults-a case report and literature review"}]},{"title2":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","References":[]},{"title2":"From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses","References":[{"title3":"Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three different mechanisms"},{"title3":"Novel beta-barrel fold in the nuclear magnetic resonance structure of the replicase nonstructural protein 1 from the severe acute respiratory syndrome coronavirus"},{"title3":"Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain"},{"title3":"Coronavirus main proteinase (3CLpro) structure: Basis for design of anti-SARS drugs"},{"title3":"Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe"},{"title3":"Hospital outbreak of Middle East respiratory syndrome coronavirus"},{"title3":"Structural insights into SARS coronavirus proteins"},{"title3":"Structural proteomics of the SARS coronavirus: a model response to emerging infectious diseases"},{"title3":"International research networks in viral structural proteomics: again, lessons from SARS"},{"title3":"The effects of temperature and relative humidity on the viability of the SARS coronavirus"},{"title3":"Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures"},{"title3":"Nuclear magnetic resonance structure shows that the severe acute respiratory syndrome coronavirus-unique domain contains a macrodomain fold"},{"title3":"Function of HAb18G/CD147 in invasion of host cells by severe acute respiratory syndrome coronavirus"},{"title3":"Structure of the SARS coronavirus nucleocapsid protein RNA-binding dimerization domain suggests a mechanism for helical packaging of viral RNA"},{"title3":"Biochemical and structural insights into the mechanisms of SARS coronavirus RNA ribose 2'-O-methylation by nsp16/nsp10 protein complex"},{"title3":"Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus"},{"title3":"Crystal structure-based exploration of the important role of Arg106 in the RNA-binding domain of human coronavirus OC43 nucleocapsid protein"},{"title3":"Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings"},{"title3":"Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus"},{"title3":"Treatment of SARS with human interferons"},{"title3":"Cyclosporin A inhibits the replication of diverse coronaviruses"},{"title3":"Human coronavirus-EMC replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-alpha treatment"},{"title3":"Crystal structure and functional analysis of the SARS-coronavirus RNA cap 2'-O-methyltransferase nsp10/nsp16 complex"},{"title3":"Structures and polymorphic interactions of two heptad-repeat regions of the SARS virus S2 protein"},{"title3":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome"},{"title3":"Central ions and lateral asparagine/glutamine zippers stabilize the post-fusion hairpin conformation of the SARS coronavirus spike glycoprotein"},{"title3":"The severe acute respiratory syndrome-coronavirus replicative protein nsp9 is a single-stranded RNA-binding subunit unique in the RNA virus world"},{"title3":"Structural and functional basis for ADP-ribose and poly(ADP-ribose) binding by viral macro domains"},{"title3":"Inhibition of novel beta coronavirus replication by a combination of interferon-alpha2b and ribavirin"},{"title3":"The nucleocapsid protein of coronavirus Infectious Bronchitis Virus: crystal structure of its N-terminal domain and multimerization properties"},{"title3":"Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid"},{"title3":"Emerging respiratory viruses: challenges and vaccine strategies"},{"title3":"Coronavirus N protein N-terminal domain (NTD) specifically binds the transcriptional regulatory sequence (TRS) and melts TRS-cTRS RNA duplexes"},{"title3":"Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China"},{"title3":"Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques"},{"title3":"Solution structure of the severe acute respiratory syndrome-coronavirus heptad repeat 2 domain in the prefusion state"},{"title3":"Solution structure of the X4 protein coded by the SARS related coronavirus reveals an immunoglobulin like fold and suggests a binding activity to integrin I domains"},{"title3":"Structure of the N-terminal RNA-binding domain of the SARS CoV nucleocapsid protein"},{"title3":"Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R"},{"title3":"Structure of alphacoronavirus transmissible gastroenteritis virus nsp1 has implications for coronavirus nsp1 function and evolution"},{"title3":"X-Ray structures of the N- and C-terminal domains of a coronavirus nucleocapsid protein: Implications for nucleocapsid formation"},{"title3":"SARS coronavirus unique domain: three-domain molecular architecture in solution and RNA binding"},{"title3":"NMR structure of the SARS-CoV nonstructural protein 7 in solution at pH 6.5"},{"title3":"Crystal structure of nonstructural protein 10 from the severe acute respiratory syndrome coronavirus reveals a novel fold with two zinc-binding motifs"},{"title3":"Solution structure of mouse hepatitis virus (MHV) nsp3a and determinants of the interaction with MHV nucleocapsid (N) protein"},{"title3":"SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum"},{"title3":"Characterization of the budding compartment of mouse hepatitis virus: evidence that transport from the RER to the Golgi complex requires only one vesicular transport step"},{"title3":"A novel coronavirus associated with severe acute respiratory syndrome"},{"title3":"Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome"},{"title3":"Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats"},{"title3":"The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients"},{"title3":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus"},{"title3":"Structure of SARS coronavirus spike receptor-binding domain complexed with receptor"},{"title3":"Bats are natural reservoirs of SARS-like coronaviruses"},{"title3":"Laboratory diagnosis of four recent sporadic cases of community-acquired SARS, Guangdong Province, China"},{"title3":"Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors"},{"title3":"Interferon Alphacon-1 plus corticosteroids in severe acute respiratory syndrome"},{"title3":"Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26"},{"title3":"Nucleocapsid protein of SARS coronavirus tightly binds to human cyclophilin A"},{"title3":"First cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013"},{"title3":"Virus-host interactomes - antiviral drug discovery"},{"title3":"Structure of the C-terminal domain of nsp4 from feline coronavirus"},{"title3":"The genome sequence of the SARS-associated coronavirus"},{"title3":"The molecular biology of coronaviruses"},{"title3":"Antiapoptotic activity by HIV protease inhibitors either alone or boostered"},{"title3":"The crystal structure of ORF-9b, a lipid binding protein from the SARS coronavirus"},{"title3":"Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines"},{"title3":"A mechanical explanation of RNA pseudoknot function in programmed ribosomal frameshifting"},{"title3":"Structure and intracellular targeting of the SARS-coronavirus Orf7a accessory protein"},{"title3":"The 29-nucleotide deletion present in human but not in animal severe acute respiratory syndrome coronaviruses disrupts the functional expression of open reading frame 8"},{"title3":"Nidovirus transcription: how to make sense?"},{"title3":"Coronavirus as a possible cause of severe acute respiratory syndrome"},{"title3":"Crystal structure of mouse coronavirus receptor-binding domain complexed with its murine receptor"},{"title3":"Perera, R.A., Wang, P., Gomaa, M.R., El-Shesheny, R., Kandeil, A., Bagato, O., Siu, L.Y., Shehata, M.M., Kayed, A.S., Moatasim, Y., Li, M., Poon, L.L., Guan, Y., Webby, R.J., Ali, M.A., Peiris, J.S.M., Kayali, G., 2013. Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. Euro Surveill. 18, pii: 20574."},{"title3":"Coronaviruses post-SARS: update on replication and pathogenesis"},{"title3":"Structural genomics of the severe acute respiratory syndrome coronavirus: nuclear magnetic resonance structure of the protein nsP7"},{"title3":"The SARS-coronavirus-host interactome: Identification of cyclophilins as target for pan-coronavirus inhibitors"},{"title3":"Crystal structures of the X-domains of a Group-1 and a Group-3 coronavirus reveal that ADP-ribose-binding may not be a conserved property"},{"title3":"Variable oligomerization modes in coronavirus non-structural protein 9"},{"title3":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC"},{"title3":"Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme"},{"title3":"Structural bases of coronavirus attachment to host aminopeptidase N and its inhibition by neutralizing antibodies"},{"title3":"The newly emerged SARS-Like coronavirus HCoV-EMC also has an &quot;Achilles' heel&quot;: current effective inhibitor targeting a 3C-like protease"},{"title3":"Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative seroligical study"},{"title3":"Crystal structure and mechanistic determinants of SARS coronavirus nonstructural protein 15 define an endoribonuclease family"},{"title3":"The structure of a rigorously conserved RNA element within the SARS virus genome"},{"title3":"Characterization of a novel coronavirus associated with severe acute respiratory syndrome"},{"title3":"Structural basis of severe acute respiratory syndrome coronavirus ADP-ribose-1''-phosphate dephosphorylation by a conserved domain of nsP3"},{"title3":"Ribonucleocapsid formation of severe acute respiratory syndrome coronavirus through molecular action of the N-terminal domain of N protein"},{"title3":"Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein"},{"title3":"Functional and genetic analysis of coronavirus replicase-transcriptase proteins"},{"title3":"A contemporary view of coronavirus transcription"},{"title3":"Nuclear magnetic resonance structure of the N-terminal domain of nonstructural protein 3 from the severe acute respiratory syndrome coronavirus"},{"title3":"Nuclear magnetic resonance structure of the nucleic acid-binding domain of severe acute respiratory syndrome coronavirus nonstructural protein 3"},{"title3":"Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic alpha, beta-unsaturated esters"},{"title3":"So, L.K.Y., Lau, A.C.-W., Yam, L.Y.-C., 2003. SARS Treatment. In: Kamps, B.S., Hoffmann, C. (Eds.), www.SARSreference.com, pp. 144-166 (last accessed on 14.07.13)."},{"title3":"Dodecamer structure of severe acute respiratory syndrome coronavirus nonstructural protein nsp10"},{"title3":"Structure of a proteolytically resistant core from the severe acute respiratory syndrome coronavirus S2 fusion protein"},{"title3":"The nsp9 replicase protein of SARS-coronavirus, structure and functional insights"},{"title3":"Solution structure of the C-terminal dimerization domain of SARS coronavirus nucleocapsid protein solved by the SAIL-NMR method"},{"title3":"PH-dependent conformational flexibility of the SARS-CoV main proteinase (Mpro) dimer: molecular dynamics simulations and multiple X-ray structure analyses"},{"title3":"The SARS-unique domain (SUD) of SARS coronavirus contains two macrodomains that bind G-quadruplexes"},{"title3":"Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China"},{"title3":"The SR-rich motif in SARS-CoV nucleocapsid protein is important for virus replication"},{"title3":"Identification of a new human coronavirus"},{"title3":"Expression cloning of functional receptor used by SARS coronavirus"},{"title3":"Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4"},{"title3":"Structure of the X (ADRP) domain of nsp3 from feline coronavirus"},{"title3":"Papain-like protease 1 from transmissible gastroenteritis virus: crystal structure and enzymatic activity toward viral and cellular substrates"},{"title3":"Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia"},{"title3":"A multicentre collaboration to investigate the cause of severe acute respiratory syndrome"},{"title3":"Small molecules targeting severe acute respiratory syndrome human coronavirus"},{"title3":"Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptor"},{"title3":"Nonstructural proteins 7 and 8 of feline coronavirus form a 2:1 heterotrimer that exhibits primer-independent RNA polymerase activity"},{"title3":"Epidemiologic clues to SARS origin in China"},{"title3":"Structural basis for coronavirus-mediated membrane fusion: crystal structure of mouse hepatitis virus spike protein fusion core"},{"title3":"New antiviral target revealed by the hexameric structure of mouse hepatitis virus nonstructural protein nsp15"},{"title3":"Crystal structures of two coronavirus ADP-ribose-1''-monophosphatases and their complexes with ADP-ribose: a systematic structural analysis of the viral ADRP domain"},{"title3":"Crystal structure of the C-terminal cytoplasmic domain of non-structural protein 4 from mouse hepatitis virus A59"},{"title3":"Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design"},{"title3":"The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor"},{"title3":"Design of wide-spectrum inhibitors targeting coronavirus main proteases"},{"title3":"Crystal structure of the severe acute respiratory syndrome (SARS) coronavirus nucleocapsid protein dimerization domain reveals evolutionary linkage between corona- and arteriviridae"},{"title3":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia"},{"title3":"Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution"},{"title3":"Insights into SARS-CoV transcription and replication from the structure of the nsp7-nsp8 hexadecamer"},{"title3":"Description and treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China"},{"title3":"Structure of the main protease from a global infectious human coronavirus, HCoV-HKU1"},{"title3":"Core structure of S2 from the human coronavirus NL63 spike glycoprotein"}]},{"title2":"Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates","References":[{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster."},{"title3":"SARS-CoV 3CL protease cleaves its C-terminal autoprocessing site by novel subsite cooperativity."},{"title3":"Improved prediction of protein side-chain conformations with SCWRL4."},{"title3":"MTiOpenScreen: a web server for structure-based virtual screening."},{"title3":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading."},{"title3":"3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism."},{"title3":"Mechanism of the maturation process of SARS-CoV 3CL protease."},{"title3":"Long-range cooperative interactions modulate dimerization in SARS 3CL pro."},{"title3":"Mutation of Asn28 disrupts the dimerization and enzymatic activity of SARS 3CL pro."},{"title3":"Two adjacent mutations on the dimer interface of SARS coronavirus 3C-like protease cause different conformational changes in crystal structure."},{"title3":"Residues on the dimer interface of SARS coronavirus 3C-like protease: dimer stability characterization and enzyme catalytic activity analysis."},{"title3":"Mutation of Glu-166 blocks the substrate-induced dimerization of SARS coronavirus main protease."},{"title3":"The penultimate rotamer library."},{"title3":"The PyMOL molecular graphics system (Schrodinger, LLC)"},{"title3":"SARS-CoV-2 (2019-nCoV) 3CLpro Model &amp; Screening."},{"title3":"Structure-based drug design, virtual screening and high-throughput screening rapidly identify antiviral leads targeting COVID-19."},{"title3":"Nucleotide analogues as inhibitors of viral polymerases."},{"title3":"Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds."},{"title3":"An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy."},{"title3":"Characterization and inhibition of the main protease of severe acute respiratory syndrome coronavirus."},{"title3":"Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings."},{"title3":"SARS: systematic review of treatment effects."},{"title3":"Coronavirus COVID-19 (formerly known as Wuhan coronavirus and 2019-nCoV) - what we can find out on a structural bioinformatics level."},{"title3":"Lopinavir; a potent drug against coronavirus infection: insight from molecular docking study."},{"title3":"Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL pro inhibitors."},{"title3":"Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs."},{"title3":"Small molecules targeting severe acute respiratory syndrome human coronavirus."},{"title3":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19."},{"title3":"Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection."},{"title3":"First case of 2019 novel coronavirus in the United States."},{"title3":"Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation."},{"title3":"Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines."},{"title3":"Homology models of Wuhan coronavirus 3CL pro protease."},{"title3":"Targeting 2019-nCoV Portal"},{"title3":"Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model."},{"title3":"Machine intelligence design of 2019-nCoV drugs."},{"title3":"Therapeutic drugs targeting 2019-nCoV main protease by high-throughput screening."},{"title3":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors."}]},{"title2":"Sofosbuvir (Sovaldi): The First-in-Class HCV NS5B Nucleotide Polymerase Inhibitor","References":[]},{"title2":"PK/PD and antiviral activity of anti-HCV therapy: is there still a role in the choice of treatment?","References":[]},{"title2":"Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses","References":[{"title3":"Isolation of a novel Coronavirus from a man with pneumonia in Saudi Arabia"},{"title3":"Coronaviruses:drug discovery and therapeutic options"},{"title3":"Pathogenesis of Middle East respiratory syndrome coronavirus"},{"title3":"Emergence of MERS-CoV in the Middle East: origins, transmission, treatment, and perspectives"},{"title3":"Isolation and characterization of viruses related to the SARS Coronavirus from animals in southern China"},{"title3":"WHO, 2016. Middle East respiratory syndrome coronavirus (MERS-CoV) WHO. "},{"title3":"Evidence supporting a zoonotic origin of human coronavirus strain NL63"},{"title3":"Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event"},{"title3":"Evidence for an ancestral association of human coronavirus 229E with bats"},{"title3":"Evidence for zoonotic origins of Middle East respiratory syndrome coronavirus"},{"title3":"Mechanisms of zoonotic severe acute respiratory syndrome Coronavirus host range expansion in human airway epithelium"},{"title3":"Mechanisms of coronavirus cell entry mediated by the viral spike protein"},{"title3":"A previously undescribed coronavirus associated with respiratory disease in humans"},{"title3":"Coronaviruses: important emerging human pathogens"},{"title3":"Evidence for camel-to-human transmission of MERS coronavirus"},{"title3":"Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels a comparative serological study"},{"title3":"From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses"},{"title3":"SARS-beginning to understand a new virus"},{"title3":"Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease"},{"title3":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus"},{"title3":"Human aminopeptidase N is a receptor for human coronavirus 229E"},{"title3":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC"},{"title3":"Human Coronavirus HKU1 spike protein uses O-Acetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-Esterase protein as a receptor-Destroying enzyme"},{"title3":"Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry"},{"title3":"Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans"},{"title3":"Anti-HCV drugs in the pipeline"},{"title3":"Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes"},{"title3":"Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy"},{"title3":"IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study"},{"title3":"The QSAR and docking calculations of fullerene derivatives as HIV-1 protease inhibitors"},{"title3":"Integrative computational modeling of protein interactions"},{"title3":"2'-Methylguanosine prodrug (IDX-184), phosphoramidate prodrug (Sofosbuvir), diisobutyryl prodrug (R7128) are better than their parent nucleotides and ribavirin in hepatitis C virus inhibition: a molecular modeling study"},{"title3":"Structural properties of metal-free apometallothioneins"},{"title3":"The EBI Search engine: providing search and retrieval functionality for biological data from EMBL-EBI"},{"title3":"Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega"},{"title3":"Deciphering key features in protein structures with the new ENDscript server"},{"title3":"The I-TASSER Suite: protein structure and function prediction"},{"title3":"Verification of protein structures: patterns of nonbonded atomic interactions"},{"title3":"Deviations from standard atomic volumes as a quality measure for protein crystal structures"},{"title3":"Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): structural evidence for nucleotide import and de-novo initiation"},{"title3":"A comparative QSAR analysis and molecular docking studies of quinazoline derivatives as tyrosine kinase (EGFR) inhibitors: a rational approach to anticancer drug design"},{"title3":"Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design"},{"title3":"1.7.6, V., The PyMOL Molecular Graphics System, Version 1.7.6 Schrodinger, LLC. "},{"title3":"Water determines the structure and dynamics of proteins"},{"title3":"Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects"},{"title3":"Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials"}]},{"title2":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19","References":[{"title3":"Pneumonia of unknown etiology in Wuhan, China: potential for international spread via commercial air travel"},{"title3":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health:the latest 2019 novel coronavirus outbreak in Wuhan, China"},{"title3":"Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease"},{"title3":"Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses"},{"title3":"Catalytic function and substrate specificity of the papain-like protease domain of nsp3 from the Middle East respiratory syndrome coronavirus"},{"title3":"Some one health based control strategies for the Middle East respiratory syndrome coronavirus"},{"title3":"Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials"},{"title3":"Zika virus: novel guanosine derivatives revealed strong binding and possible inhibition of the polymerase"},{"title3":"Novel guanosine derivatives as anti-HCV NS5b polymerase: a QSAR and molecular docking study"},{"title3":"IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study"},{"title3":"Molecular dynamics simulation revealed binding of nucleotide inhibitors to ZIKV polymerase over 444 nanoseconds"},{"title3":"Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes"},{"title3":"Molecular dynamics and docking reveal the potency of novel GTP derivatives against RNA dependent RNA polymerase of genotype 4a HCV"},{"title3":"Molecular modeling and docking revealed superiority of IDX-184 as HCV polymerase inhibitor"},{"title3":"Applications of computer-aided approaches in the development of hepatitis C antiviral agents"},{"title3":"The mechanism of action of T7 DNA polymerase"},{"title3":"Molecular docking revealed the binding of nucleotide/side inhibitors to Zika viral polymerase solved structures"},{"title3":"Novel inhibitors against wild-type and mutated HCV NS3 serine protease: an in silico study"},{"title3":"Anti-HCV drugs in the pipeline"},{"title3":"Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon"},{"title3":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"},{"title3":"Sofosbuvir, a significant paradigm change in HCV treatment"},{"title3":"Announcing the worldwide Protein Data Bank"},{"title3":"National Center of Biotechnology Informatics (NCBI) database website"},{"title3":"SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information"},{"title3":"Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors"},{"title3":"MolProbity: more and better reference data for improved all-atom structure validation"},{"title3":"AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR"},{"title3":"VERIFY3D: assessment of protein models with three-dimensional profiles"},{"title3":"Deviations from standard atomic volumes as a quality measure for protein crystal structures"},{"title3":"Errors in protein structures"},{"title3":"The antiviral Sofosbuvir against mucormycosis: an in silico perspective"},{"title3":"Structural properties of metal-free apometallothioneins"},{"title3":"Molecular mechanics. The MM3 force field for hydrocarbons. 3. The van der Waals' potentials and crystal data for aliphatic and aromatic hydrocarbons"},{"title3":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading"},{"title3":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus"},{"title3":"Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977"},{"title3":"The FDA-approved drug sofosbuvir inhibits Zika virus infection"},{"title3":"The clinically approved antiviral drug sofosbuvir impairs Brazilian zika virus replication"},{"title3":"588 in vitro antiviral activity and pharmacology of IDX184, a novel and potent inhibitor of HCV replication"},{"title3":"2'-Methylguanosine prodrug (IDX-184), phosphoramidate prodrug (Sofosbuvir), diisobutyryl prodrug (R7128) are better than their parent nucleotides and ribavirin in hepatitis C virus inhibition: a molecular modeling study"},{"title3":"Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects"},{"title3":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C"},{"title3":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial"},{"title3":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys"},{"title3":"PLIP: fully automated protein-ligand interaction profiler"},{"title3":"Density-functional thermochemistry. III. The role of exact exchange"},{"title3":"Optimization of parameters for semiempirical methods V: modification of NDDO approximations and application to 70 elements"},{"title3":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility"},{"title3":"COVID-19 Spike-host cell receptor GRP78 binding site prediction"}]},{"title2":"Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study","References":[{"title3":"Pneumonia of unknown etiology in Wuhan, China: potential for international spread via commercial air travel"},{"title3":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health:the latest 2019 novel coronavirus outbreak in Wuhan, China"},{"title3":"The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak"},{"title3":"Pneumonia in China: lack of information raises concerns among Hong Kong health workers"},{"title3":"Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease"},{"title3":"Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses"},{"title3":"COVID-19 spike-host cell receptor GRP78 binding site prediction"},{"title3":"Catalytic function and substrate specificity of the papain-like protease domain of nsp3 from the Middle East respiratory syndrome coronavirus"},{"title3":"Some one health based control strategies for the Middle East respiratory syndrome coronavirus"},{"title3":"Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials"},{"title3":"Zika virus: novel guanosine derivatives revealed strong binding and possible inhibition of the polymerase"},{"title3":"Novel guanosine derivatives as anti-HCV NS5b polymerase: a QSAR and molecular docking study"},{"title3":"IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study"},{"title3":"Molecular dynamics simulation revealed binding of nucleotide inhibitors to ZIKV polymerase over 444 nanoseconds"},{"title3":"Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes"},{"title3":"Molecular dynamics and docking reveal the potency of novel GTP derivatives against RNA dependent RNA polymerase of genotype 4a HCV"},{"title3":"Molecular modeling and docking revealed superiority of IDX-184 as HCV polymerase inhibitor"},{"title3":"Applications of computer-aided approaches in the development of hepatitis C antiviral agents"},{"title3":"The mechanism of action of T7 DNA polymerase"},{"title3":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19"},{"title3":"Molecular docking revealed the binding of nucleotide/side inhibitors to Zika viral polymerase solved structures"},{"title3":"Announcing the worldwide Protein Data Bank"},{"title3":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods"},{"title3":"National center of biotechnology informatics (NCBI) database website"},{"title3":"SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information"},{"title3":"Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors"},{"title3":"MolProbity: more and better reference data for improved all-atom structure validation"},{"title3":"AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR"},{"title3":"Deviations from standard atomic volumes as a quality measure for protein crystal structures"},{"title3":"Errors in protein structures"},{"title3":"The antiviral Sofosbuvir against mucormycosis: an in silico perspective"},{"title3":"Structural properties of metal-free apometallothioneins"},{"title3":"Molecular mechanics. The MM3 force field for hydrocarbons. 3. The van der Waals' potentials and crystal data for aliphatic and aromatic hydrocarbons"},{"title3":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading"},{"title3":"PLIP: fully automated protein-ligand interaction profiler"},{"title3":"Density-functional thermochemistry. III. The role of exact exchange"},{"title3":"Optimization of parameters for semiempirical methods V: modification of NDDO approximations and application to 70 elements"},{"title3":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility"}]},{"title2":"Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial","References":[{"title3":"World Health Organization (WHO). Coronavirus Disease (COVID-19) Situation Report 116 https://www.who.int/emergencies/diseases/novel-coronavirus-2019."},{"title3":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention"},{"title3":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial"},{"title3":"A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19"},{"title3":"Emerging coronaviruses: genome structure, replication, and pathogenesis"},{"title3":"PolyPill for prevention of cardiovascular disease in an urban Iranian population with special focus on nonalcoholic steatohepatitis: a pragmatic randomized controlled trial within a cohort (PolyIran:Liver):study protocol"},{"title3":"Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses"},{"title3":"Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase"},{"title3":"Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model"},{"title3":"In silico study of various antiviral drugs, vitamins, and natural substances as potential binding compounds with SARS-CoV-2 main protease"},{"title3":"Evaluation of 19 antiviral drugs against SARS-CoV-2 infection"},{"title3":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir"},{"title3":"Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo"},{"title3":"The FDA-approved drug sofosbuvir inhibits Zika virus infection"},{"title3":"Beyond members of the flaviviridae family, sofosbuvir also inhibits chikungunya virus replication"},{"title3":"Sofosbuvir as treatment against dengue?"},{"title3":"Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial"},{"title3":"Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial"},{"title3":"Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1"},{"title3":"Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial"},{"title3":"Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study"},{"title3":"Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study"},{"title3":"Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1"},{"title3":"Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation:implications for maternal dosing, foetal exposure, and safety for mother and child"},{"title3":"The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment"},{"title3":"Minimum costs to manufacture new treatments for COVID-19"},{"title3":"Radiologic management of COVID-19: preliminary experience of the Iranian Society of Radiology COVID-19 Consultant Group (ISRCC)"},{"title3":"Observational study of hydroxychloroquine in hospitalized patients with COVID-19"},{"title3":"Understanding COVID-19: what does viral RNA load really mean?"},{"title3":"Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study"},{"title3":"Viral dynamics in mild and severe cases of COVID-19"},{"title3":"Virological assessment of hospitalized patients with COVID-2019"},{"title3":"The trinity of COVID-19: immunity, inflammation and intervention"}]},{"title2":"Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a singlecentre, randomized controlled trial","References":[{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"A systematic review of COVID-19 epidemiology based on current evidence"},{"title3":"Coronavirus disease 2019 (COVID-19) outbreak in Iran: actions and problems"},{"title3":"WHO. WHO COVID-19 Data Explorer. https://covid19.who.int/explorer."},{"title3":"Observational study of hydroxychloroquine in hospitalized patients with Covid-19"},{"title3":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19"},{"title3":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial"},{"title3":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial"},{"title3":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review"},{"title3":"Remdesivir for the treatment of COVID-19:preliminary report"},{"title3":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus"},{"title3":"SD1000: high sustained viral response rate in 1361 patients with hepatitis C genotypes 1, 2, 3, and 4 using a low-cost, fixed-dose combination tablet of generic sofosbuvir and daclatasvir: a multicenter, Phase III clinical trial"},{"title3":"Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo"},{"title3":"The FDA-approved drug sofosbuvir inhibits Zika virus infection"},{"title3":"Sofosbuvir as treatment against dengue?"},{"title3":"Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication"},{"title3":"Emerging coronaviruses: genome structure, replication, and pathogenesis"},{"title3":"Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase"},{"title3":"Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses"},{"title3":"Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19)"},{"title3":"Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study"},{"title3":"In silico study of various antiviral drugs, vitamins, and natural substances as potential binding compounds with SARS-CoV-2 main protease"},{"title3":"Simeprevir suppresses SARS-CoV-2 replication and synergizes with remdesivir"},{"title3":"The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2"},{"title3":"Evaluation of 19 antiviral drugs against SARS-CoV-2 infection"},{"title3":"Minimum costs to manufacture new treatments for COVID-19"},{"title3":"Radiologic management of COVID-19: preliminary experience of the Iranian Society of Radiology COVID-19 Consultant Group (ISRCC)"},{"title3":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial"}]},{"title2":"The impact of sofosbuvir/ daclatasvir or ribavirin in patients with severe COVID-19","References":[]},{"title2":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention","References":[]},{"title2":"The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak","References":[{"title3":"Pneumonia of unknown etiology in wuhan, China: potential for international spread via commercial air travel"},{"title3":"Outbreak of pneumonia of unknown etiology in wuhan China: the mystery and the miracle"},{"title3":"Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak"},{"title3":"Outbreak of a novel coronavirus"},{"title3":"Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Drug treatment options for the 2019-new coronavirus (2019-nCoV)"},{"title3":"Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China"},{"title3":"The extent of transmission of novel coronavirus in wuhan, China, 2020"},{"title3":"The Novel Chinese Coronavirus (2019-nCoV) Infections: challenges for fighting the storm"},{"title3":"First case of 2019 novel coronavirus in the United States"},{"title3":"Early transmission dynamics in wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"Novel wuhan (2019-nCoV) coronavirus"},{"title3":"CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia"},{"title3":"Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study"},{"title3":"A major outbreak of severe acute respiratory syndrome in Hong Kong"},{"title3":"Importation and human-to-human transmission of a novel coronavirus in Vietnam"},{"title3":"Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human"},{"title3":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding"},{"title3":"Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS"},{"title3":"Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020"},{"title3":"A tale of two viruses: the distinct spike glycoproteins of feline coronaviruses"},{"title3":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China"},{"title3":"Origin and evolution of pathogenic coronaviruses"},{"title3":"A novel coronavirus from patients with pneumonia in China"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia"},{"title3":"A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)"}]},{"title2":"Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis","References":[]},{"title2":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","References":[{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China."},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study."},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China."},{"title3":"Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province."},{"title3":"Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings."},{"title3":"In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds."},{"title3":"Small molecules targeting severe acute respiratory syndrome human coronavirus."},{"title3":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture."},{"title3":"Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset."},{"title3":"Combination therapy with lopinavir/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome."},{"title3":"Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen."},{"title3":"Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity."},{"title3":"Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus."},{"title3":"Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays."},{"title3":"Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial."},{"title3":"International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) home page ()."},{"title3":"Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection."},{"title3":"Coronavirus disease (COVID-2019) R&amp;D. Geneva: World Health Organization ()."},{"title3":"National Early Warning Score (NEWS) 2: standardising the assessment of acute-illness severity in the NHS. London: Royal College of Physicians, 2017 ()."},{"title3":"Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study."},{"title3":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data."},{"title3":"Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09."},{"title3":"Early oseltamivir after hospital admission is associated with shortened hospitalization: a 5-year analysis of oseltamivir timing and clinical outcomes."},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study."},{"title3":"SARS-CoV-2 viral load in upper respiratory specimens of infected patients."},{"title3":"HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus."}]},{"title2":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial","References":[{"title3":"Coronavirus covid-19 global cases by Johns Hopkins CSSE. https://www.arcgis.com/apps/opsdashboard/index.html#/85320e2ea5424dfaaa75ae62e5c06e61."},{"title3":"Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies"},{"title3":"A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19"},{"title3":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"},{"title3":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)"},{"title3":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of covid-19 associated pneumonia in clinical studies"},{"title3":"National Health Commission of the People's Republic of China. Chinese guideline for the management COVID-19 (version 7.0, in Chinese). 2020. http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989/files/ce3e6945832a438eaae415350a8ce964.pdf."},{"title3":"US Food and Drug Administration. Emergency Use Authorization. Hydroxychloroquine sulfate health care provider fact sheet. https://www.fda.gov/media/136534/download."},{"title3":"Piller C. &quot;This is insane!&quot; Many scientists lament Trump's embrace of risky malaria drugs for coronavirus. 2020. https://www.sciencemag.org/news/2020/03/insane-many-scientists-lament-trump-s-embrace-risky-malaria-drugs-coronavirus#."},{"title3":"Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases"},{"title3":"Covid-19 - the search for effective therapy"},{"title3":"National Health Commission of the People's Republic of China. Chinese guideline for the management covid-19 (version 5.0, in Chinese). 2020. http://www.nhc.gov.cn/yzygj/s7653p/202002/d4b895337e19445f8d728fcaf1e3e13a/files/ab6bec7f93e64e7f998d802991203cd6.pdf."},{"title3":"Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study [correction in: BMJ 2020;368:m1295]"},{"title3":"Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study"},{"title3":"Seasonal influenza in adults and children-diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America"},{"title3":"Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis"},{"title3":"Rapid onset of retinal toxicity from high-dose hydroxychloroquine given for cancer therapy"},{"title3":"An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists"},{"title3":"Oral erythromycin and the risk of sudden death from cardiac causes"},{"title3":"Antimicrobial-associated QT interval prolongation: pointes of interest"},{"title3":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology"},{"title3":"Detection of SARS-CoV-2 in different types of clinical specimens"}]},{"title2":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","References":[{"title3":"Letter to the editor about &quot;Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial&quot;"},{"title3":"Novel coronavirus infection during the 2019-2020 epidemic: preparing intensive care units-the experience in Sichuan Province, China"},{"title3":"European Centre for Disease Prevention and Control. Guidance for discharge and ending isolation in the context of widespread community transmission of COVID-19 - first update. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-guidance-discharge-and-ending-isolation-first%20update.pdf (Accessed 4 October, 2020)."},{"title3":"Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis"},{"title3":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial"}]},{"title2":"Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis","References":[]},{"title2":"Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state","References":[{"title3":"Small-molecule antiviral agents in ongoing clinical trials for COVID-19"},{"title3":"Hydroxychloroquine and chloroquine for treatment of coronavirus disease 19 (COVID-19): a systematic review and meta-analysis of randomized and non-randomized controlled trials"},{"title3":"Review: hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19)"},{"title3":"Hydroxychloroquine in COVID-19 patients: pros and cons"},{"title3":"A pharmacological perspective of chloroquine in SARS-CoV-2 infection: an old drug for the fight against a new coronavirus?"},{"title3":"Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): speed is life"},{"title3":"Early hydroxychloroquine administration for rapid severe acute respiratory syndrome coronavirus 2 eradication"},{"title3":"Sputum TNF markers are increased in neutrophilic and severe asthma and are reduced by azithromycin treatment"},{"title3":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial"},{"title3":"Effect of chloroquine on lysosomes and on growth of mouse hepatitis virus (MHV-3)"},{"title3":"Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents"},{"title3":"Comparison of different autophagic vacuoles with regard to ultrastructure, enzymatic composition, and degradation capacity:formation of crinosomes"},{"title3":"Effects of chloroquine on viral infections: an old drug against today's diseases?"},{"title3":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus"},{"title3":"In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine"},{"title3":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread"},{"title3":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"},{"title3":"Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection"},{"title3":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro"},{"title3":"In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication"},{"title3":"Prioritization of anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics"},{"title3":"Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: what molecular dynamics studies of virus-host interactions reveal"},{"title3":"In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect"},{"title3":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing"},{"title3":"Potential therapies for coronaviruses"},{"title3":"Resolucion ministerial No 139-2020-MINSA"},{"title3":"Pathophysiological basis and rationale for early outpatient treatment of SARS-CoV-2 (COVID-19) infection"},{"title3":"Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France"},{"title3":"SARS-CoV-2: a storm is raging"},{"title3":"Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review"},{"title3":"Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study"},{"title3":"Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A"},{"title3":"Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection"},{"title3":"Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: a retrospective observational study (COQUIMA cohort)"},{"title3":"COVID-19 outpatients - early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin: a retrospective case series study"},{"title3":"CO VID-19 mortality risk factors in older people in a long-term care center"},{"title3":"Chen L., Zhang Z.Y., Fu J.G., Feng Z.P., Zhang S.Z., Han Q.Y., et al. Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study. MedRxiv 2020.06.19.20136093. doi:10.1101/2020.06.19.20136093."},{"title3":"Azithromycin and hydroxychloroquine accelerate recovery of outpatients with mild/moderate"},{"title3":"Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China"},{"title3":"Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting"},{"title3":"Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study"},{"title3":"Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: comparative analysis"},{"title3":"Sulaiman T., Mohana A., Alawdah L., Mahmoud N., Hassanein M., Wani T., et al. The effect of early hydroxychloroquine-based therapy in COVID-19 patients in ambulatory care settings: a nationwide prospective cohort study. medRxiv 2020.09.09.20184143. doi:10.1101/2020.09.09.20184143."},{"title3":"Therapeutic potential of ivermectin as add on treatment in COVID 19: a systematic review and meta-analysis: ivermectin in COVID-19: a meta-analysis"},{"title3":"Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial"},{"title3":"Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial"},{"title3":"Sex-derived attributes contributing to SARS-CoV-2 mortality"},{"title3":"Sex differences in resident immune cell phenotype underlie more efficient acute inflammatory responses in female mice"},{"title3":"Sex drives dimorphic immune responses to viral infections"},{"title3":"Sex differences in severity and mortality among patients with COVID-19: evidence from pooled literature analysis and insights from integrated bioinformatic analysis"},{"title3":"Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat"},{"title3":"Estrogen regulates the expression of SARS-CoV-2 receptor ACE2 in differentiated airway epithelial cells"},{"title3":"Expression profiling meta-analysis of ACE2 and TMPRSS2, the putative anti-inflammatory receptor and priming protease of SARS-CoV-2 in human cells, and identification of putative modulators"},{"title3":"Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2"},{"title3":"The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of &quot;inflame-aging&quot;"},{"title3":"Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis"},{"title3":"Obesity and COVID-19: molecular mechanisms linking both pandemics"},{"title3":"Coronavirus disease (COVID-19): a systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events"},{"title3":"The impact of pre-existing comorbidities and therapeutic interventions on COVID-19"},{"title3":"Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis"},{"title3":"Sensitivity of chest CT for COVID-19: Comparison to RT-PCR"},{"title3":"Seropositivity rate and diagnostic accuracy of serological tests in 2019-nCoV cases: a pooled analysis of individual studies"},{"title3":"Sobre las recomendaciones del Ministerio de Salud para el tratamiento farmacologico de la COVID-19 en el Peru"}]},{"title2":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","References":[{"title3":"COVID-19 map. Johns Hopkins Coronavirus Resource Centre"},{"title3":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"},{"title3":"Covid-19 in critically ill patients in the Seattle region-case series"},{"title3":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"},{"title3":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro"},{"title3":"Hydroxychloroquine in patients with COVID-19: an open-label, randomized, controlled trial"},{"title3":"Favipiravir versus arbidol for COVID-19: a randomized clinical trial"},{"title3":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma"},{"title3":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19"},{"title3":"GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses"},{"title3":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses"},{"title3":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys"},{"title3":"Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase"},{"title3":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV"},{"title3":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection"},{"title3":"Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia"},{"title3":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2"},{"title3":"A randomized, controlled trial of Ebola virus disease therapeutics"},{"title3":"Compassionate use of remdesivir for patients with severe Covid-19"},{"title3":"First case of 2019 novel coronavirus in the United States"},{"title3":"Group sequential clinical trials with triangular continuation regions"},{"title3":"Gilead Sciences. Investigator's brochure of remdesivir, 5th edition. Feb 21, 2020."},{"title3":"Late Ebola virus relapse causing meningoencephalitis: a case report"},{"title3":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease"},{"title3":"Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients"},{"title3":"Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome"}]},{"title2":"Remdesivir for the Treatment of Covid-19:Preliminary Report","References":[]},{"title2":"Remdesivir for 5 or 10 Days in Patients with Severe Covid-19","References":[]},{"title2":"Experimental treatment with favipiravir for COVID-19: an open-label control study","References":[{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"National Health Commission of the People's Republic of China. Daily briefing on novel coronavirus cases in China [Internet]. Beijing: National Health Commission of the People's Republic of China; c2020 [updated 2020 Mar 12; cited 2020; c2020 Feb 25]. Available form: http://en.nhc.gov.cn/DailyBriefing.html."},{"title3":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding"},{"title3":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"},{"title3":"Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model"},{"title3":"Computed tomography findings from patients with ARDS due to Influenza A (H1N1) virus-associated pneumonia"},{"title3":"Pulmonary sequelae in convalescent patients after severe acute respiratory syndrome: evaluation with thin-section CT"},{"title3":"Ebola virus dynamics in mice treated with favipiravir"},{"title3":"Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea"},{"title3":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor"},{"title3":"Favipiravir for children with Ebola"},{"title3":"MDVI, LLC. Phase 3 efficacy and safety study of favipiravir for treatment of uncomplicated influenza in adults [Internet]. Bethesda: National Library of Medicine; [update 2015 Nov 11; cited 2020 Mar 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT02008344."},{"title3":"MERS-CoV: understanding the latest human coronavirus threat"}]},{"title2":"Interferon-a2b treatment for COVID-19","References":[]},{"title2":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","References":[{"title3":"Coronavirus disease 2019 (COVID-19) situation report-107"},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"A pathological report of three COVID-19 cases by minimally invasive autopsies"},{"title3":"Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in golden syrian hamster model: implications for disease pathogenesis and tansmissibility"},{"title3":"In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds"},{"title3":"Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus"},{"title3":"Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings"},{"title3":"Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset"},{"title3":"Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study"},{"title3":"Medical treatment of viral pneumonia including SARS in immunocompetent adult"},{"title3":"Antiviral combinations for severe influenza"},{"title3":"Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: an open-label randomized, controlled, phase IIb/III trial"},{"title3":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonulcease"},{"title3":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)"},{"title3":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"},{"title3":"Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus"},{"title3":"Advances in respiratory virus therapeutics - a meeting report from the 6th isirv Antiviral Group conference"},{"title3":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV"},{"title3":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis"},{"title3":"Treatment of COVID-19: old tricks for new challenges"},{"title3":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)"},{"title3":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19"},{"title3":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial"},{"title3":"Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: a retrospective cohort study"},{"title3":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents"},{"title3":"Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture"},{"title3":"Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs"},{"title3":"Ribavirin and interferon therapy for critically ill patients with Middle East Respiratory Syndrome: a multicentre observational study"},{"title3":"Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19"},{"title3":"TLR9-induced interferon beta is associated with protection from gammaherpesvirus-induced exacerbation of lung fibrosis"}]},{"title2":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","References":[{"title3":"The novel coronavirus originating in Wuhan, China: challenges for global health governance"},{"title3":"Severe acute respiratory syndrome-related coronavirus: the species and its viruses:a statement of the Coronavirus Study Group"},{"title3":"Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)"},{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society"},{"title3":"KDIGO clinical practice guidelines for acute kidney injury"},{"title3":"Acute respiratory distress syndrome: the Berlin Definition"},{"title3":"Chinese management guideline for COVID-19 (version 6.0)"},{"title3":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study"},{"title3":"Middle East respiratory syndrome"},{"title3":"Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong"},{"title3":"Predictors of mortality in Middle East respiratory syndrome (MERS)"},{"title3":"Exacerbated innate host response to SARS-CoV in aged non-human primates"},{"title3":"The immunopathogenesis of sepsis in elderly patients"},{"title3":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)"},{"title3":"Serial evaluation of the SOFA score to predict outcome in critically ill patients"},{"title3":"Disease severity and clinical outcomes of community-acquired pneumonia caused by non-influenza respiratory viruses in adults: a multicentre prospective registry study from the CAP-China Network"},{"title3":"Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study"},{"title3":"Acute pneumonia and the cardiovascular system"},{"title3":"Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis"},{"title3":"Laboratory-confirmed respiratory infections as predictors of hospital admission for myocardial infarction and stroke: time-series analysis of English data for 2004-2015"},{"title3":"Prevalence and significance of coagulation abnormalities in community-acquired pneumonia"},{"title3":"D-dimer is a significant prognostic factor in patients with suspected infection and sepsis"},{"title3":"Risk of myocardial infarction and stroke after acute infection or vaccination"},{"title3":"Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality"},{"title3":"Cardiovascular complications of acute respiratory infections: current research and future directions"},{"title3":"Regulation of ACE2 in cardiac myocytes and fibroblasts"},{"title3":"ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension"},{"title3":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome"},{"title3":"Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase"},{"title3":"Viral shedding and antibody response in 37 patients with Middle East Respiratory Syndrome coronavirus infection"},{"title3":"Viral load kinetics of MERS coronavirus infection"},{"title3":"Factors associated with prolonged viral shedding in patients with avian influenza A(H7N9) virus infection"},{"title3":"SARS-CoV-2 viral load in upper respiratory specimens of infected patients"}]},{"title2":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","References":[]},{"title2":"Treating influenza with statins and other immunomodulatory agents","References":[]},{"title2":"A practical treatment for patients with Ebola virus disease","References":[]},{"title2":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","References":[{"title3":"Epidemiology, genetic recombination, and pathogenesis of coronaviruses"},{"title3":"Coronavirus avian infectious bronchitis virus"},{"title3":"Pathogenicity of turkey coronavirus in turkeys and chickens"},{"title3":"Fatal swine acute diarrhoea syndrome caused by an HKU2-related coronavirus of bat origin"},{"title3":"Severe acute respiratory syndrome"},{"title3":"SARS: epidemiology"},{"title3":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia"},{"title3":"A dynamic compartmental model for the Middle East respiratory syndrome outbreak in the Republic of Korea: a retrospective analysis on control interventions and superspreading events"},{"title3":"The clinical and virological features of the first imported case causing MERS-CoV outbreak in South Korea, 2015"},{"title3":"A novel coronavirus genome identified in a cluster of pneumonia cases:Wuhan, China 2019-2020"},{"title3":"A novel coronavirus from patients with pneumonia in China, 2019"},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Two-tube multiplex real-time reverse transcription PCR to detect six human coronaviruses"},{"title3":"Fast and accurate short read alignment with Burrows-Wheeler transform"},{"title3":"RAPSearch2: a fast and memory-efficient protein similarity search tool for next-generation sequencing data"},{"title3":"Human infection with a novel, highly pathogenic avian influenza A (H5N6) virus: virological and clinical findings"},{"title3":"CDD/SPARCLE: functional classification of proteins via subfamily domain architectures"},{"title3":"Full-length human immunodeficiency virus type 1 genomes from subtype C-infected seroconverters in India, with evidence of intersubtype recombination"},{"title3":"Parallelization of MAFFT for large-scale multiple sequence alignments"},{"title3":"RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies"},{"title3":"Genomic characterization and infectivity of a novel SARS-like coronavirus in Chinese bats"},{"title3":"Structure, function, and evolution of coronavirus spike proteins"},{"title3":"Bat-to-human: spike features determining 'host jump' of coronaviruses SARS-CoV, MERS-CoV, and beyond"},{"title3":"MERS-CoV spike protein: targets for vaccines and therapeutics"},{"title3":"Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine"},{"title3":"Evidence for a common evolutionary origin of coronavirus spike protein receptor-binding subunits"},{"title3":"Structure of SARS coronavirus spike receptor-binding domain complexed with receptor"},{"title3":"Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26"},{"title3":"Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4"},{"title3":"Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26"},{"title3":"SWISS-MODEL: homology modelling of protein structures and complexes"},{"title3":"Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody"},{"title3":"Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China"},{"title3":"Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia"},{"title3":"Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin"}]},{"title2":"Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: Role of epigenetic histone modifications","References":[]},{"title2":"Hiding in plain sight: an approach to treating patients with severe COVID-19 infection","References":[{"title3":"Emerging coronaviruses: genome structure, replication, and pathogenesis"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19):China, 2020"},{"title3":"A practical treatment for patients with Ebola virus disease"},{"title3":"Simvastatin decreases lipopoly-saccharide-induced pulmonary inflammation in healthy volunteers"},{"title3":"Role of claudin-5 in the attenuation of murine acute lung injury by simvastatin"},{"title3":"Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases"},{"title3":"Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis prevents lipopolysaccharide-induced apoptosis of pulmonary microvascular endothelial cells by inhibiting JNK/NF-kappaB pathways"},{"title3":"Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola"},{"title3":"Treating the host response to Ebola virus disease with generic statins and angiotensin receptor blockers"},{"title3":"Treating Ebola patients: a 'bottom up' approach using generic statins and angiotensin receptor blockers"},{"title3":"A randomized, controlled trial of Ebola virus disease therapeutics"},{"title3":"Treating Ebola in eastern DRC"},{"title3":"Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist"},{"title3":"Tissue specific up regulation of ACE2 in rabbit model of atherosclerosis by atorvastatin: role of epigenetic histone modifications"},{"title3":"Imbalance between pulmonary angiotensin-converting enzyme and angiotensin-converting enzyme 2 activity in acute respiratory distress syndrome"},{"title3":"Do viral infections mimic bacterial sepsis? The role of microvascular permeability: a review of mechanisms and methods"},{"title3":"The Damage-Response Framework as a tool for the physician-scientist to understand the pathogenesis of infectious diseases"},{"title3":"Clinician-initiated research on treating the host response to pandemic influenza"}]},{"title2":"Potential effects of coronaviruses on the cardiovascular system: a review","References":[]},{"title2":"A new clinical trial to test high-dose vitamin C in patients with COVID-19","References":[{"title3":"Hypovitaminosis C and vitamin C deficiency in critically ill patients despite recommended enteral and parenteral intakes"},{"title3":"Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9."},{"title3":"Effect of vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: the CITRIS-ALI randomized clinical trial"},{"title3":"Combined vitamin C, hydrocortisone, and thiamine therapy for patients with severe pneumonia who were admitted to the intensive care unit: propensity score-based analysis of a before-after cohort study"},{"title3":"Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, Xiao W, Wang YN, Zhong MH, Li CH, Li GC, Liu HG. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020. 10.1097/CM9.0000000000000744."}]},{"title2":"Drug targets for corona virus: A systematic review. Indian journal of pharmacology","References":[]},{"title2":"Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy","References":[{"title3":"Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation"},{"title3":"The origin of hepatitis C virus"},{"title3":"Dengue and other flavivirus infections"},{"title3":"How current direct-acting antiviral and novel cell culture systems for HCV are shaping therapy and molecular diagnosis of chronic HCV infection"},{"title3":"Hepatitis C virus RNA replication and assembly: Living on the fat of the land"},{"title3":"Characterization of low- and very-low-density hepatitis C virus RNA-containing particles"},{"title3":"Hepatitis C virus RNA replication"},{"title3":"Hepatitis C virus RNA translation"},{"title3":"The past, present and future of neutralizing antibodies for hepatitis C virus"},{"title3":"Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies"},{"title3":"Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents"},{"title3":"Cell-to-cell contact with hepatitis C virus-infected cells reduces functional capacity of natural killer cells"},{"title3":"Determining the involvement and therapeutic implications of host cellular factors in hepatitis C virus cell-to-cell spread"},{"title3":"Complete replication of hepatitis C virus in cell culture"},{"title3":"Production of infectious hepatitis C virus in tissue culture from a cloned viral genome"},{"title3":"Efficient trans-encapsidation of hepatitis C virus RNAs into infectious virus-like particles"},{"title3":"Trans-complemented hepatitis C virus particles as a versatile tool for study of virus assembly and infection"},{"title3":"Resistance to hepatitis C virus: Potential genetic and immunological determinants"},{"title3":"Hepatitis C virus and antiviral innate immunity: Who wins at tug-of-war?"},{"title3":"Host-targeting agents in the treatment of hepatitis C: A beginning and an end?"},{"title3":"Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence"},{"title3":"Epidemiology and natural history of HCV infection"},{"title3":"Natural history of hepatitis C"},{"title3":"Hepatitis C"},{"title3":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide"},{"title3":"Epidemiology of viral hepatitis and hepatocellular carcinoma"},{"title3":"Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression"},{"title3":"All-cause mortality and progression risks to hepatic decompensation and hepatocellular carcinoma in patients infected with hepatitis C virus"},{"title3":"Genetic variation in IL28b and spontaneous clearance of hepatitis C virus"},{"title3":"Acute hepatitis C in a contemporary US cohort: Modes of acquisition and factors influencing viral clearance"},{"title3":"The effects of female sex, viral genotype, and il28b genotype on spontaneous clearance of acute hepatitis C virus infection"},{"title3":"Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish hepatology research group"},{"title3":"Too low to measure, infectious nonetheless"},{"title3":"Immune control and failure in HCV infection--tipping the balance"},{"title3":"Innate immune responses to hepatitis C virus"},{"title3":"Regulation of hepatic innate immunity by hepatitis C virus"},{"title3":"Innate immune responses in hepatitis C virus infection"},{"title3":"Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness"},{"title3":"Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver"},{"title3":"Interferon lambda: Opportunities, risks, and uncertainties in the fight against HCV"},{"title3":"T cell responses in hepatitis C virus infection: Historical overview and goals for future research"},{"title3":"Will there be a vaccine to prevent HCV infection?"},{"title3":"Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response"},{"title3":"The humoral immune response to HCV: Understanding is key to vaccine development"},{"title3":"Broadly neutralizing antibodies abrogate established hepatitis C virus infection"},{"title3":"T cell responses in hepatitis C: The good, the bad and the unconventional"},{"title3":"Interferon signaling and treatment outcome in chronic hepatitis C"},{"title3":"Immune responses to HCV and other hepatitis viruses"},{"title3":"Hepatitis C virus infection from the perspective of heterologous immunity"},{"title3":"Natural killer cells and hepatitis C: Action and reaction"},{"title3":"EASL Recommendations on Treatment of Hepatitis C 2015"},{"title3":"Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy"},{"title3":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus"},{"title3":"HCV RNA viral load assessments in the era of direct-acting antivirals"},{"title3":"Performance of the new Aptima HCV Quant Dx assay in comparison to the COBAS TaqMan HCV2 assay for use with the High Pure System in the Detection and Quantification of HCV RNA in plasma or serum"},{"title3":"HCV RNA quantification with different assays: implications for protease-inhibitor-based response-guided therapy"},{"title3":"Performance characteristics of the COBAS Ampliprep/COBAS TaqMan v2. 0 and the Abbott RealTime hepatitis C assays - implications for response-guided therapy in genotype 1 infections"},{"title3":"HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals"},{"title3":"An OPTIMIZE Study retrospective analysis for the management of telaprevir-treated HCV patients using the Abbott RealTime HCV RNA assay"},{"title3":"Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection"},{"title3":"Multicentric performance analysis of HCV quantification assays and its potential relevance for HCV treatment"},{"title3":"Real-Time PCR Assays for the Quantification of HCV RNA: Concordance, Discrepancies and Implications for Response Guided Therapy"},{"title3":"Comparison of three quantitative HCV RNA assays in samples from HCV genotype 1- or 4-infected patients treated with the NS3/4A protease inhibitor simeprevir"},{"title3":"Potential implication of residual viremia in patients on effective antiretroviral therapy"},{"title3":"Standardization and performance evaluation of 'modified' and 'ultrasensitive' versions of the Abbott RealTime HIV-1 assay, adapted to quantify minimal residual viremia"},{"title3":"Ultrasensitive HCV-RNA quantification in PEG-Interferon, Telaprevir and Ribavirin standard treatment protocol: new insights into viral clearance dynamics and treatment outcome predictors"},{"title3":"Patterns of HCV-RNA and HCV core antigen in the early monitoring of standard treatment for chronic hepatitis C"},{"title3":"Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection"},{"title3":"Clinical utility of hepatitis C virus core antigen quantification in patients with chronic hepatitis C"},{"title3":"The clinical significance of HCV core antigen detection during Telaprevir/Peg-Interferon/Ribavirin therapy in patients with HCV 1 genotype infection"},{"title3":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource"},{"title3":"Emerging therapies for the treatment of hepatitis C"},{"title3":"Chronic hepatitis C virus infection: genotyping and its clinical role"},{"title3":"Resistance to direct antiviral agents in patients with hepatitis C virus infection"},{"title3":"Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)"},{"title3":"Drug resistance testing in hepatitis C therapy"},{"title3":"Sofosbuvir-based treatment under real life conditions in Germany (The SOFGER trial)"},{"title3":"Validation of HIV-1 drug resistance testing by deep sequencing: insights from comparative Sanger sequencing"},{"title3":"Ultra-deep pyrosequencing (UDPS) data treatment to study amplicon HCV minor variants"},{"title3":"HCV NS3 quasispecies in liver and plasma and dynamics of telaprevir-resistant variants in breakthrough patients assessed by UDPS: A case study"},{"title3":"Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV+daclatasvir: a case study using ultra deep pyrosequencing"},{"title3":"Amplification and pyrosequencing of near-full-length hepatitis C virus for typing and monitoring antiviral resistant strains"},{"title3":"Analysis of hepatitis C NS5A resistance associated polymorphisms using ultra deep single molecule real time (SMRT) sequencing"},{"title3":"The role of resistance in HCV treatment"},{"title3":"Hepatitis C treatment: the data flood goes on-an update from the liver meeting 2014"},{"title3":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice"},{"title3":"Development and persistence of DAA resistance associated mutations in patients failing HCV treatment"},{"title3":"HCV in 2015: Advances in hepatitis c research and treatment"},{"title3":"Medicine"},{"title3":"Global control of hepatitis C: Where challenge meets opportunity"},{"title3":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection"}]},{"title2":"Zika virus structure, maturation, and receptors","References":[]},{"title2":"Coronaviruses: An Overview of Their Replication and Pathogenesis","References":[{"title3":"Expression of hemagglutinin esterase protein from recombinant mouse hepatitis virus enhances neurovirulence"},{"title3":"The group-specific murine coronavirus genes are not essential, but their deletion, by reverse genetics, is attenuating in the natural host"},{"title3":"Coronavirus gene 7 counteracts host defenses and modulates virus virulence"},{"title3":"Severe acute respiratory syndrome coronavirus protein 6 accelerates murine coronavirus infections"},{"title3":"Evidence for camel-to-human transmission of MERS coronavirus"},{"title3":"MERS-CoV Accessory ORFs Play Key Role for Infection and Pathogenesis"},{"title3":"Inhibition of Stress Granule Formation by Middle East Respiratory Syndrome Coronavirus 4a Accessory Protein Facilitates Viral Translation, Leading to Efficient Virus Replication"},{"title3":"Middle East Respiratory Coronavirus Accessory Protein 4a Inhibits PKR-Mediated Antiviral Stress Responses"},{"title3":"Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets"},{"title3":"MERS-CoV 4b protein interferes with the NF-kappaB-dependent innate immune response during infection"},{"title3":"Antagonism of the interferon-induced OAS-RNase L pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology"},{"title3":"Cryo-electron tomography of mouse hepatitis virus: Insights into the structure of the coronavirion"},{"title3":"Supramolecular architecture of severe acute respiratory syndrome coronavirus revealed by electron cryomicroscopy"},{"title3":"Architecture of the SARS coronavirus prefusion spike"},{"title3":"Assembly of coronavirus spike protein into trimers and its role in epitope expression"},{"title3":"The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex"},{"title3":"Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein"},{"title3":"Deduced sequence of the bovine coronavirus spike protein and identification of the internal proteolytic cleavage site"},{"title3":"Primary structure of the glycoprotein E2 of coronavirus MHV-A59 and identification of the trypsin cleavage site"},{"title3":"Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer"},{"title3":"Pre-fusion structure of a human coronavirus spike protein"},{"title3":"Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy"},{"title3":"Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains"},{"title3":"Glycan Shield and Fusion Activation of a Deltacoronavirus Spike Glycoprotein Fine-Tuned for Enteric Infections"},{"title3":"Cryo-EM structure of infectious bronchitis coronavirus spike protein reveals structural and functional evolution of coronavirus spike proteins"},{"title3":"Isolation of coronavirus envelope glycoproteins and interaction with the viral nucleocapsid"},{"title3":"Assembly in vitro of a spanning membrane protein of the endoplasmic reticulum: the E1 glycoprotein of coronavirus mouse hepatitis virus A59"},{"title3":"Analyses of Coronavirus Assembly Interactions with Interspecies Membrane and Nucleocapsid Protein Chimeras"},{"title3":"Characterization and translation of transmissible gastroenteritis virus mRNAs"},{"title3":"Differential maturation and subcellular localization of severe acute respiratory syndrome coronavirus surface proteins S, M and E"},{"title3":"Structural requirements for O-glycosylation of the mouse hepatitis virus membrane protein"},{"title3":"Single amino acid changes in the viral glycoprotein M affect induction of alpha interferon by the coronavirus transmissible gastroenteritis virus"},{"title3":"The glycosylation status of the murine hepatitis coronavirus M protein affects the interferogenic capacity of the virus in vitro and its ability to replicate in the liver but not the brain"},{"title3":"Membrane assembly of the triple-spanning coronavirus M protein. Individual transmembrane domains show preferred orientation"},{"title3":"A specific transmembrane domain of a coronavirus E1 glycoprotein is required for its retention in the Golgi region"},{"title3":"The amino-terminal signal peptide on the porcine transmissible gastroenteritis coronavirus matrix protein is not an absolute requirement for membrane translocation and glycosylation"},{"title3":"A structural analysis of M protein in coronavirus assembly and morphology"},{"title3":"Functional analysis of the murine coronavirus genomic RNA packaging signal"},{"title3":"The molecular biology of coronaviruses"},{"title3":"Nucleocapsid-independent assembly of coronavirus-like particles by co-expression of viral envelope protein genes"},{"title3":"The cytoplasmic tail of infectious bronchitis virus E protein directs Golgi targeting"},{"title3":"A single polar residue and distinct membrane topologies impact the function of the infectious bronchitis coronavirus E protein"},{"title3":"SARS coronavirus E protein forms cation-selective ion channels"},{"title3":"Structure and inhibition of the SARS coronavirus envelope protein ion channel"},{"title3":"A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo"},{"title3":"Analysis of constructed E gene mutants of mouse hepatitis virus confirms a pivotal role for E protein in coronavirus assembly"},{"title3":"Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis"},{"title3":"Role of Severe Acute Respiratory Syndrome Coronavirus Viroporins E, 3a, and 8a"},{"title3":"Modular organization of SARS coronavirus nucleocapsid protein"},{"title3":"Identification of in vivo-interacting domains of the murine coronavirus nucleocapsid protein"},{"title3":"Phosphoproteins of murine hepatitis viruses"},{"title3":"The coronavirus nucleocapsid protein is ADP-ribosylated"},{"title3":"Specific interaction between coronavirus leader RNA and nucleocapsid protein"},{"title3":"Characterization of a critical interaction between the coronavirus nucleocapsid protein and nonstructural protein 3 of the viral replicase-transcriptase complex"},{"title3":"Identification of a coronavirus hemagglutinin-esterase with a substrate specificity different from those of influenza C virus and bovine coronavirus"},{"title3":"Hemagglutinin-esterase, a novel structural protein of torovirus"},{"title3":"Luxury at a cost? Recombinant mouse hepatitis viruses expressing the accessory hemagglutinin esterase protein display reduced fitness in vitro"},{"title3":"Localization of neutralizing epitopes and the receptor-binding site within the amino-terminal 330 amino acids of the murine coronavirus spike protein"},{"title3":"A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2"},{"title3":"Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4"},{"title3":"Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26"},{"title3":"Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E"},{"title3":"Identification of the Receptor-Binding Domain of the Spike Glycoprotein of Human Betacoronavirus HKU1"},{"title3":"Identification of residues in the receptor-binding domain (RBD) of the spike protein of human coronavirus NL63 that are critical for the RBD-ACE2 receptor interaction"},{"title3":"Major receptor-binding and neutralization determinants are located within the same domain of the transmissible gastroenteritis virus (coronavirus) spike protein"},{"title3":"Purification of the 110-kilodalton glycoprotein receptor for mouse hepatitis virus (MHV)-A59 from mouse liver and identification of a nonfunctional, homologous protein in MHV-resistant SJL/J mice"},{"title3":"Receptor for mouse hepatitis virus is a member of the carcinoembryonic antigen family of glycoproteins"},{"title3":"Cloning of the mouse hepatitis virus (MHV) receptor: expression in human and hamster cell lines confers susceptibility to MHV"},{"title3":"Mouse Hepatitis Virus Receptor as a Determinant of the Mouse Susceptibility to MHV Infection"},{"title3":"Aminopeptidase N is a major receptor for the entero-pathogenic coronavirus TGEV"},{"title3":"Human aminopeptidase N is a receptor for human coronavirus 229E"},{"title3":"Feline aminopeptidase N serves as a receptor for feline, canine, porcine, and human coronaviruses in serogroup I"},{"title3":"Broad receptor engagement of an emerging global coronavirus may potentiate its diverse cross-species transmissibility"},{"title3":"Porcine Deltacoronavirus Engages the Transmissible Gastroenteritis Virus Functional Receptor Porcine Aminopeptidase N for Infectious Cellular Entry"},{"title3":"Further characterization of aminopeptidase-N as a receptor for coronaviruses"},{"title3":"Interspecies aminopeptidase-N chimeras reveal species-specific receptor recognition by canine coronavirus, feline infectious peritonitis virus, and transmissible gastroenteritis virus"},{"title3":"Determinants essential for the transmissible gastroenteritis virus-receptor interaction reside within a domain of aminopeptidase-N that is distinct from the enzymatic site"},{"title3":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus"},{"title3":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis"},{"title3":"Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry"},{"title3":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC"},{"title3":"Receptor recognition mechanisms of coronaviruses: a decade of structural studies"},{"title3":"Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites"},{"title3":"Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein"},{"title3":"Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism"},{"title3":"Fusion of Enveloped Viruses in Endosomes"},{"title3":"Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China"},{"title3":"Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study"},{"title3":"Variations in Spike Glycoprotein Gene of MERS-CoV, South Korea, 2015"},{"title3":"Spread of Mutant Middle East Respiratory Syndrome Coronavirus with Reduced Affinity to Human CD26 during the South Korean Outbreak"},{"title3":"The tetraspanin CD9 facilitates MERS-coronavirus entry by scaffolding host cell receptors and proteases"},{"title3":"Programmed ribosomal frameshifting in decoding the SARS-CoV genome"},{"title3":"Characterization of an efficient coronavirus ribosomal frameshifting signal: requirement for an RNA pseudoknot"},{"title3":"Pathogenic virus-specific T cells cause disease during treatment with the calcineurin inhibitor FK506: implications for transplantation"},{"title3":"Virus-encoded proteinases and proteolytic processing in the Nidovirales"},{"title3":"Nidovirus papain-like proteases: multifunctional enzymes with protease, deubiquitinating and deISGylating activities"},{"title3":"Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain"},{"title3":"Temperature-sensitive mutants and revertants in the coronavirus nonstructural protein 5 protease (3CLpro) define residues involved in long-distance communication and regulation of protease activity"},{"title3":"Design of wide-spectrum inhibitors targeting coronavirus main proteases"},{"title3":"Atlas of coronavirus replicase structure"},{"title3":"Topology and membrane anchoring of the coronavirus replication complex: not all hydrophobic domains of nsp3 and nsp6 are membrane spanning"},{"title3":"Membrane topology of murine coronavirus replicase nonstructural protein 3"},{"title3":"Bioinformatics and functional analyses of coronavirus nonstructural proteins involved in the formation of replicative organelles"},{"title3":"Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein"},{"title3":"Proteomics analysis unravels the functional repertoire of coronavirus nonstructural protein 3"},{"title3":"An interaction between the nucleocapsid protein and a component of the replicase-transcriptase complex is crucial for the infectivity of coronavirus genomic RNA"},{"title3":"Solution structure of mouse hepatitis virus (MHV) nsp3a and determinants of the interaction with MHV nucleocapsid (N) protein"},{"title3":"Viral Macro Domains Reverse Protein ADP-Ribosylation"},{"title3":"Viral Macrodomains: Unique Mediators of Viral Replication and Pathogenesis"},{"title3":"Mutations in coronavirus nonstructural protein 10 decrease virus replication fidelity"},{"title3":"Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing"},{"title3":"High fidelity of murine hepatitis virus replication is decreased in nsp14 exoribonuclease mutants"},{"title3":"Discovery of an RNA virus 3'-&gt;5' exoribonuclease that is critically involved in coronavirus RNA synthesis"},{"title3":"Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase"},{"title3":"Coronavirus nonstructural protein 16 is a cap-0 binding enzyme possessing (nucleoside-2'O)-methyltransferase activity"},{"title3":"Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response"},{"title3":"Coronavirus nonstructural protein 15 mediates evasion of dsRNA sensors and limits apoptosis in macrophages"},{"title3":"Early endonuclease-mediated evasion of RNA sensing ensures efficient coronavirus replication"},{"title3":"Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage"},{"title3":"Minus-strand copies of replicating coronavirus mRNAs contain antileaders"},{"title3":"An RNA stem-loop within the bovine coronavirus nsp1 coding region is a cis-acting element in defective interfering RNA replication"},{"title3":"An optimal cis-replication stem-loop IV in the 5' untranslated region of the mouse coronavirus genome extends 16 nucleotides into open reading frame 1"},{"title3":"Mouse hepatitis virus stem-loop 2 adopts a uYNMG(U)a-like tetraloop structure that is highly functionally tolerant of base substitutions"},{"title3":"Stem-loop III in the 5' untranslated region is a cis-acting element in bovine coronavirus defective interfering RNA replication"},{"title3":"Secondary structural elements within the 3' untranslated region of mouse hepatitis virus strain JHM genomic RNA"},{"title3":"A hypervariable region within the 3' cis-acting element of the murine coronavirus genome is nonessential for RNA synthesis but affects pathogenesis"},{"title3":"A phylogenetically conserved hairpin-type 3' untranslated region pseudoknot functions in coronavirus RNA replication"},{"title3":"A bulged stem-loop structure in the 3' untranslated region of the genome of the coronavirus mouse hepatitis virus is essential for replication"},{"title3":"Characterization of an essential RNA secondary structure in the 3' untranslated region of the murine coronavirus genome"},{"title3":"A contemporary view of coronavirus transcription"},{"title3":"Nucleocapsid phosphorylation and RNA helicase DDX1 recruitment enables coronavirus transition from discontinuous to continuous transcription"},{"title3":"RNA recombination of coronavirus"},{"title3":"Recombination between nonsegmented RNA genomes of murine coronaviruses"},{"title3":"Retargeting of coronavirus by substitution of the spike glycoprotein ectodomain: crossing the host cell species barrier"},{"title3":"Characterization of the budding compartment of mouse hepatitis virus: Evidence that transport from the RER to the golgi complex requires only one vesicular transport step"},{"title3":"Replication of coronavirus MHV-A59 in sac- cells: determination of the first site of budding of progeny virions"},{"title3":"Molecular interactions in the assembly of coronaviruses"},{"title3":"The production of recombinant infectious DI-particles of a murine coronavirus in the absence of helper virus"},{"title3":"The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles"},{"title3":"Characterization of the coronavirus mouse hepatitis virus strain A59 small membrane protein E"},{"title3":"Infectious bronchitis virus E protein is targeted to the Golgi complex and directs release of virus-like particles"},{"title3":"Envelope protein palmitoylations are crucial for murine coronavirus assembly"},{"title3":"Role of the coronavirus E viroporin protein transmembrane domain in virus assembly"},{"title3":"A major determinant for membrane protein interaction localizes to the carboxy-terminal domain of the mouse coronavirus nucleocapsid protein"},{"title3":"Selective Packaging in Murine Coronavirus Promotes Virulence by Limiting Type I Interferon Responses"},{"title3":"Genome-Wide Screen Reveals Valosin-Containing Protein Requirement for Coronavirus Exit from Endosomes"},{"title3":"Fatal swine acute diarrhoea syndrome caused by an HKU2-related coronavirus of bat origin"},{"title3":"Natural history of a recurrent feline coronavirus infection and the role of cellular immunity in survival and disease"},{"title3":"Bovine respiratory coronavirus"},{"title3":"Avian infectious bronchitis virus"},{"title3":"Identification of a novel coronavirus from a beluga whale by using a panviral microarray"},{"title3":"Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group"},{"title3":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia"},{"title3":"Identification of diverse alphacoronaviruses and genomic characterization of a novel severe acute respiratory syndrome-like coronavirus from bats in china"},{"title3":"Discovery of the first insect nidovirus, a missing evolutionary link in the emergence of the largest RNA virus genomes"},{"title3":"Mesoniviridae: a proposed new family in the order Nidovirales formed by a single species of mosquito-borne viruses"},{"title3":"A planarian nidovirus expands the limits of RNA genome size"},{"title3":"Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis"},{"title3":"Mechanism of demyelination in JHM virus encephalomyelitis"},{"title3":"Pathogenesis of demyelination induced by a mouse hepatitis virus (JHM virus)"},{"title3":"Pathogenesis of mouse hepatitis virus-induced demyelination"},{"title3":"Demyelination induced by murine hepatitis virus JHM strain (MHV-4) is immunologically mediated"},{"title3":"CD4 and CD8 T cells have redundant but not identical roles in virus-induced demyelination"},{"title3":"Macrophage infiltration, but not apoptosis, is correlated with immune-mediated demyelination following murine infection with a neurotropic coronavirus"},{"title3":"Microglia are required for protection against lethal coronavirus encephalitis in mice"},{"title3":"Growth in suckling-mouse brain of &quot;IBV-like&quot; viruses from patients with upper respiratory tract disease"},{"title3":"Effects of a &quot;new&quot; human respiratory virus in volunteers"},{"title3":"A new virus isolated from the human respiratory tract"},{"title3":"Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia"},{"title3":"Identification of a new human coronavirus"},{"title3":"Evidence supporting a zoonotic origin of human coronavirus strain NL63"},{"title3":"Severity and outcome associated with human coronavirus OC43 infections among children"},{"title3":"Croup is associated with the novel coronavirus NL63"},{"title3":"Analysis of human coronavirus 229E spike and nucleoprotein genes demonstrates genetic drift between chronologically distinct strains"},{"title3":"Circulation of genetically distinct contemporary human coronavirus OC43 strains"},{"title3":"Neuroinvasion by human respiratory coronaviruses"},{"title3":"Severe acute respiratory syndrome"},{"title3":"Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats"},{"title3":"Bats are natural reservoirs of SARS-like coronaviruses"},{"title3":"Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor"},{"title3":"Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China"},{"title3":"The severe acute respiratory syndrome"},{"title3":"Severe acute respiratory syndrome"},{"title3":"Lung pathology of fatal severe acute respiratory syndrome"},{"title3":"Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study"},{"title3":"Interaction of severe acute respiratory syndrome-associated coronavirus with dendritic cells"},{"title3":"Chemokine upregulation in SARS coronavirus infected human monocyte derived dendritic cells"},{"title3":"Pathogenesis of severe acute respiratory syndrome"},{"title3":"Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans"},{"title3":"T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice"},{"title3":"Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice"},{"title3":"Occurrence of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) across the Gulf Corporation Council countries: Four years update"},{"title3":"Clinical Presentation and Outcomes of Middle East Respiratory Syndrome in the Republic of Korea"},{"title3":"2015 MERS outbreak in Korea: hospital-to-hospital transmission"},{"title3":"Reported Direct and Indirect Contact with Dromedary Camels among Laboratory-Confirmed MERS-CoV Cases"},{"title3":"Middle East Respiratory Syndrome Coronavirus (MERS-CoV) origin and animal reservoir"},{"title3":"Human Infection with MERS Coronavirus after Exposure to Infected Camels, Saudi Arabia, 2013"},{"title3":"Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans"},{"title3":"Further Evidence for Bats as the Evolutionary Source of Middle East Respiratory Syndrome Coronavirus"},{"title3":"Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice"},{"title3":"Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease"},{"title3":"Rapid generation of a mouse model for Middle East respiratory syndrome"},{"title3":"A mouse model for MERS coronavirus-induced acute respiratory distress syndrome"},{"title3":"Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus"},{"title3":"Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method"},{"title3":"A Rapid and Specific Assay for the Detection of MERS-CoV"},{"title3":"Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study"},{"title3":"Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice"},{"title3":"IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes"},{"title3":"Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape"},{"title3":"A review of treatment modalities for Middle East Respiratory Syndrome"},{"title3":"Vaccination against infectious bronchitis virus: A continuous challenge"},{"title3":"An overview of successful TGEV vaccination strategies and discussion on the interrelationship between TGEV and PRCV"},{"title3":"Global trends in emerging infectious diseases"},{"title3":"Porcine respiratory coronavirus: molecular features and virus-host interactions"},{"title3":"Severe acute respiratory syndrome (SARS) S protein production in plants: development of recombinant vaccine"},{"title3":"Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant"},{"title3":"Severe acute respiratory syndrome (SARS) coronavirus: application of monoclonal antibodies and development of an effective vaccine"},{"title3":"Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential"},{"title3":"Middle East Respiratory Syndrome Vaccine Candidates"},{"title3":"Vaccine against Middle East respiratory syndrome coronavirus"},{"title3":"Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial"},{"title3":"First clinical trial of a MERS coronavirus DNA vaccine"},{"title3":"Type I feline coronavirus spike glycoprotein fails to recognize aminopeptidase N as a functional receptor on feline cell lines"},{"title3":"Porcine aminopeptidase N is not a cellular receptor of porcine epidemic diarrhea virus, but promotes its infectivity via aminopeptidase activity"},{"title3":"Aminopeptidase N is not required for porcine epidemic diarrhea virus cell entry"},{"title3":"Bovine coronavirus uses N-acetyl-9-O-acetylneuraminic acid as a receptor determinant to initiate the infection of cultured cells"},{"title3":"Structural and functional analysis of the surface protein of human coronavirus OC43"},{"title3":"Mapping of the receptor-binding domain and amino acids critical for attachment in the spike protein of avian coronavirus infectious bronchitis virus"},{"title3":"Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines"},{"title3":"The Endonucleolytic RNA Cleavage Function of nsp1 of Middle East Respiratory Syndrome Coronavirus Promotes the Production of Infectious Virus Particles in Specific Human Cell Lines"},{"title3":"The nsp2 replicase proteins of murine hepatitis virus and severe acute respiratory syndrome coronavirus are dispensable for viral replication"},{"title3":"Severe acute respiratory syndrome coronavirus nonstructural protein 2 interacts with a host protein complex involved in mitochondrial biogenesis and intracellular signaling"},{"title3":"Nuclear magnetic resonance structure shows that the severe acute respiratory syndrome coronavirus-unique domain contains a macrodomain fold"},{"title3":"Structural and functional basis for ADP-ribose and poly(ADP-ribose) binding by viral macro domains"},{"title3":"Mouse hepatitis virus liver pathology is dependent on ADP-ribose-1&quot;-phosphatase, a viral function conserved in the alpha-like supergroup"},{"title3":"Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling"},{"title3":"Nuclear magnetic resonance structure of the N-terminal domain of nonstructural protein 3 from the severe acute respiratory syndrome coronavirus"},{"title3":"Nuclear magnetic resonance structure of the nucleic acid-binding domain of severe acute respiratory syndrome coronavirus nonstructural protein 3"},{"title3":"The autocatalytic release of a putative RNA virus transcription factor from its polyprotein precursor involves two paralogous papain-like proteases that cleave the same peptide bond"},{"title3":"Mutation in murine coronavirus replication protein nsp4 alters assembly of double membrane vesicles"},{"title3":"Murine hepatitis virus nonstructural protein 4 regulates virus-induced membrane modifications and replication complex function"},{"title3":"Identification and characterization of a serine-like proteinase of the murine coronavirus MHV-A59"},{"title3":"Porcine deltacoronavirus nsp5 inhibits interferon-beta production through the cleavage of NEMO"},{"title3":"Insights into SARS-CoV transcription and replication from the structure of the nsp7-nsp8 hexadecamer"},{"title3":"Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors"},{"title3":"The severe acute respiratory syndrome-coronavirus replicative protein nsp9 is a single-stranded RNA-binding subunit unique in the RNA virus world"},{"title3":"Dimerization of Coronavirus nsp9 with Diverse Modes Enhances Its Nucleic Acid Binding Affinity"},{"title3":"In vitro reconstitution of SARS-coronavirus mRNA cap methylation"},{"title3":"Crystal structure and functional analysis of the SARS-coronavirus RNA cap 2'-O-methyltransferase nsp10/nsp16 complex"},{"title3":"Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design"},{"title3":"Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase"},{"title3":"Human coronavirus 229E nonstructural protein 13: characterization of duplex-unwinding, nucleoside triphosphatase, and RNA 5'-triphosphatase activities"},{"title3":"Mutagenesis of Coronavirus nsp14 Reveals Its Potential Role in Modulation of the Innate Immune Response"},{"title3":"Murine Hepatitis Virus nsp14 Exoribonuclease Activity Is Required for Resistance to Innate Immunity"},{"title3":"RNA recognition and cleavage by the SARS coronavirus endoribonuclease"},{"title3":"Major genetic marker of nidoviruses encodes a replicative endoribonuclease"},{"title3":"In Situ Tagged nsp15 Reveals Interactions with Coronavirus Replication/Transcription Complex-Associated Proteins"},{"title3":"Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5"}]},{"title2":"Sofosbuvir and ribavirin liver pharmacokinetics in patients infected with hepatitis C virus","References":[]},{"title2":"Nucleoside/nucleotide analogue polymerase inhibitors in development","References":[]},{"title2":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus","References":[]},{"title2":"Antiviral nucleotide incorporation by recombinant human mitochondrial RNA polymerase is predictive of increased in vivo mitochondrial toxicity risk","References":[]},{"title2":"Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive effect when combined with ribavirin","References":[]},{"title2":"Antiviral candidates for treating hepatitis E virus infection","References":[]},{"title2":"Distinct antiviral potency of sofosbuvir against hepatitis C and E viruses","References":[]},{"title2":"Sofosbuvir inhibits hepatitis A virus replication in vitro assessed by a cell-based fluorescent reporter system","References":[]},{"title2":"The FDA-approved drug sofosbuvir inhibits Zika virus infection","References":[{"title3":"Characterization of Lethal Zika Virus Infection in AG129 Mice"},{"title3":"The Emergence of Zika Virus: A Narrative Review"},{"title3":"Guillain-Barre syndrome associated with the Zika virus outbreak in Brazil"},{"title3":"Infection dynamics in a traveller with persistent shedding of Zika virus RNA in semen for six months after returning from Haiti to Italy, January 2016"},{"title3":"Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era"},{"title3":"Recognition of RNA cap in the Wesselsbron virus NS5 methyltransferase domain: implications for RNA-capping mechanisms in Flavivirus"},{"title3":"Zika Virus Infection in Pregnant Women in Rio de Janeiro - Preliminary Report"},{"title3":"Guillain-Barre syndrome associated with Zika virus infection"},{"title3":"Sofosbuvir"},{"title3":"Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study"},{"title3":"Zika Virus Associated with Meningoencephalitis"},{"title3":"The structure of the RNA-dependent RNA polymerase from bovine viral diarrhea virus establishes the role of GTP in de novo initiation"},{"title3":"Sofosbuvir: a novel oral agent for chronic hepatitis C"},{"title3":"Adenosine Analog NITD008 Is a Potent Inhibitor of Zika Virus"},{"title3":"Zika virus. II. Pathogenicity and physical properties"},{"title3":"Zika virus. I. Isolations and serological specificity"},{"title3":"General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2'-modified nucleotide analogues"},{"title3":"Structural and functional analysis of methylation and 5'-RNA sequence requirements of short capped RNAs by the methyltransferase domain of dengue virus NS5"},{"title3":"Analysis of flavivirus NS5 methyltransferase cap binding"},{"title3":"Zika virus infection damages the testes in mice"},{"title3":"Characterization of West Nile virus RNA-dependent RNA polymerase and cellular terminal adenylyl and uridylyl transferases in cell-free extracts"},{"title3":"The flavivirus NS5 protein is a true RNA guanylyltransferase that catalyzes a two-step reaction to form the RNA cap structure"},{"title3":"Sofosbuvir: first global approval"},{"title3":"Evolution and taxonomy of positive-strand RNA viruses: implications of comparative analysis of amino acid sequences"},{"title3":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus"},{"title3":"Zika Virus: New Clinical Syndromes and Its Emergence in the Western Hemisphere"},{"title3":"A Mouse Model of Zika Virus Pathogenesis"},{"title3":"Assessing the global threat from Zika virus"},{"title3":"The dengue virus NS5 protein as a target for drug discovery"},{"title3":"Zika virus: high infectious viral load in semen, a new sexually transmitted pathogen?"},{"title3":"Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro"},{"title3":"Zika Virus Infection during Pregnancy in Mice Causes Placental Damage and Fetal Demise"},{"title3":"Zika Virus Infection in Mice Causes Panuveitis with Shedding of Virus in Tears"},{"title3":"Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977"},{"title3":"Zika virus infection complicated by Guillain-Barre syndrome--case report, French Polynesia, December 2013"},{"title3":"Zika Virus Disrupts Phospho-TBK1 Localization and Mitosis in Human Neuroepithelial Stem Cells and Radial Glia"},{"title3":"Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial"},{"title3":"Time Lags between Exanthematous Illness Attributed to Zika Virus, Guillain-Barre Syndrome, and Microcephaly, Salvador, Brazil"},{"title3":"Interim Guidelines for Pregnant Women During a Zika Virus Outbreak--United States, 2016"},{"title3":"Zika Virus"},{"title3":"Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors"},{"title3":"Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir"},{"title3":"Zika Virus and Birth Defects--Reviewing the Evidence for Causality"},{"title3":"Assessment of the clinical cardiac drug-drug interaction associated with the combination of hepatitis C virus nucleotide inhibitors and amiodarone in guinea pigs and rhesus monkeys"},{"title3":"Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial"},{"title3":"Rapid emergence of protease inhibitor resistance in hepatitis C virus"},{"title3":"Resistance to direct antiviral agents in patients with hepatitis C virus infection"},{"title3":"Discovery of a beta-d-2'-Deoxy-2'-alpha-fluoro-2'-beta-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus"},{"title3":"Identification of a novel antiviral inhibitor of the flavivirus guanylyltransferase enzyme"},{"title3":"Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity"},{"title3":"Late sexual transmission of Zika virus related to persistence in the semen"},{"title3":"Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen"},{"title3":"Genomic characterization and phylogenetic analysis of Zika virus circulating in the Americas"},{"title3":"Structural Basis of Zika Virus-Specific Antibody Protection"},{"title3":"The Viral Polymerase Inhibitor 7-Deaza-2'-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model"},{"title3":"Three atypical lethal cases associated with acute Zika virus infection in Suriname"},{"title3":"Functional analysis of two cavities in flavivirus NS5 polymerase"}]},{"title2":"Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication","References":[]},{"title2":"The clinically approved antiviral drug sofosbuvir impairs Brazilian zika virus replication","References":[]},{"title2":"Cell-line dependent antiviral activity of sofosbuvir against Zika virus","References":[]},{"title2":"Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro","References":[]}]},{"title1":"Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial","References":[{"title2":"Treatment options for COVID-19: the reality and challenges","References":[{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"},{"title3":"2019 Novel coronavirus: where we are and what we know"},{"title3":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention"},{"title3":"First case of 2019 novel coronavirus in the United States"},{"title3":"Are children less susceptible to COVID-19?"},{"title3":"2019 Novel coronavirus disease (COVID-19) in Taiwan: reports of two cases from Wuhan, China"},{"title3":"Active monitoring of persons exposed to patients with confirmed COVID-19 - United States, January-February 2020"},{"title3":"Neutrophil-to-lymphocyte ratio predicts severe illness patients with 2019 novel coronavirus in the early stage"},{"title3":"SARS-CoV-2 infection in children: transmission dynamics and clinical characteristics"},{"title3":"Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry"},{"title3":"Characteristics of community-acquired respiratory viruses infections except seasonal influenza in transplant recipients and non-transplant critically ill patients"},{"title3":"Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV"},{"title3":"Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study"},{"title3":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)"},{"title3":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) Is mediated by the viral polymerase and the proofreading exoribonuclease"},{"title3":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses"},{"title3":"Compounds with therapeutic potential against novel respiratory 2019 coronavirus"},{"title3":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys"},{"title3":"A randomized, controlled trial of Ebola virus disease therapeutics"},{"title3":"Medrxiv News"},{"title3":"Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase"},{"title3":"Arguments in favour of remdesivir for treating SARS-CoV-2 infections"},{"title3":"Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection"},{"title3":"Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection"},{"title3":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase"},{"title3":"Favipiravir shows good clinical efficacy in treating COVID-19: official. From"},{"title3":"Treatment with lopinavir/ritonavir or interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset"},{"title3":"Coronaviruses - drug discovery and therapeutic options"},{"title3":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV"},{"title3":"A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19"},{"title3":"COVID-19 - the search for effective therapy"},{"title3":"Abidol and darunavir can effectively inhibit coronavirus"},{"title3":"Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques"},{"title3":"Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings"},{"title3":"Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model"},{"title3":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread"},{"title3":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"},{"title3":"A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19"},{"title3":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)"},{"title3":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial"},{"title3":"Evaluation of Ebola virus inhibitors for drug repurposing"},{"title3":"Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial"},{"title3":"Teicoplanin inhibits Ebola pseudovirus infection in cell culture"},{"title3":"Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome coronavirus (SARS-CoV)"},{"title3":"Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?"},{"title3":"Advances in respiratory virus therapeutics - a meeting report from the 6th isirv Antiviral Group conference"},{"title3":"Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study"},{"title3":"A mouse model for MERS coronavirus-induced acute respiratory distress syndrome"},{"title3":"Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response"},{"title3":"Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry"},{"title3":"Protease inhibitors targeting coronavirus and filovirus entry"},{"title3":"FDA approves COVACTA trial for RA drug Actemra in COVID-19 patients"},{"title3":"Convalescent plasma as a potential therapy for COVID-19"},{"title3":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma"},{"title3":"Treatment of COVID-19: old tricks for new challenges"},{"title3":"Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs"},{"title3":"Lai CC, Wang CY, Hsueh PR.Co-infection among patients with COVID-19.(manuscript submitted)."},{"title3":"Recommendations and guidelines for the treatment of pneumonia in Taiwan"},{"title3":"Epidemiology, treatment, and prevention of nosocomial bacterial pneumonia"},{"title3":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study"},{"title3":"Clinical characteristics of coronavirus disease 2019 in China"},{"title3":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?"},{"title3":"No scientific evidence that NSAID use worsens COVID-19 symptoms"},{"title3":"COVID-19: ibuprofen should not be used for managing symptoms, say doctors and scientists"},{"title3":"COVID-19 Guidelines"},{"title3":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China"},{"title3":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy"},{"title3":"Imbalance between pulmonary angiotensin-converting enzyme and angiotensin-converting enzyme 2 activity in acute respiratory distress syndrome"},{"title3":"Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola"},{"title3":"Hiding in plain sight: an approach to treating patients with severe COVID-19 infection"}]},{"title2":"The current understanding and potential therapeutic options to combat COVID-19","References":[{"title3":"Viruses in biology"},{"title3":"Mechanisms of coronavirus cell entry mediated by the viral spike protein"},{"title3":"Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus"},{"title3":"The acetyl-esterase activity of the hemagglutinin-esterase protein of human coronavirus OC43 strongly enhances the production of infectious virus"},{"title3":"Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution"},{"title3":"Coronaviruses: an overview of their replication and pathogenesis"},{"title3":"Infection of the Cloaca with the virus of infectious bronchitis"},{"title3":"Human coronavirus circulation in the United States 2014-2017"},{"title3":"Molecular epidemiology of human coronavirus OC43 reveals evolution of different genotypes over time and recent emergence of a novel genotype due to natural recombination"},{"title3":"Review of bats and SARS"},{"title3":"Middle East respiratory syndrome coronavirus (MERS-CoV)"},{"title3":"The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2"},{"title3":"SARS-CoV-2: an emerging coronavirus that causes a global threat"},{"title3":"Human coronavirus OC43 associated with fatal encephalitis"},{"title3":"Human coronavirus-HKU1 infection among adults in Cleveland, Ohio"},{"title3":"Human Coronavirus 229E - an overview"},{"title3":"The novel human coronaviruses NL63 and HKU1"},{"title3":"Pathology and pathogenesis of severe acute respiratory syndrome"},{"title3":"Middle East respiratory syndrome coronavirus (MERS-CoV): a review"},{"title3":"Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"2019 novel coronavirus (2019-nCoV) update: uncoating the virus"},{"title3":"The establishment of reference sequence for SARS-CoV-2 and variation analysis"},{"title3":"A new coronavirus associated with human respiratory disease in China"},{"title3":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV"},{"title3":"Host factors in coronavirus replication"},{"title3":"The PDZ-binding motif of severe acute respiratory syndrome coronavirus envelope protein is a determinant of viral pathogenesis"},{"title3":"Renin-angiotensin-aldosterone system: double-edged sword in COVID-19 infection"},{"title3":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China"},{"title3":"COVID-19 map"},{"title3":"Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2"},{"title3":"Transmission dynamics and evolutionary history of 2019-nCoV"},{"title3":"Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin"},{"title3":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding"},{"title3":"A pneumonia outbreak associated with a new coronavirus of probable bat origin"},{"title3":"Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak"},{"title3":"Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2"},{"title3":"Evidence of the recombinant origin and ongoing mutations in severe acute respiratory syndrome 2 (SARS-COV-2)"},{"title3":"Isolation and characterization of 2019-nCoV-like coronavirus from Malayan pangolins"},{"title3":"Early release - possible bat origin of severe acute respiratory syndrome coronavirus 2"},{"title3":"Moderately strong confirmation of a laboratory origin of 2019-nCoV"},{"title3":"Is SARS-CoV-2 originated from laboratory? A rebuttal to the claim of formation via laboratory recombination"},{"title3":"The proximal origin of SARS-CoV-2"},{"title3":"Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations"},{"title3":"COVID-19: faecal-oral transmission?"},{"title3":"Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records"},{"title3":"Pathogenicity and transmissibility of 2019-nCoV:a quick overview and comparison with other emerging viruses"},{"title3":"Preliminary estimation of the basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 2020: a data-driven analysis in the early phase of the outbreak"},{"title3":"Early release - high contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2"},{"title3":"The reproductive number of COVID-19 is higher compared to SARS coronavirus"},{"title3":"Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients"},{"title3":"Bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar features presenting as ground-glass opacities on CT"},{"title3":"The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak"},{"title3":"The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China"},{"title3":"Clinical and immunological features of severe and moderate coronavirus disease 2019"},{"title3":"SARS-CoV-2: a storm is raging"},{"title3":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)"},{"title3":"SARS-CoV-2 and viral sepsis: observations and hypotheses"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?"},{"title3":"Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome"},{"title3":"Advice for public"},{"title3":"High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa"},{"title3":"Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease"},{"title3":"Serum concentration of renin-angiotensin system components in association with ACE I/D polymorphism among hypertensive subjects in response to ACE inhibitor therapy"},{"title3":"Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension"},{"title3":"Antihypertensive drugs and risk of COVID-19? - authors' reply"},{"title3":"Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19"},{"title3":"Novel peptide inhibitors of angiotensin-converting enzyme 2"},{"title3":"Experimental drug APN01 prevents COVID-19 infection in the lab"},{"title3":"The chemotherapy of amoebiasis"},{"title3":"Chloroquine in rheumatoid arthritis"},{"title3":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro"},{"title3":"Malarial hemozoin: from target to tool"},{"title3":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"},{"title3":"Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus"},{"title3":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread"},{"title3":"Insights from nanomedicine into chloroquine efficacy against COVID-19"},{"title3":"Side effects of chloroquine and primaquine and symptom reduction in malaria endemic area (Mancio Lima, Acre, Brazil)"},{"title3":"The unique antiviral activity of artesunate is broadly effective against human cytomegaloviruses including therapy-resistant mutants"},{"title3":"The artemisinin derivative artemisone is a potent inhibitor of human cytomegalovirus replication"},{"title3":"Azithromycin: mechanisms of action and their relevance for clinical applications"},{"title3":"Azithromycin induces anti-viral responses in bronchial epithelial cells"},{"title3":"Azithromycin shows anti-zika virus activity in human glial cells"},{"title3":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial"},{"title3":"Anti-BK virus activity of ciprofloxacin and related antibiotics"},{"title3":"Topical application of aminoglycoside antibiotics enhances host resistance to viral infections in a microbiota-independent manner"},{"title3":"Anti-herpes virus activity of polyether antibiotic CP-44161 in vivo"},{"title3":"Antiviral properties of ehrlichin, an antibiotic produced by Streptomyces lavendulae"},{"title3":"Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV)"},{"title3":"Studies on the antiviral effect of rifampicin in volunteers"},{"title3":"A combination of doxycycline and ribavirin alleviated chikungunya infection"},{"title3":"Broad spectrum antiviral agent niclosamide and its therapeutic potential"},{"title3":"Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs"},{"title3":"The pharmacokinetics and interactions of ivermectin in humans:a mini-review"},{"title3":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro"},{"title3":"Hundreds of virus patients allowed to try Gilead's Ebola drug"},{"title3":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus"},{"title3":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease"},{"title3":"Neuraminidase inhibitors for influenza"},{"title3":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors"},{"title3":"Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach"},{"title3":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor"},{"title3":"Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings"},{"title3":"Lopinavir-ritonavir was not effective for COVID-19"},{"title3":"Ribavirin in the treatment of SARS: a new trick for an old drug?"},{"title3":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19"},{"title3":"Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road?"},{"title3":"Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase"},{"title3":"Sofosbuvir: a novel treatment option for chronic hepatitis C infection"},{"title3":"Identification of nafamostat as a potent inhibitor of Middle East respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay"},{"title3":"D.T.T. says, Nafamostat can inhibit SARS-CoV-2 infection"},{"title3":"Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C"},{"title3":"Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models"},{"title3":"Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study"},{"title3":"Characterization of the antiviral effects of interferon-alpha against a SARS-like coronoavirus infection in vitro"},{"title3":"Interferon priming enables cells to partially overturn the SARS coronavirus-induced block in innate immune activation"},{"title3":"Interferon-beta 1a and SARS coronavirus replication"},{"title3":"Human amniotic fluid: a source of stem cells for possible therapeutic use"},{"title3":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma"},{"title3":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody"},{"title3":"Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies"},{"title3":"A human monoclonal antibody blocking SARS-CoV-2 infection"},{"title3":"Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters"},{"title3":"Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)"},{"title3":"Tocilizumab: a review in rheumatoid arthritis"},{"title3":"Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis"},{"title3":"Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis"},{"title3":"Remdesivir and sarilumab - COVID-19 clinical trials begin"},{"title3":"Curcumin suppression of cytokine release and cytokine storm. A potential therapy for patients with Ebola and other severe viral infections"},{"title3":"Specific plant terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus"},{"title3":"In vitro antiviral activity of neem (Azardirachta indica L.) bark extract against herpes simplex virus type-1 infection"},{"title3":"Induction of apoptosis in human breast cancer cells by nimbolide through extrinsic and intrinsic pathway"},{"title3":"Nimbolide protects against endotoxin-induced acute respiratory distress syndrome by inhibiting TNF-alpha mediated NF-kappaB and HDAC-3 nuclear translocation"},{"title3":"Non-nucleosidic inhibition of Herpes simplex virus DNA polymerase: mechanistic insights into the anti-herpetic mode of action of herbal drug withaferin A"},{"title3":"Andrographolide, a potential cancer therapeutic agent isolated from Andrographis paniculata"},{"title3":"Broad-spectrum antiviral properties of andrographolide"},{"title3":"Effects of low dose quercetin: cancer cell-specific inhibition of cell cycle progression"},{"title3":"Antiviral activity of four types of bioflavonoid against dengue virus type-2"},{"title3":"Small molecules blocking the entry of severe acute respiratory syndrome coronavirus into host cells"},{"title3":"Antiviral effects of saikosaponins on human coronavirus 229e in vitro"},{"title3":"The roles of vitamin C in skin health"},{"title3":"Vitamin C and immune function"},{"title3":"Vitamin C alleviates LPS-induced cognitive impairment in mice by suppressing neuroinflammation and oxidative stress"},{"title3":"Beneficial effects of ascorbic acid to treat lung fibrosis induced by paraquat"},{"title3":"The antiviral properties of vitamin C"},{"title3":"Inhibitory effects of 6-O-acylated L-ascorbic acids possessing a straight- or branched-acyl chain on Epstein-Barr virus activation"},{"title3":"Vitamin C, respiratory infections and the immune system"},{"title3":"Antiviral natural products and herbal medicines"},{"title3":"In vitro virucidal effects of Allium sativum (garlic) extract and compounds"},{"title3":"In vitro antiviral activity of clove and ginger aqueous extracts against feline calicivirus, a surrogate for human norovirus"},{"title3":"In vitro antiviral activity of Cinnamomum cassia and its nanoparticles against H7N3 influenza a virus"},{"title3":"Evaluation of antiviral activity of Ocimum sanctum and Acacia arabica leaves extracts against H9N2 virus using embryonated chicken egg model"},{"title3":"Small molecules targeting severe acute respiratory syndrome human coronavirus"},{"title3":"Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus"},{"title3":"Inhibition of SARS-CoV 3C-like protease activity by theaflavin-3,3'-digallate (TF3)"},{"title3":"Effective inhibition of MERS-CoV infection by resveratrol"},{"title3":"Anti-influenza A virus effects of fructan from Welsh onion (Allium fistulosum L.)"},{"title3":"Vitamin D for treatment and prevention of infectious diseases: a systematic review of randomized controlled trials"},{"title3":"Zn2+ inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture"},{"title3":"Novel antiviral activity of baicalein against dengue virus"},{"title3":"Antiviral activity of raoulic acid from Raoulia australis against Picornaviruses"},{"title3":"A plant-derived flavonoid inhibits entry of all HCV genotypes into human hepatocytes"},{"title3":"COVID-19, SARS and MERS: are they closely related?"},{"title3":"A review of treatment modalities for Middle East Respiratory Syndrome"},{"title3":"Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia"},{"title3":"Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study"},{"title3":"Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection"},{"title3":"Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses"},{"title3":"Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies"},{"title3":"Novavax advances development of novel COVID-19 vaccine"},{"title3":"Coronavirus vaccine: when will it be ready?"},{"title3":"Moderna charts fast track of SARS-CoV-2 vaccine to clinical trials, clinical OMICs - molecular diagnostics in precision medicine"},{"title3":"25, 2020, 12:20 Pm, Meet the company that has just begun testing a coronavirus vaccine in the United States, Science"},{"title3":"Safety and immunogenicity study of 2019-nCoV vaccine (mRNA-1273) to prevent SARS-CoV-2 infection - full text view - ClinicalTrials.gov"},{"title3":"BioNTech and Pfizer get German nod for Covid-19 vaccine trial"},{"title3":"Function and safety study of SARS-CoV-2 synthetic minigene vaccines"},{"title3":"I.| U. Mar 28, 2020, 18:56 Ist, COVID-19 vaccine trial: Oxford University to recruit 500 volunteers"},{"title3":"Effectiveness of routine BCG vaccination on buruli ulcer disease: a case-control study in the Democratic Republic of Congo, Ghana and Togo"},{"title3":"Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study"},{"title3":"AFP, Australia's trialing a TB vaccine against COVID-19, and health workers get it first"},{"title3":"Coronavirus vaccine: Zydus, Serum Institute among 43 global firms in race"},{"title3":"Mesenchymal stem cells: immune evasive, not immune privileged"},{"title3":"Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia"},{"title3":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients"},{"title3":"Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV"},{"title3":"Immunobiology of the IL-15-IL-15Ralpha complex as an antitumor and antiviral agent"},{"title3":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts"},{"title3":"A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses"},{"title3":"Debate on MERS-CoV respiratory precautions: surgical mask or N95 respirators?"},{"title3":"WHO Director-General's opening remarks at the media briefing on COVID-19 - 16 March 2020"}]},{"title2":"Role of drug repurposing in current treatment strategies against COVID-19; systemic review","References":[]},{"title2":"Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease","References":[]},{"title2":"Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses","References":[{"title3":"Isolation of a novel Coronavirus from a man with pneumonia in Saudi Arabia"},{"title3":"Coronaviruses:drug discovery and therapeutic options"},{"title3":"Pathogenesis of Middle East respiratory syndrome coronavirus"},{"title3":"Emergence of MERS-CoV in the Middle East: origins, transmission, treatment, and perspectives"},{"title3":"Isolation and characterization of viruses related to the SARS Coronavirus from animals in southern China"},{"title3":"WHO, 2016. Middle East respiratory syndrome coronavirus (MERS-CoV) WHO. "},{"title3":"Evidence supporting a zoonotic origin of human coronavirus strain NL63"},{"title3":"Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event"},{"title3":"Evidence for an ancestral association of human coronavirus 229E with bats"},{"title3":"Evidence for zoonotic origins of Middle East respiratory syndrome coronavirus"},{"title3":"Mechanisms of zoonotic severe acute respiratory syndrome Coronavirus host range expansion in human airway epithelium"},{"title3":"Mechanisms of coronavirus cell entry mediated by the viral spike protein"},{"title3":"A previously undescribed coronavirus associated with respiratory disease in humans"},{"title3":"Coronaviruses: important emerging human pathogens"},{"title3":"Evidence for camel-to-human transmission of MERS coronavirus"},{"title3":"Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels a comparative serological study"},{"title3":"From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses"},{"title3":"SARS-beginning to understand a new virus"},{"title3":"Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease"},{"title3":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus"},{"title3":"Human aminopeptidase N is a receptor for human coronavirus 229E"},{"title3":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC"},{"title3":"Human Coronavirus HKU1 spike protein uses O-Acetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-Esterase protein as a receptor-Destroying enzyme"},{"title3":"Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry"},{"title3":"Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans"},{"title3":"Anti-HCV drugs in the pipeline"},{"title3":"Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes"},{"title3":"Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy"},{"title3":"IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study"},{"title3":"The QSAR and docking calculations of fullerene derivatives as HIV-1 protease inhibitors"},{"title3":"Integrative computational modeling of protein interactions"},{"title3":"2'-Methylguanosine prodrug (IDX-184), phosphoramidate prodrug (Sofosbuvir), diisobutyryl prodrug (R7128) are better than their parent nucleotides and ribavirin in hepatitis C virus inhibition: a molecular modeling study"},{"title3":"Structural properties of metal-free apometallothioneins"},{"title3":"The EBI Search engine: providing search and retrieval functionality for biological data from EMBL-EBI"},{"title3":"Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega"},{"title3":"Deciphering key features in protein structures with the new ENDscript server"},{"title3":"The I-TASSER Suite: protein structure and function prediction"},{"title3":"Verification of protein structures: patterns of nonbonded atomic interactions"},{"title3":"Deviations from standard atomic volumes as a quality measure for protein crystal structures"},{"title3":"Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): structural evidence for nucleotide import and de-novo initiation"},{"title3":"A comparative QSAR analysis and molecular docking studies of quinazoline derivatives as tyrosine kinase (EGFR) inhibitors: a rational approach to anticancer drug design"},{"title3":"Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design"},{"title3":"1.7.6, V., The PyMOL Molecular Graphics System, Version 1.7.6 Schrodinger, LLC. "},{"title3":"Water determines the structure and dynamics of proteins"},{"title3":"Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects"},{"title3":"Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials"}]},{"title2":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19","References":[{"title3":"Pneumonia of unknown etiology in Wuhan, China: potential for international spread via commercial air travel"},{"title3":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health:the latest 2019 novel coronavirus outbreak in Wuhan, China"},{"title3":"Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease"},{"title3":"Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses"},{"title3":"Catalytic function and substrate specificity of the papain-like protease domain of nsp3 from the Middle East respiratory syndrome coronavirus"},{"title3":"Some one health based control strategies for the Middle East respiratory syndrome coronavirus"},{"title3":"Zika viral polymerase inhibition using anti-HCV drugs both in market and under clinical trials"},{"title3":"Zika virus: novel guanosine derivatives revealed strong binding and possible inhibition of the polymerase"},{"title3":"Novel guanosine derivatives as anti-HCV NS5b polymerase: a QSAR and molecular docking study"},{"title3":"IDX-184 is a superior HCV direct-acting antiviral drug: a QSAR study"},{"title3":"Molecular dynamics simulation revealed binding of nucleotide inhibitors to ZIKV polymerase over 444 nanoseconds"},{"title3":"Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes"},{"title3":"Molecular dynamics and docking reveal the potency of novel GTP derivatives against RNA dependent RNA polymerase of genotype 4a HCV"},{"title3":"Molecular modeling and docking revealed superiority of IDX-184 as HCV polymerase inhibitor"},{"title3":"Applications of computer-aided approaches in the development of hepatitis C antiviral agents"},{"title3":"The mechanism of action of T7 DNA polymerase"},{"title3":"Molecular docking revealed the binding of nucleotide/side inhibitors to Zika viral polymerase solved structures"},{"title3":"Novel inhibitors against wild-type and mutated HCV NS3 serine protease: an in silico study"},{"title3":"Anti-HCV drugs in the pipeline"},{"title3":"Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon"},{"title3":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"},{"title3":"Sofosbuvir, a significant paradigm change in HCV treatment"},{"title3":"Announcing the worldwide Protein Data Bank"},{"title3":"National Center of Biotechnology Informatics (NCBI) database website"},{"title3":"SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information"},{"title3":"Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors"},{"title3":"MolProbity: more and better reference data for improved all-atom structure validation"},{"title3":"AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR"},{"title3":"VERIFY3D: assessment of protein models with three-dimensional profiles"},{"title3":"Deviations from standard atomic volumes as a quality measure for protein crystal structures"},{"title3":"Errors in protein structures"},{"title3":"The antiviral Sofosbuvir against mucormycosis: an in silico perspective"},{"title3":"Structural properties of metal-free apometallothioneins"},{"title3":"Molecular mechanics. The MM3 force field for hydrocarbons. 3. The van der Waals' potentials and crystal data for aliphatic and aromatic hydrocarbons"},{"title3":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading"},{"title3":"Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus"},{"title3":"Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977"},{"title3":"The FDA-approved drug sofosbuvir inhibits Zika virus infection"},{"title3":"The clinically approved antiviral drug sofosbuvir impairs Brazilian zika virus replication"},{"title3":"588 in vitro antiviral activity and pharmacology of IDX184, a novel and potent inhibitor of HCV replication"},{"title3":"2'-Methylguanosine prodrug (IDX-184), phosphoramidate prodrug (Sofosbuvir), diisobutyryl prodrug (R7128) are better than their parent nucleotides and ribavirin in hepatitis C virus inhibition: a molecular modeling study"},{"title3":"Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus, in healthy subjects"},{"title3":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C"},{"title3":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial"},{"title3":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys"},{"title3":"PLIP: fully automated protein-ligand interaction profiler"},{"title3":"Density-functional thermochemistry. III. The role of exact exchange"},{"title3":"Optimization of parameters for semiempirical methods V: modification of NDDO approximations and application to 70 elements"},{"title3":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility"},{"title3":"COVID-19 Spike-host cell receptor GRP78 binding site prediction"}]},{"title2":"Anti-HIV and Anti-HCV drugs are the putative inhibitors of RNA-dependent-RNA polymerase activity of NSP12 of the SARS CoV-2 (COVID-19)","References":[]},{"title2":"Structural elucidation of SARS-CoV-2 vital proteins: computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase","References":[{"title3":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"},{"title3":"First case of 2019 novel coronavirus in the United States"},{"title3":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro"},{"title3":"Chloroquine and hydroxychloroquine as available weapons to fight COVID-19"},{"title3":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial"},{"title3":"Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19"},{"title3":"Coronaviruses: genome structure, replication, and pathogenesis"},{"title3":"Return of the coronavirus: 2019-nCoV"},{"title3":"Potential antivirals and antiviral strategies against SARS coronavirus infections"},{"title3":"Design of wide-spectrum inhibitors targeting coronavirus main proteases"},{"title3":"The genome sequence of the SARS-associated coronavirus"},{"title3":"Characterization of a novel coronavirus associated with severe acute respiratory syndrome"},{"title3":"Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia"},{"title3":"Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro"},{"title3":"SWISS-MODEL: an automated protein homology-modeling server"},{"title3":"ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB"},{"title3":"modeling, ZINC- a free database of commercially available compounds for virtual screening"},{"title3":"A public web service for drug discovery"},{"title3":"Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading"},{"title3":"Inhibition of oncogenic kinases: an in vitro validated computational approach identified potential multi-target anticancer compounds"},{"title3":"In silico structural elucidation of RNA-dependent RNA polymerase towards the identification of potential Crimean-Congo hemorrhagic fever virus inhibitors"},{"title3":"Assessing the performance of the MM/PBSA and MM/GBSA methods. 1. The accuracy of binding free energy calculations based on molecular dynamics simulations"},{"title3":"Molecular dynamics investigation on a series of HIV protease inhibitors: assessing the performance of MM-PBSA and MM-GBSA approaches"},{"title3":"Investigating interactions between HIV-1 gp41 and inhibitors by molecular dynamics simulation and MM-PBSA/GBSA calculations"},{"title3":"Severe acute respiratory syndrome coronavirus 2 isolate Wuhan-Hu-1, complete genome"},{"title3":"Reversible unfolding of the severe acute respiratory syndrome coronavirus main protease in guanidinium chloride"},{"title3":"Picornaviral polymerase structure, function, and fidelity modulation"},{"title3":"Identification of four conserved motifs among the RNA-dependent polymerase encoding elements"},{"title3":"Structural basis for active site closure by the poliovirus RNA-dependent RNA polymerase"},{"title3":"RNA-dependent RNA polymerase of Japanese encephalitis virus binds the initiator nucleotide GTP to form a mechanistically important pre-initiation state"},{"title3":"Pharmacoinformatics approach for investigation of alternative potential hepatitis C virus nonstructural protein 5B inhibitors"},{"title3":"Integrated computational approach for virtual hit identification against ebola viral proteins VP35 and VP40"},{"title3":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules"},{"title3":"Mutational analysis of the conserved motifs of influenza A virus polymerase basic protein 1"},{"title3":"Mutation analysis of the GDD sequence motif of a calicivirus RNA-dependent RNA polymerase"},{"title3":"Mutational analysis of the SDD sequence motif of a PRRSV RNA-dependent RNA polymerase"},{"title3":"Structure of the RNA-dependent RNA Polymerase from COVID-19 Virus"},{"title3":"Structural basis for RNA replication by the hepatitis C virus polymerase"},{"title3":"Delicate structural coordination of the severe acute respiratory syndrome coronavirus Nsp13 upon ATP hydrolysis"},{"title3":"J. Bajorath, Chemoinformatics and Computational Chemical Biology, Springer, 2011."},{"title3":"Perspectives towards antiviral drug discovery against Ebola virus"},{"title3":"Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods"},{"title3":"Molecular targets for flavivirus drug discovery"},{"title3":"Learning from the past: Possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV"},{"title3":"3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism"},{"title3":"pH-dependent conformational flexibility of the SARS-CoV main proteinase (Mpro) dimer: molecular dynamics simulations and multiple X-ray structure analyses"},{"title3":"D.E. Pires, L.M. Kaminskas, D.B. Ascher, Prediction and Optimization of Pharmacokinetic and Toxicity Properties of the Ligand, Computational Drug Discovery and Design, Springer, 2018, pp. 271-284."},{"title3":"Strategies to address low drug solubility in discovery and development"},{"title3":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities and impact of genetic variation"},{"title3":"Design and synthesis of a pan-Janus kinase inhibitor clinical candidate (PF-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin"}]},{"title2":"Highlights on evidence-based treatment strategies for COVID-19: a review","References":[]},{"title2":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","References":[{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study"},{"title3":"A new coronavirus associated with human respiratory disease in China"},{"title3":"A pneumonia outbreak associated with a new coronavirus of probable bat origin"},{"title3":"The coronavirus replicase"},{"title3":"One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities"},{"title3":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro"},{"title3":"First Case of 2019 Novel Coronavirus in the United States"},{"title3":"Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors"},{"title3":"Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerase-containing protein of all nidoviruses"},{"title3":"Insights into SARS-CoV transcription and replication from the structure of the nsp7-nsp8 hexadecamer"},{"title3":"RNA synthetic mechanisms employed by diverse families of RNA viruses"},{"title3":"Structural basis for RNA replication by the hepatitis C virus polymerase"},{"title3":"Structural basis for active site closure by the poliovirus RNA-dependent RNA polymerase"},{"title3":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys"},{"title3":"Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C"},{"title3":"Automated electron microscope tomography using robust prediction of specimen movements"},{"title3":"MotionCor2: Anisotropic correction of beam-induced motion for improved cryo-electron microscopy"},{"title3":"cryoSPARC: Algorithms for rapid unsupervised cryo-EM structure determination"},{"title3":"New nsp8 isoform suggests mechanism for tuning viral RNA synthesis"},{"title3":"UCSF Chimera:A visualization system for exploratory research and analysis"},{"title3":"Features and development of Coot"},{"title3":"Towards automated crystallographic structure refinement with phenix.refine"}]},{"title2":"Editorial - sofosbuvir/velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents","References":[]},{"title2":"Sofosbuvir as repurposed antiviral drug against COVID-19: why were we convinced to evaluate the drug in a registered/approved clinical trial?","References":[{"title3":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?"},{"title3":"Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus"},{"title3":"Is the ACE2 Overexpression a Risk Factor for COVID-19 Infection?"},{"title3":"Does COVID19 infect the brain? If so, smokers might be at a higher risk"},{"title3":"A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19"},{"title3":"Practical Strategies Against the Novel Coronavirus and COVID-19:the Imminent Global Threat"},{"title3":"Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase"},{"title3":"Nucleotide Analogues as Inhibitors of SARS-CoV Polymerase"},{"title3":"Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication"},{"title3":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19"},{"title3":"Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection"},{"title3":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability"},{"title3":"The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C"},{"title3":"Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938"},{"title3":"No Resistance Detected in four Phase 3 Clinical Studies in HCV Genotype 1-6 of Sofosbuvir+ Ribavirin with or without Peginterferon: 1843"},{"title3":"Sofosbuvir for previously untreated chronic hepatitis C infection"},{"title3":"Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options"},{"title3":"Naggie S, Sulkowski M, Lalezari J, et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). 21st Conference on Retroviruses and Opportunistic Infections (CROI) 2014."},{"title3":"Comprehensive Resistance Testing in Patients Who Relapsed after Treatment with Sofosbuvir (GS-7977)-Containing Regimens in Phase 2 Studies: 753"},{"title3":"In Vitro Pan-genotypic and Combination Activity of Sofosbuvir (GS-7977) in Stable Replicon Cell Lines: 1875"},{"title3":"New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C"},{"title3":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir"},{"title3":"Sofosbuvir protects Zika virus-infected mice from mortality, preventing short-and long-term sequelae"},{"title3":"The FDA-approved drug sofosbuvir inhibits Zika virus infection"},{"title3":"The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication"},{"title3":"Zika virus disrupts phospho-TBK1 localization and mitosis in human neuroepithelial stem cells and radial glia"},{"title3":"Evaluation of Sofosbuvir (beta-D-2'-deoxy-2'-alpha-fluoro-2'-beta-C-methyluridine) as an inhibitor of Dengue virus replication"},{"title3":"Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo"},{"title3":"In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir"},{"title3":"Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977"},{"title3":"Nucleoside diphosphate kinase A as a controller of AMP-kinase in airway epithelia"},{"title3":"The cell biology of C hikungunya virus infection"},{"title3":"Cell-line dependent antiviral activity of sofosbuvir against Zika virus"},{"title3":"The NDPK/NME superfamily: state of the art"},{"title3":"The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue"},{"title3":"Nature and role of xenobiotic metabolizing esterases in rat liver, lung, skin and blood"},{"title3":"Nucleoside diphosphate and triphosphate prodrugs-An unsolvable task?"},{"title3":"Sofosbuvir and ribavirin liver pharmacokinetics in patients infected with hepatitis C virus"},{"title3":"Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates"},{"title3":"PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication"},{"title3":"Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies"}]},{"title2":"In silico studies on therapeutic agents for COVID-19: drug repurposing approach","References":[{"title3":"The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak"},{"title3":"Research and Development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases"},{"title3":"Pneumonia of unknown etiology in Wuhan, China: potential for international spread via commercial air travel"},{"title3":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19"},{"title3":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation"},{"title3":"Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms"},{"title3":"World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19)"},{"title3":"New insights on the antiviral effects of chloroquine against coronavirus:what to expect for COVID-19?"},{"title3":"Approved antiviral drugs over the past 50 years"},{"title3":"Clinical trials of antiviral agents"},{"title3":"Novel ligand-based docking; molecular dynamic simulations; and absorption, distribution, metabolism, and excretion approach to analyzing potential acetylcholinesterase inhibitors for Alzheimer's disease"},{"title3":"Structure-based design, synthesis and biological evaluation of a newer series of pyrazolo [1, 5-a] pyrimidine analogues as potential anti-tubercular agents"},{"title3":"A rational approach to selective pharmacophore designing: an innovative strategy for specific recognition of Gsk3b"},{"title3":"Structure-based identification of novel sirtuin inhibitors against triple negative breast cancer: an in silico and in vitro study"},{"title3":"Glide: a new approach for rapid, accurate docking and scoring 2. Enrichment factors in database screening"},{"title3":"Dual inhibitors of Janus kinase 2 and 3 (JAK2/3): designing by pharmacophore- and docking-based virtual screening approach"},{"title3":"Merits and pitfalls of conventional and covalent docking in identifying new hydroxyl aryl aldehyde like compounds as human IRE1 inhibitors"},{"title3":"Reverse screening methods to search for the protein targets of chemopreventive compounds"},{"title3":"Identification of potential CRAC channel inhibitors: pharmacophore mapping, 3D-QSAR modelling, and molecular docking approach"},{"title3":"History and progress of antiviral drugs: from acyclovir to direct-acting antiviral agents (DAAs) for Hepatitis C"},{"title3":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19"},{"title3":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro"},{"title3":"T. Smith, J. Bushek, T. Prosser, COVID-19 Drug Therapy. Clinical Drug Information, Clinical Solutions."},{"title3":"Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study"},{"title3":"L. Zhang, R. Zhou, Binding Mechanism of Remdesivir to SARS-CoV-2 RNA Dependent RNA Polymerase. Preprints. 10.20944/preprints202003.0267.v1."},{"title3":"Aromatic thiosemicarbazones, their antiviral action and interferon. 1. The decreasing of adenovirus type 1 resistance against interferon by methisazone in vitro"},{"title3":"ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection"}]},{"title2":"Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic","References":[{"title3":"Severe acute respiratory syndrome: historical, epidemiological and clinical features"},{"title3":"The Middle East respiratory syndrome (MERS)"},{"title3":"WHO. Coronavirus disease (COVID-19) Situation dashboard - April 18th, 2020, https://covid19.who.int/ (2020)."},{"title3":"A yellow flag on the horizon: the looming threat of yellow fever to North America"},{"title3":"The curious case of the Nidovirus exoribonuclease: its role in RNA synthesis and replication fidelity"},{"title3":"WHO. Solidarity clinical trial for the COVID-19 treatments, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments (2020)"},{"title3":"Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 cofactors"},{"title3":"Structural analysis of monomeric RNA-dependent polymerases: evolutionary and therapeutic implications"},{"title3":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase"},{"title3":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in Rhesus monkeys"},{"title3":"Coronavirus susceptibility to the antiviral Remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exonuclease"},{"title3":"Wang, M. et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res., 10.1038/s41422-020-0282-0 (2020)"},{"title3":"Structural basis for RNA replication by the Hepatitis C virus polymerase"},{"title3":"Sofosbuvir as treatment against Dengue?"},{"title3":"Blocking Zika virus vertical transmission"},{"title3":"Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro"},{"title3":"Anti-HCV, nucleotide inhibitors, repurposing against COVID-19"},{"title3":"More than 80 clinical trials launch to test coronavirus treatment"},{"title3":"Sofosbuvir, a significant paradigm change in HCV treatment"},{"title3":"Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir"},{"title3":"Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics"},{"title3":"Shu, Y., McCauley, J. GISAID: Global initiative on sharing all influenza data - from vision to reality. EuroSurveillance, 22, 10.2807/1560-7917.ES.2017.22.13.30494 (2017)."},{"title3":"MEGA X: molecular evolutionary genetics analysis across computing platforms"},{"title3":"BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT"},{"title3":"UCSF Chimera - a visualization system for exploratory research and analysis"},{"title3":"Tools for integrated sequence-structure analysis with UCSF Chimera"}]},{"title2":"Sofosbuvir and ribavirin liver pharmacokinetics in patients infected with hepatitis C virus","References":[]},{"title2":"Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre randomized controlled trial","References":[{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"A systematic review of COVID-19 epidemiology based on current evidence"},{"title3":"Coronavirus disease 2019 (COVID-19) outbreak in Iran: actions and problems"},{"title3":"WHO. WHO COVID-19 Data Explorer. https://covid19.who.int/explorer."},{"title3":"Observational study of hydroxychloroquine in hospitalized patients with Covid-19"},{"title3":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19"},{"title3":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial"},{"title3":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial"},{"title3":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review"},{"title3":"Remdesivir for the treatment of COVID-19:preliminary report"},{"title3":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus"},{"title3":"SD1000: high sustained viral response rate in 1361 patients with hepatitis C genotypes 1, 2, 3, and 4 using a low-cost, fixed-dose combination tablet of generic sofosbuvir and daclatasvir: a multicenter, Phase III clinical trial"},{"title3":"Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo"},{"title3":"The FDA-approved drug sofosbuvir inhibits Zika virus infection"},{"title3":"Sofosbuvir as treatment against dengue?"},{"title3":"Beyond members of the Flaviviridae family, sofosbuvir also inhibits chikungunya virus replication"},{"title3":"Emerging coronaviruses: genome structure, replication, and pathogenesis"},{"title3":"Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase"},{"title3":"Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses"},{"title3":"Advanced bioinformatics rapidly identifies existing therapeutics for patients with coronavirus disease-2019 (COVID-19)"},{"title3":"Ribavirin, remdesivir, sofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study"},{"title3":"In silico study of various antiviral drugs, vitamins, and natural substances as potential binding compounds with SARS-CoV-2 main protease"},{"title3":"Simeprevir suppresses SARS-CoV-2 replication and synergizes with remdesivir"},{"title3":"The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2"},{"title3":"Evaluation of 19 antiviral drugs against SARS-CoV-2 infection"},{"title3":"Minimum costs to manufacture new treatments for COVID-19"},{"title3":"Radiologic management of COVID-19: preliminary experience of the Iranian Society of Radiology COVID-19 Consultant Group (ISRCC)"},{"title3":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial"}]},{"title2":"The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19","References":[]},{"title2":"Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial","References":[{"title3":"World Health Organization (WHO). Coronavirus Disease (COVID-19) Situation Report 116 https://www.who.int/emergencies/diseases/novel-coronavirus-2019."},{"title3":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention"},{"title3":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial"},{"title3":"A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19"},{"title3":"Emerging coronaviruses: genome structure, replication, and pathogenesis"},{"title3":"PolyPill for prevention of cardiovascular disease in an urban Iranian population with special focus on nonalcoholic steatohepatitis: a pragmatic randomized controlled trial within a cohort (PolyIran:Liver):study protocol"},{"title3":"Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses"},{"title3":"Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase"},{"title3":"Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model"},{"title3":"In silico study of various antiviral drugs, vitamins, and natural substances as potential binding compounds with SARS-CoV-2 main protease"},{"title3":"Evaluation of 19 antiviral drugs against SARS-CoV-2 infection"},{"title3":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir"},{"title3":"Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo"},{"title3":"The FDA-approved drug sofosbuvir inhibits Zika virus infection"},{"title3":"Beyond members of the flaviviridae family, sofosbuvir also inhibits chikungunya virus replication"},{"title3":"Sofosbuvir as treatment against dengue?"},{"title3":"Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial"},{"title3":"Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial"},{"title3":"Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1"},{"title3":"Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial"},{"title3":"Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study"},{"title3":"Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study"},{"title3":"Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1"},{"title3":"Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation:implications for maternal dosing, foetal exposure, and safety for mother and child"},{"title3":"The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment"},{"title3":"Minimum costs to manufacture new treatments for COVID-19"},{"title3":"Radiologic management of COVID-19: preliminary experience of the Iranian Society of Radiology COVID-19 Consultant Group (ISRCC)"},{"title3":"Observational study of hydroxychloroquine in hospitalized patients with COVID-19"},{"title3":"Understanding COVID-19: what does viral RNA load really mean?"},{"title3":"Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study"},{"title3":"Viral dynamics in mild and severe cases of COVID-19"},{"title3":"Virological assessment of hospitalized patients with COVID-2019"},{"title3":"The trinity of COVID-19: immunity, inflammation and intervention"}]},{"title2":"Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis","References":[]},{"title2":"Gender differences in patients with COVID-19: focus on severity and mortality","References":[{"title3":"A novel coronavirus from patients with Pneumonia in China, 2019"},{"title3":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome"},{"title3":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia"},{"title3":"Early Transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS"},{"title3":"Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes"},{"title3":"Emerging markers in cardiovascular disease: where does angiotensin-converting enzyme 2 fit in?"},{"title3":"Gender differences in patients with COVID-19: focus on severity and mortality"}]},{"title2":"COVID-19: the gendered impacts of the outbreak","References":[{"title3":"Overcoming the &quot;tyranny of the urgent&quot;: integrating gender into disease outbreak preparedness and response"},{"title3":"The epidemiological characteristics of an outbreak of 2019 novel coronavirus disease (COVD-19)"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"Prevalence and patterns of tobacco smoking among Chinese adult men and women: findings of the 2010 national smoking survey"},{"title3":"Coronavirus: Hong Kong families await return of thousands of stranded domestic helpers as the Philippines lifts travel ban"},{"title3":"A gendered human rights analysis of Ebola and Zika: locating gender in global health emergencies"},{"title3":"Ebola, gender and conspicuously invisible women in global health governance"},{"title3":"Counting indirect crisis-related deaths in the context of a low-resilience health system: the case of maternal and neonatal health during the Ebola epidemic in Sierra Leone"},{"title3":"Zika, abortion and health emergencies: a review of contemporary debates"},{"title3":"Gender mainstreaming as a pathway for sustainable arbovirus control in Latin America"},{"title3":"Indian-American Seema Verma appointed as key member of US COVID-19 Task Force"}]},{"title2":"Sex and gender differences in the outcome of patients with COVID-19","References":[{"title3":"Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: comparison with SARS and MERS"},{"title3":"Positive rate of RT-PCR detection of SARS-CoV-2 infection in 4880 cases from one hospital in Wuhan, China, from Jan to Feb 2020"},{"title3":"Gender-based disparities in COVID-19 patient outcomes: a propensity-matched Analysis."},{"title3":"Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: a single center study J Clin Virol."},{"title3":"COVID-19: the gendered impacts of the outbreak"},{"title3":"COVID-19 sex-disaggregated data tracker. Sex, gender, and COVID-19"},{"title3":"Gender differences in patients with COVID-19: focus on severity and mortality"},{"title3":"Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection"},{"title3":"A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: a possible reason underlying different outcome between sex"},{"title3":"Sex differences in respiratory function"},{"title3":"expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov BioRxiv."},{"title3":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome"},{"title3":"Review of the clinical characteristics of coronavirus disease 2019 (COVID-19)"},{"title3":"Individual variation of the SARS-CoV2 receptor ACE2 gene expression and regulation Preprints"},{"title3":"COVID-19 infection and circulating ACE2 levels: protective role in women and children"},{"title3":"Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients"},{"title3":"Sex differences in inflammation, redox biology, mitochondria, and autoimmunity"},{"title3":"Metabolic impact of sex hormones on obesity"},{"title3":"Gender differences in COVID-19: some open questions. Italian"}]},{"title2":"Sofosbuvir with velpatasvir","References":[]},{"title2":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","References":[{"title3":"The novel coronavirus originating in Wuhan, China: challenges for global health governance"},{"title3":"Severe acute respiratory syndrome-related coronavirus: the species and its viruses:a statement of the Coronavirus Study Group"},{"title3":"Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)"},{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society"},{"title3":"KDIGO clinical practice guidelines for acute kidney injury"},{"title3":"Acute respiratory distress syndrome: the Berlin Definition"},{"title3":"Chinese management guideline for COVID-19 (version 6.0)"},{"title3":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study"},{"title3":"Middle East respiratory syndrome"},{"title3":"Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong"},{"title3":"Predictors of mortality in Middle East respiratory syndrome (MERS)"},{"title3":"Exacerbated innate host response to SARS-CoV in aged non-human primates"},{"title3":"The immunopathogenesis of sepsis in elderly patients"},{"title3":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)"},{"title3":"Serial evaluation of the SOFA score to predict outcome in critically ill patients"},{"title3":"Disease severity and clinical outcomes of community-acquired pneumonia caused by non-influenza respiratory viruses in adults: a multicentre prospective registry study from the CAP-China Network"},{"title3":"Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study"},{"title3":"Acute pneumonia and the cardiovascular system"},{"title3":"Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis"},{"title3":"Laboratory-confirmed respiratory infections as predictors of hospital admission for myocardial infarction and stroke: time-series analysis of English data for 2004-2015"},{"title3":"Prevalence and significance of coagulation abnormalities in community-acquired pneumonia"},{"title3":"D-dimer is a significant prognostic factor in patients with suspected infection and sepsis"},{"title3":"Risk of myocardial infarction and stroke after acute infection or vaccination"},{"title3":"Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality"},{"title3":"Cardiovascular complications of acute respiratory infections: current research and future directions"},{"title3":"Regulation of ACE2 in cardiac myocytes and fibroblasts"},{"title3":"ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension"},{"title3":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome"},{"title3":"Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase"},{"title3":"Viral shedding and antibody response in 37 patients with Middle East Respiratory Syndrome coronavirus infection"},{"title3":"Viral load kinetics of MERS coronavirus infection"},{"title3":"Factors associated with prolonged viral shedding in patients with avian influenza A(H7N9) virus infection"},{"title3":"SARS-CoV-2 viral load in upper respiratory specimens of infected patients"}]},{"title2":"Factors associated with duration of viral shedding in adults with COVID-19 outside of Wuhan, China: a retrospective cohort study","References":[{"title3":"The outbreak of Coronavirus Disease 2019 (COVID-19)-An emerging global health threat"},{"title3":"A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"Relating oxygen partial pressure, saturation and content: the haemoglobin-oxygen dissociation curve"},{"title3":"Clinical Characteristics of Coronavirus Disease 2019 in China"},{"title3":"Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19"},{"title3":"Viral shedding and clinical illness in naturally acquired influenza virus infections"},{"title3":"Viral loads and duration of viral shedding in adult patients hospitalized with influenza"},{"title3":"Interpretation of Guidelines for the Diagnosis and Treatment of Novel Coronavirus (2019-nCoV) Infection by the National Health Commission (Trial Version 5)"},{"title3":"Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease"},{"title3":"The value of early transmission dynamic studies in emerging infectious diseases"},{"title3":"COVID-19 and Italy: what next?"},{"title3":"Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China"},{"title3":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury"},{"title3":"Factors promoting the prolonged shedding of the pandemic (H1N1) 2009 influenza virus in patients treated with oseltamivir for 5 days"},{"title3":"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study"},{"title3":"Covid-19: cases grow in US as Trump pushes promise of a malaria drug"},{"title3":"Characteristics of COVID-19 infection in Beijing"},{"title3":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China"},{"title3":"Virological assessment of hospitalized patients with COVID-2019"},{"title3":"Prolonged presence of SARS-CoV-2 viral RNA in faecal samples"},{"title3":"Factors associated with prolonged viral RNA shedding in patients with COVID-19"},{"title3":"Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of China: retrospective case series"},{"title3":"Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China"},{"title3":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study"},{"title3":"Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore"},{"title3":"Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China"},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"},{"title3":"SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients"}]},{"title2":"The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2","References":[]},{"title2":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir","References":[]},{"title2":"Risk factors for severe illness with 2009 pandemic influenza A (H1N1) virus infection in China","References":[]}]}]}